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Summary  
Paediatric brain tumours are the second most frequent malignancy in children, and the most 
common cause of cancer-related deaths in both the 0-14-year and the 15-24-year age 
group. In this thesis we focused our studies in paediatric malignant brain tumours of glial 
origin (grade III and IV): astrocytomas, oligodendrogliomas and glioblastomas.  Although, 
paediatric high grade glioma (pHGG) is a histologically similar tumour to that arising in 
adults, these are distinct biological diseases, differing in copy number profiles and driver 
genetic alterations. Recent sequencing initiatives have conclusively shown the existence of 
subgroups of HGG marked by distinct driver mutations, which are significantly enriched in 
young children (H3F3A K27M), teenagers and young adults (H3F3A G34R/V), and middle-
aged adults (IDH1/2). Structural rearrangements resulting in novel fusion genes are strongly 
associated with cancer, and numerous examples exist in both adult and childhood 
malignancies. Although, only few have been described in pHGG. Structural variants (SV) 
frequently result in chimeric proteins targetable by novel therapeutic approaches, an 
outcome desperately needed in pHGG. The work summarized in this thesis aims to explore 
novel structural rearrangements in childhood malignant gliomas, contributing to uncover the 
molecular mechanisms underpinning pHGG, to further contribute to distinguish the adult and 
childhood disease.   
PDGFRA is a receptor tyrosine kinase (RTK) that triggers essential cellular responses such 
as proliferation, migration, and survival. This gene is commonly amplified and overexpressed 
in paediatric malignant gliomas, playing an important role in this disease. To determine 
whether PDGFRA was also targeted by more subtle mutations missed by copy number 
analysis, we screened a large series of cases for single base changes and small indels, as 
well as the PDGFRAΔ8,9 deletion and KDR:PDGFRA (KP) fusion gene, previously reported 
in adult high grade glioma (aHGG). Somatic-activating mutations were identified in 
nonbrainstem pHGG and Diffuse Intrinsic Pontine Gliomas (DIPG), including missense 
mutations and in-frame deletions and insertions not previously described. In our studies 
PDGFRA alterations were more common in pHGG arising outside the brainstem (14% vs 
6%), and 8/18 (44%) cases had concomitant amplification and mutation of PDGFRA. The 
adult rearrangements (KP and PDGFRAΔ8,9) were only found in adult cases and one case 
of pHGG. Thus, a distinct spectrum of PDGFRA alterations is present in pHGG.  
As functionally important intragenic copy number aberrations (iCNA) and fusion genes begin 
to be identified in aHGG, the same has not yet been done in the childhood setting. We 
applied an iCNA algorithm to our previously published dataset of DNA copy number profiling 
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in pHGG with a view to identify novel intragenic breakpoints. We reported a series of 288 
iCNA events in pHGG, with the presence of intragenic breakpoints itself a negative 
prognostic factor. We identified an increased number of iCNA in older children compared to 
infants, and increased iCNA in H3F3A K27M mutant tumours compared to G34R/V and wild-
type. We observed numerous gene disruptions by iCNA due to both deletions and 
amplifications, targeting known HGG-associated genes such as RB1 and NF1, putative 
tumour suppressors such as FAF1 and KIDINS220, and novel candidates such as PTPRE 
and KCND2. We further identified two novel fusion genes in pHGG – CSGALNACT2:RET 
and the complex fusion DHX57:TMEM178: MAP4K3.  
To further examine whether SVs that lead to the production of oncogenic fusion proteins 
were present in pHGG, we used whole genome and transcriptome paired end sequencing to 
detect novel gene fusions in pHGG model cell lines – KNS42, SF188 and UW479. Our study 
showed for the first time that glioma cell lines are highly rearranged and that they are 
characterized by several fusion genes. We discovered three extra-chromosomal structural 
rearrangement structures in SF188, which involve chromosomes 4q12 (SCFD2, FIP1L1), 
8q24 (MYC), 11p11, 11q13 (CCND1), 11p14, 11q23 (MLL) and 12q14 (CDK4). The 
amplified loci represented three very complex structures, which were present in the form of 
three double minutes (DM). We characterized a fusion gene in each cell line: 
GORASP2:CDADC1 in KNS42, NUBPL:AKAP6 in UW479 and RPTOR:TULP4 in SF188. 
The RPTOR:TULP4 fusion gene described in SF188 involved RPTOR, an important 
component of mTOR signalling. This fusion leads to the expression of a truncated form of 
RPTOR in SF188. We discovered that RPTOR was disrupted 2.2% of pHGG cases and that 
patient samples harboured similar truncations to the SF188 cell line. As the roles of these 
fusion genes are still unclear, further studies need to be performed in order to better 
understand their role in pHGG. 
In summary these data expand upon our understanding of the genomic events driving these 
tumours and represent novel targets for therapeutic intervention in these poor prognosis 
cancers of childhood. 
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Resumo 
Os tumores cerebrais pediátricos são a segundo tumor maligno mais comum em crianças. 
Estes tumores são a principal causa de morte por cancro nos grupos dos 0-14 e dos 15-24 
anos. Nesta tese, centramos os nossos estudos em tumores pediátricos malignos de origem 
glial (grau III e IV): astrocitomas, oligodendrogliomas, e glioblastomas (GBM). Apesar dos 
gliomas pediátricos de alto grau serem histologicamente semelhantes aos gliomas adultos 
malignos, estes são doenças biologicamente diferentes, possuindo perfis de número de 
cópias de ADN e alterações genéticas diferentes. As recentes iniciativas de sequenciação 
de última geração demonstraram a existência de sub-grupos de gliomas de alto grau que 
são caracterizados por mutações distintas: nas crianças (H3F3A K27M), nos adolescentes e 
jovens adultos (H3F3A G34R/V) e nos adultos de meia-idade (IDH1/2). As aberrações 
estruturais dos cromossomas dão origem à formação de genes de fusão que estão 
normalmente associados com cancro, existindo vários casos descritos em cancros de 
crianças e adultos. No entanto, nos gliomas pediátricos de alto grau apenas alguns genes 
de fusão foram descritos. Estes rearranjos estruturais normalmente dão origem a proteínas 
quiméricas que potencialmente podem ser importantes na resposta tumoral à terapia 
dirigida, algo extremamente necessário para o tratamento desta doença. O trabalho 
resumido nesta tese pretende explorar os mecanismos moleculares que estão por detrás 
dos gliomas pediátricos de alto grau, contribuindo desta forma para a distinção entre os 
gliomas malignos pediátricos e adultos. 
O PDGFRA é um receptor de tirosina cinase (RTK) que activa várias respostas celulares, 
tais como a proliferação, a migração e a sobrevivência das células. Este gene está 
normalmente amplificado e é sobre-expresso em gliomas malignos pediátricos, 
desempenhando um papel muito importante nesta doença. De forma a determinar se o 
PDGFRA é alvo de mutações que não são detectadas através da análise do número de 
cópias de ADN, decidimos estudar a presença de alterações moleculares do PDGFRA 
(mutações pontuais e pequenas inserções/deleções), assim como a deleção Δ8,9 no 
PDGFRA e o gene de fusão KDR:PDGFRA (KP), anteriormente descritos em gliomas 
malignos em adultos. Os nossos resultados demonstraram a presença de mutações 
somáticas de ganho de função, incluindo mutações missense e deleções/inserções in-frame 
que não tinham sido descritas anteriormente na literatura. Estas alterações estão presentes 
em ambos gliomas pediátricos supratentoriais de alto grau e em gliomas pontinos difusos 
(DIPG). Os nossos estudos demonstraram que as alterações no PDGFRA são mais comuns 
em gliomas supratentoriais malignos do que em DIPG, e 8/18 (44%) dos casos possuem 
simultaneamente amplificação e mutação no PDGFRA. Os rearranjos estruturais 
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normalmente presentes em adultos (KP e PDGFRAΔ8,9) foram apenas encontrados num 
caso de glioma pediátrico de alto grau. Estes resultados indicam que as alterações 
presentes no PDGFRA em crianças são diferentes daquelas presentes em adultos. 
Enquanto que as alterações do número de cópias intragénicas (iCNA) e de genes de fusão 
funcionalmente importantes começam a ser identificados em gliomas de alto grau em 
adultos, o mesmo ainda não ocorreu nos gliomas pediátricos. Ao aplicar o algoritmo iCNA a 
um conjunto de dados de perfis do número de cópias de ADN em casos de gliomas 
pediátricos malignos, previamente publicado pelo nosso grupo, identificamos novas 
alterações intragénicas. Neste estudo, identificamos 288 eventos iCNA em gliomas 
pediátricos de alto grau, sendo que a presença destes breakpoints intragénicos é por si só 
um factor de prognóstico negativo. Quando comparadas com crianças mais jovens, os 
adolescentes possuem maior número de iCNA. Os tumores que têm a mutação H3F3A 
K27M também apresentam maior número de iCNA quando comparados com os tumores 
que tem a mutação H3F3A G34R/V ou com os casos normais. No nosso estudo também 
observamos inúmeras disrupções de genes por iCNA devido a deleções e amplificações. Os 
genes alvo destas disrupções estão associados a gliomas malignos, tais como RB1 e NF1, 
a supressores tumorais putativos, como por exemplo o FAF1 e o KIDINS220, e também a 
novos candidatos tumorais, como o PTPRE e KCND2. Identificamos também dois novos 
genes de fusão, CSGALNACT2:RET e DHX57:TMEM178:MAP4K3.  
De forma a explorar a ocorrência de alterações cromossómicas estruturais que dão origem 
a proteínas de fusão oncogénicas, utilizamos a sequenciação de ultima geração do ADN e 
ARN de linhas celulares de gliomas pediátricos de alto grau – KNS42, SF188 e UW479. O 
nosso estudo mostrou pela primeira vez que estas linhas celulares são caracterizadas por 
vários genes de fusão. Descobrimos ainda a presença de três estruturas extra-
cromossomais presentes na linha celular SF188. Estas estruturas envolvem os 
cromossomas 4q12 (SCFD2, FIP1L1), 8q24 (MYC), 11p11, 11q13 (CCND1), 11p14, 11q23 
(MLL) e o 12q14 (CDK4). Estas regiões estão amplificadas e estão presentes em três 
estruturas muito complexas sob a forma de double minutes (DM). Caracterizamos ainda um 
gene de fusão por cada linha celular: o GORASP2:CDADC1 na KNS42, o NUBPL:AKAP6 
na UW479 e o RPTOR:TULP4 na SF188. O gene de fusão RPTOR:TULP4 descrito na 
SF188 envolve o gene RPTOR, um importante componente da via de sinalização do mTOR, 
e leva a expressão de uma forma truncada do RPTOR. Esta quimera foi encontrada em 
2.2% dos gliomas pediátricos de alto grau 
. 
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Concluindo, o trabalho resumido nesta tese amplia o nosso conhecimento sobre os eventos 
genómicos característicos destes tumores, e representa novos e potenciais targets para a 
terapia dirigida, numa doença que ainda não tem cura.  
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Thesis Layout 
Chapter 1 is a general introduction to paediatric high grade gliomas (pHGG), the disease 
explored during my PhD, and the occurrence of structural variants (SVs) in cancer and 
pHGG, describing the most up-to-date relevant literature for both topics. 
Chapter 2 describes the general aims of this thesis. 
Chapter 3 presents two studies which report the characterization of PDGFRA in a series of 
pHGG, looking at PDGFRA mutation status and structural rearrangements in the context of 
paediatric glioblastoma.  
Chapter 4 comprises a study which identified numerous potentially functional gene 
disruptions and a novel validated complex fusion, DHX57:TMEM178:MAP4K3 in a pHGG 
cohort, using an algorithm designed to identify intragenic copy number breakpoints.  
Chapter 5 describes the genomic characterization of the few pHGG models commonly used 
for the study of this disease. The structural rearrangements present in KNS42, SF188 and 
UW479 are described and validated using different techniques.  
Chapter 6 reports a rearrangement found in SF188, RPTOR:TULP4. This fusion gene is 
described, validated and further screened in a series of paediatric and adult HGG.   
Chapter 7, the final chapter, discusses the major findings reported in this thesis, supported 
by the most up-to-date literature in pHGG and structural rearrangements. 
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1. INTRODUCTION 
1.1. Incidence and general overview  
Cancer is the third leading cause of death in the world and the first in economically 
developed countries [1, 2]. Worldwide, based on GLOBOCAN 2012, approximately 14.1 
million new cases of cancer and nearly 8.2 million cancer-related deaths are estimated to 
have occurred within the space of 12 months (excluding non-melanoma skin cancer) [2-4].  
Regarding the paediatric population, cancer is the leading cause of death by disease in the 
United States [5]. Approximately 14,276 new cases of paediatric cancers were diagnosed in 
children between 0–19 years in 2010, with nearly 2000 deaths estimated to occur [6].  In the 
UK, between 2006-2008, approximately 850 children and young adults (0-24 years) were 
newly diagnosed with cancer [7]. Despite an overall improvement in survival of both 
paediatric and adult tumours, some cancers have had no changes in decades.  
1.1.1. Histological classification and clinical features of central nervous system 
tumours 
Brain tumours are classified according to The World Health Organization (WHO) criteria, 
according to the morphological resemblance to the differentiated cells in the brain, 
cytoarchitecture and immunohistological marker profile [8, 9]. In addition to a morphological 
grouping, the WHO classification system also clusters tumours according to its grade – I, II, 
III and IV, in ascending order of malignancy. Higher grade tumours (grade III and IV) have a 
worst clinical outcome and are histologically characterized by the presence of nuclear atypia, 
increased proliferation, microvascular proliferation and necrosis. Lower grade tumours 
(grade I and II) have low proliferative potential and the possibility of cure after surgical 
resection [8, 9]. This thesis will focus on high grade tumours of glial origin, astrocytomas 
(grade III), oligodendroglioma (grade III and IV) and glioblastoma (GBM) (grade IV) in the 
paediatric setting (Figure 1.1). 
High grade gliomas (HGG) are histologically characterized by microvascular proliferation, 
cellular atypia, elevated mitotic activity and high cell density (Figure 1.2). The grade IV 
glioma, also known as GBM (previously multiforme, GBM), is the most aggressive variant of 
diffuse glioma with a very poor prognosis of approximately 1 year, which may be extended 
by a few months using surgery and radiochemotherapy [10, 11]. These lesions show 
increased vascular endothelial proliferation, necrosis as well as a very high cell density and 
morphological atypia (Figure 1.2C). Mostly it occurs de novo – primary GBM – but it can also 
evolve from a preceding low-grade lesion, described as secondary GBM. 
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Figure 1.1. Overview of histological subtypes of glial brain tumours and WHO grading based on the 
2007 WHO classification [8, 9]. Highlighted in grey are the tumours studied in this thesis. 
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Despite their distinct clinical histories, they are morphologically and clinically 
indistinguishable [12, 13]. Secondary GBMs occur less frequently (~5% of GBMs) and 
predominantly in younger patients (median age ~45 years vs ~60 years for primary GBMs).  
Despite the many differences between the adult and paediatric population, the WHO 
classification does not make a distinction for a specific diagnosis based on the patient’s age. 
 
Figure 1.2. Schematic showing the classification of diffuse gliomas of astrocytic and oligodendroglial 
lineages. Representative micrographs for each tumour (anaplastic astrocytoma (A), anaplastic 
oligondendroglioma (B) and glioblastoma (C)) class studied in this thesis are given.    
 
In the central nervous system (CNS) it is a common idea that a sequential differentiation 
takes place, starting with stem cells that give rise to progenitor cells that finally progress to 
fully differentiated cells. In the normal brain the CNS stem cell gives rise to neuronal and 
glial progenitors, which subsequently give rise to the mature cell types found in the brain, 
including neurons, oligodendrocytes and astrocytes [14]. Brain tumours may have its origin 
from either these CNS stem cells or their immediate downstream more proliferative 
progenitors (glial or neuronal), but the precise cell of origin remains largely unknown [15, 16]. 
It is generally believed that astrocytomas arise from astrocytic precursors, whereas 
oligodendrogliomas arise from oligodendrocytic, and that mixed gliomas arise from both 
progenitors (Figure 1.3). Interestingly, all of these cell types can give rise to glioma if 
genetically modified and even mature neurons and astrocytes can also generate malignant 
gliomas [17]. 
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Figure 1.3. The neuroglial lineage tree. Committed glial progenitors, previously produced by self-
renewing, common progenitors eventually differentiate into mature astrocytes and oligodendrocytes. 
Dashed arrows indicate a selection of likely candidates as cell of origin for each glioma variant [15]. 
1.1.2. Malignant glioma epidemiology 
The annual age-adjusted worldwide incidence of primary brain and CNS tumours is 3.4 per 
100,000 people with a mortality rate of more than two-thirds (2.5 per 100,000 people per 
year) [3, 4]. The incidence and mortality rates are different between men and women, with 
both rates being higher in men (3.9 vs 3.0 per 100,000 people and 3.0 vs 2.1 per 100,000 
people, respectively) [3, 4]. In the paediatric population, there is a slight incidence difference 
between male and female, with a higher rate in male (1.2 vs 1.0 per 100 000 people per 
year). The mortality rate for both males and females is approximately 0.5-0.6 per 100 0000 
per year [3, 4] . 
In the paediatric population the world annual incidence of brain and CNS neoplasia is lower 
than in adults with a rate of 1.1 per 100,000 people per year [3, 4]. Nevertheless brain and 
CNS tumours are the second most frequent malignancy in children, just after leukaemia. 
These tumours account for 24.5% of all tumours in those 0–14 years of age and 8.9% in 
those 15–24 years of age [18]. More importantly, CNS tumours are the most common cause 
of cancer-related deaths in both the 0-14 year and the 15-24 year age group.   
The majority of CNS tumours in all age groups are gliomas. There is an increased incidence 
of malignant glioma with increasing age (Table 1.1), with low grade glioma (LGG) being 
more common in children, whereas HGG is more common in adults [19]. Tumour location is 
one of the key differences between adult HGG (aHGG) and paediatric HGG (pHGG). While 
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Table 1.1. Rate (95%CI) of malignant glioma per 100.000 person/years. 
Age range  
(years) 
AA AO GBM 
Glioma Malignant,  
NOS 
0-4 0.05 (0.04-0.07) NR 0.09 (0.07-0.11) 0.86 (0.81-0.92) 
5-9 0.08 (0.07-0.10) NR 0.14 (0.12-0.17) 0.8 (0.75-0.87) 
10-14 0.09 (0.07-0.11) NR 0.16 (0.14-0.19) 0.43 (0.39-0.47) 
15-19 0.09 (0.08-0.11) 0.02 (0.02-0.04) 0.17 (0.14-0.19) 0.24 (0.22-0.28) 
0-14 0.08 (0.07-0.09) 0.01 (0.01-0.01) 0.13 (0.12-0.15) 0.70 (0.67-0.73) 
0-19 0.08 (0.07-0.09) 0.01 (0.01-0.01) 0.14 (0.13-0.15) 0.58 (0.56-0.61) 
20-34 0.26 (0.24-0.28) 0.09 (0.08-0.10) 0.39 (0.37-0.41) 0.23 (0.22-0.25) 
35-44 0.35 (0.33-0.38) 0.17 (0.15-0.19) 1.21 (1.16-1.25) 0.24 (0.22-0.26) 
45-54 0.43 (0.41-0.46) 0.18 (0.17-0.20) 3.66 (3.58-3.74) 0.28 (0.25-0.30) 
55-64 0.67 (0.63-0.71) 0.22 (0.20-0.25) 8.16 (8.02-8.30) 0.39 (0.36-0.42) 
65-74 0.92 (0.86-0.98) 0.19 (0.17-0.22) 13.21 (12.98-13.45) 0.68 (0.63-0.73) 
75-84 0.96 (0.88-1.04) 0.14 (0.11-0.17) 14.64 (14.34-14.94) 1.22 (1.14-1.31) 
85+ 0.40 (0.33-0.48) NR 8.96 (8.59-9.33) 1.55 (1.40-1.71) 
Data from Therese A. Dolecek et al, Neuro-Oncology, 2012 CBRTU, age-adjusted to the 2000 US. 
standard population. Abbreviations: NOS, not otherwise specified; NR, not reported; AA: Anaplastic 
Astrocytoma; AO: Anaplastic Oligodendroglioma; GBM: Glioblastoma 
in adults tumours occur mainly in the supratentorial regions of the brain (cerebral 
hemispheres and midline structures above the tentorium), in children the infratentorial region 
(brainstem and cerebellum) is more commonly affected (Figure 1.4) [20, 21]. Infratentorial 
malignant gliomas of the brainstem represent 10% of pHGG and 80% of these are 
characterized as diffuse intrinsic pontine gliomas (DIPG) [22]. Supratentorial HGG occur 
more frequently in young children than in adolescents or adults. The malignant gliomas that 
arise in the thalamus represent 12% of pHGG and are more common in children than adults 
[23, 24]. Less commonly, malignant glioma arises in the spine with an incidence of 3% in 
both adults and children [25].  
The majority of HGG symptoms are common to the paediatric and adult populations. The 
patients normally present focal neurological deficits, cognitive decline, seizures, and 
symptoms of increased intracranial pressure, such as headaches, drowsiness, confusion, 
nausea and vomiting [26]. These symptoms can occur at any stage of the disease and they 
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Figure 1.4. Representation of different anatomical regions of the brain. The cerebrum corresponds to 
the supratentorial region (above the tentorium cerebelli) of the brain and comprises the cerebral 
cortex (the left and right cerebral hemispheres), as well as several subcortical structures, including the 
hippocampus, basal ganglia, and olfactory bulb. The brainstem is part of the infratentorial region 
(below the tentorium cerebelli) of the brain and it includes the medulla oblongata, pons, and midbrain.  
depend on the location and growth rate of the tumour. A rapidly growing and/or more 
aggressive tumour normally present symptoms that arise suddenly. On the other hand, a 
more prolonged clinical history possibly represents a slow growing, low grade tumour. 
Moreover, infants (>3 years) may also present with head enlargement, due to an incomplete 
fused skull [26, 27].  
pHGG has always been a biologically understudied cancer when compared with aHGG, 
despite being one of the leading causes of cancer-related deaths in children, representing 
15-20% of all childhood tumours of the CNS. Like in adults, even with aggressive multimodal 
therapy, children with GBM have a poor clinical outcome, with a current two-year survival 
rate of 10-15% [28].   
1.1.3. Current therapy for paediatric high grade glioma 
The initial treatment for a child with a newly diagnosed HGG is to attempt a maximal safe 
surgical resection [29, 30]. The ultimate goal of surgery is to obtain a complete resection 
without postoperative complications, however, even when a complete clear radiographic 
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scan is achieved, it is understood that microscopic tumour cells are still present due to the 
infiltrative nature of these lesions [30]. Sometimes a complete resection is not feasible due to 
tumour location (eg. brainstem HGG), in which case a biopsy might be performed. Additional 
treatments are normally required, including chemotherapy, radiation therapy or a 
combination of both in order to minimise the high likelihood of local recurrence [29, 30]. 
Radiotherapy was the first adjuvant therapy that improved survival in aHGG, and it also 
become the mainstay of therapy for children, especially for children older than 3 years old 
with newly diagnosed HGG [30]. Normally, the conventional dosing for a child is 50-60 Gy 
delivered in daily fractions of approximately 180-200 cGy over a 6 week period [31].  Based 
on strong research evidence [32], it has been shown that a combination of chemotherapy 
and radiotherapy brings benefits to children with newly diagnosed HGG. Since the CCG-943 
trial, the addition of chemotherapy to radiotherapy has been adopted by many as the 
accepted standard of care for these patients. In this trial, patients were randomized to 
receive either radiotherapy alone versus radiotherapy followed by prednisone, lomustine and 
vincristine (PCV) chemotherapy. Five-year event free survival was 46% in the chemotherapy 
treated group versus 18% in the radiation alone group, showing a significant survival 
advantage [33]. The immediate successor to CCG-943 was the CCC-945 trial, in which an 
additional chemotherapy arm was added to PCV (PCV in combination with eight agents: 
prednisone, lomustine, vincristine, hydroxyurea, cisplatin, cytarabine, dacarbazine, and 
procarbazine). There was no statistical difference between the two arms and the outcomes 
were worse as compared to the previous CCG-943 study [34], although a subsequent 
central pathology review revealed that many patients enrolled in the CCG-943 and CCG-945 
included LGG [35]. 
In 1995, Stupp and colleagues demonstrated that the addition of temozolomide (TMZ), an 
oral alkylating agent, to GBM treatment in adult patients gave meaningful significant survival 
benefit with minimal additional toxicity as compared to radiation alone [36]. The TMZ clinical 
trial in children with HGG by contrast showed no survival benefits when compared with 
control [37]. The Stupp protocol is nevertheless, due to TMZ tolerability and ease of 
administration, still used by many clinicians to treat newly diagnosed patients who are not 
enrolled on a clinical trial [30].  
The increased understanding of signalling pathways involved in the initiation of malignant 
gliomas led to the development of novel targeted therapies, such as compounds directed 
against a variety of receptor tyrosine kinases (RTKs) (eg. erlotinib, gefinitnib, cetuximab) and 
anti-angiogenic drugs (bevacizumab and cediranib).  
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Table 1.2. A summary of targeted therapies in adult and paediatric malignant glioma, including pontine 
glioma. Adapted from [38]. 
Agent Tumour OR (%) 
Median PFS  
(months) 
6-month  
PFS (%) 
Comments 
EGFR 
     
Erlotinib aHGG  0–25 1.8–5.2 0–19 Recurrent or relapsed 
 pHGG 0 1.5 34 Recurrent or relapsed 
 DIPG 17 8 90 
Newly diagnosed with 
radiotherapy 
Gefitinib aHGG  0–18 2.0–6.8 9–62 Recurrent or relapsed 
 pHGG 0 NR 15* Recurrent or relapsed 
 DIPG 14 7.4 88 
Newly diagnosed with 
radiotherapy 
Nimotuzumab aHGG  NS NS NS NS 
 pHGG 4 1.8 NR Recurrent or relapsed 
 DIPG 10 5.5 NR 
Newly diagnosed with 
radiotherapy 
PDGFR 
     
Imatinib aHGG  0–18 1.8–9.5 3–52 Recurrent or relapsed 
 pHGG 0 NR 18 Recurrent or relapsed 
 DIPG 3 NR 70 
Newly diagnosed with 
radiotherapy 
VEGFR/EGFR 
Vandetanib aHGG  16 NR  NR  Recurrent or relapsed 
 pHGG NS NS NS NS 
 DIPG NR NR 88 
Newly diagnosed with 
radiotherapy 
VEGF 
Bevacizumab aHGG  20–26 4–4.2 20–36 Recurrent or relapsed 
 pHGG 0 4.5 42 
Recurrent or relapsed  with 
irinotecan 
 DIPG 0 2.5 10 
Recurrent or relapsed with 
irinotecan 
mTOR 
Temsirolimus aHGG 0–7 2.3 2–8 Recurrent or relapsed  
 pHGG 0 1.9 NR Recurrent or relapsed 
 DIPG 0 2.5 NR Recurrent or relapsed 
Farnesyltransferase 
Tipifarnib aHGG 6 2 11 Recurrent or relapsed 
 pHGG NS NS NS NS 
 DIPG NR NR 44 
Newly diagnosed with 
radiotherapy 
*1-year PFS.  Abbreviations: aHGG, adult high-grade glioma; DIPG, diffuse intrinsic pontine glioma; 
pHGG, paediatric high-grade glioma; NR, not reported; NS, not studied; OR, objective response; PFS, 
progression-free survival. 
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Unfortunately to date, these have not been shown to provide significant survival benefit 
when used alone or in combination with other therapies (Table 1.2) [39]. Despite combined 
surgery, chemotherapy, and radiation treatments, a significant proportion of children will still 
have progressive or recurrent disease. 
1.2. Molecular biology of high grade glioma 
The biology of HGG in children and young adolescents was for a long time woefully 
understudied, in part due to limited number of paediatric samples and the belief that this 
disease was likely identical to aHGG. In the last few years large scale genomic profiling 
studies have helped to elucidate a clearer biological picture of pHGG and provided a deeper 
insight into gliomagenesis across all age groups. With the help of exome and whole genome 
sequencing (WGS) the genetic alterations underpinning pHGG are starting to be revealed.  
1.2.1. Molecular profile of pHGG  
Gene expression 
In terms of gene expression signatures, in 2006 Philips and colleagues proposed for the first 
time the clustering of adult GBMs into three groups, designated Proneural, Mesenchymal 
and Proliferative. Both Mesenchymal and Proliferative types showed the most pronounced 
expression of stem-cell-related genes, similar chromosomal losses on chromosome 10 and 
gains on chromosome 7, with worse survival compared with the Proneural subtype.  
Later, Verhaak and colleagues studying The Cancer Genome Atlas (TCGA) dataset 
proposed the existence of four subtypes instead of three [40, 41], described as Proneural, 
Neural, Classical and Mesenchymal. In the Classical subtype the vast majority of GBMs 
present chromosome 7 amplification paired with chromosome 10 loss, along with high rates 
of EGFR (epidermal growth factor receptor) alterations (amplification and mutation) and Rb 
(retinoblastoma protein) pathway disruption, mediated in part by CDKN2A (cyclin-dependent 
kinase inhibitor 2A) homozygous deletion and other alterations on RB1, CDK4 (cyclin-
dependent kinase 4) and CCND2 (cyclin D2) genes, but no TP53 (tumour protein p53) 
mutations were found [41, 42]. The Neural subclass included tumours that contain mutations 
and deoxyribonucleic acid (DNA) copy number aberrations (CNA) but surprisingly their 
expression patterns are the most similar to normal brain tumours. These tumours express 
neuronal markers, such as NEFL (neurofilament light polypeptide), GABRA1 (gamma-
aminobutyric acid A receptor, alpha 1) and SLC12A5 (solute carrier family 12 member 5) 
[41]. In the Mesenchymal subtype focal NF1 (neurofibromin 1) hemizygous deletions were 
the most common event. CNAs were described for EGFR and MET (mesenchymal epithelial 
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transition factor receptor), together with a high expression of CH13L1 (chitinase-3-like-1) and 
MET. The Proneural subset is associated with a younger age and expression of genes 
typical of an oligodendrocytic lineage, including PDGFRA (platelet-derived growth factor 
receptor), NKX2-2 (NK2 homeobox 2) and OLIG2 (oligodendrocyte lineage transcription 
factor 2), and also presented point mutations in IDH1 (isocitrate dehydrogenase 1) gene, 
which have been previously associated with secondary GBM [43-45]. The Proneural group 
was further subdivided into glioma-CpG island methylator phenotype (G-CIMP)-positive and 
G-CIMP negative [46], with a subset of samples showing robust hyperrmethylation at a large 
number of loci, which correlated strongly with the presence of IDH1 mutations. When 
comparing the Philips versus the Noushmer classification schemes, it appears that the 
Proneural and the Mesenchymal signatures are the most robustly defined. Putative drivers of 
mesenchymal transformation have been recently identified, including CTNND2 (encoding 
catenin-δ) as a negative driver and RHPN2 (Rho GTPase binding protein 2) as a positive 
driver [47, 48]. Moreover, three transcription factors, STAT3 (signal transducer and activator 
of transcription 3), C/EBPβ (CCTA/enhancer-binding protein-β) and TAZ (transcriptional co-
activator with PDZ-binding motif), have recently emerged as epigenetic master regulators of 
the mesenchymal subgroup and can be used to predict poor clinical outcome [49, 50]. In 
addition, a study by Brennan and colleagues [51] measured the relative protein levels of 
signalling molecules within pathways crucial to glioma biology [42], a targeted proteomic 
analysis which showed some overlap with the genomic GBM subclasses previously 
described. Three distinct patterns were each associated with EGFR activation, PDGF 
activation or NF1 silencing, which correspond to the Classical-Neural, Proneural and 
Mesenchymal groups. The EGFR group has elevated expression of Notch ligands, leading 
to Notch pathway activation. The high levels of PDGFB ligand and PDGFRB phosphorylation 
characterize the PDGF subclass. The NF1 group is associated with low levels of NF1 and 
suppressed levels of PI3K (phosphatidylinositol-4, 5-bisphosphate 3-kinase) and MAPK 
(mitogen-activated protein kinase) pathways proteins [51].  
Physiologic miRNA activity has been shown to also play an important role in gliomagenesis, 
through the regulation of genes involved in proliferation, apoptosis, migration, angiogenesis 
and aspects of stem cell biology.  A recent study by Sumazin and colleagues showed that 
drivers of tumour initiation and different GBM subtypes, like PTEN (phosphatase and tensin 
homolog), PDGFRA, RB1 and VEGFA (vascular endothelial growth factor A), are regulated 
by a distinct set of miRNAs [52].  
The first gene expression profiling studies of pHGG underlined both the similarities and 
differences of these tumours when compared with aHGG. A study by Paugh et al used gene 
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expression profiles to distinguish different subgroups of pHGG, identifying three main groups 
– HC1, HC2 and HC3 [53]. The HC1 subgroup showed overexpression of genes associated 
with cell cycle regulation; overexpression of neuronal differentiation genes was seen in HC2 
group and finally the HC3 group overexpressed genes related to cellular matrix-receptor 
interactions and cell adhesion. Using a gene set enrichment analysis, they showed that 
these three paediatric subgroups seem to overlap with the subgroups previously identified in 
aHGG - Proliferative, Proneural and Mesenchymal [54]. Significantly, 88% of PDGFR 
(platelet-derived growth factor receptor) driven tumours clustered into the Proliferative/HC1 
subclass, showing that this pathway is a strong driver of proliferation in pHGG, and distinct 
to the strong PDGFRA/IDH1/Proneural associations observed in aHGG. Gain of 1q was 
found at high frequency both in Proliferative/HC1 and Proneural/HC2 subgroup, but highly 
underrepresented in the Mesenchymal/HC3 subclass. In addition, the Verhaak et al [41] 
Proneural subgroup, as well as being associated with PDGFRA, is closely correlated with 
IDH1 mutations, a genotype largely absent from the Paugh et al data . Furthermore, the 
PDGFRA-driven gene expression signature in pHGG is different from that seen in aHGG, 
which is associated with cell-cycle regulators and genes associated with proliferation . 
Hence, pHGG are preferentially and differentially driven by PDGFRA amplification, in 
contrast to EGFR in adult tumours. 
Copy Number aberrations 
Some of the most common chromosomal aberrations found in aHGG are also described in 
pHGG but at significantly lower frequency. Chromosome 7 gain (74-83%) together with 10q 
loss (80-86%) is by far the most commonly described abnormality in adult GBM [55, 56]. In 
the paediatric setting these are far less common (13-19%, 16-38%, respectively) (Table 1.3) 
[55, 56]. Tumours with 7+/10- are highly enriched in the Classic adult subclass but are less 
common in the Proneural subtype, and completely absent in the IDH-mutant G-CIMP 
positive tumours [41, 46, 54, 57]. In addition, aHGG have also consistently, though at lower 
frequency, revealed gains of chromosomes 19 and 20, and losses of 9p, 22q, 13q, 14q and 
6q [55, 56] (Table 1.3). Paediatric tumours normally display gain of 1q (19-20%) and, to a 
lesser extent, losses of 16q (7-18%) and 4q (2-15%) [38]. On average, childhood HGG 
harbour considerably fewer DNA copy number alterations than their adult counterparts, with 
~15% of these tumours lacking any detectable CNAs  [38, 57-59]                         
 
. 
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Table 1.3. Location-specific and age specific genetic differences in malignant glioma. Adapted from 
[38, 60]. 
Genetic Abnormality DIPG* HGG# 
  
Infant Child  Adolescent Young adults Adults 
   <3ys 3-14ys 14-21ys 21-44ys >45ys 
Gain of 1 q ++ ++ ++ ++ + - 
Loss of 16q + ++ ++ ++ - - 
Stable Genome - ++ ++ ++ - - 
Gain of 7 + - - - ++ +++ 
Loss of 10q ++ + + + ++ +++ 
EGFR Amp + - + + ++ +++ 
PDGFRA Amp +++ - ++ ++ ++ + 
CDKN2A/2B Del - + ++ ++ +++ +++ 
p53 pathway Alt +++ +++ ++ ++ ++ ++ 
PI3K pathway Alt ++ + ++ ++ ++ +++ 
Rb pathway Alt ++ + + + ++ +++ 
BRAF V600E - - + ++ + - 
IDH1 R132X - - - + +++ + 
H3F3A K27M +++ NR +++ ++ + - 
H3F3A G34R/V - NR + ++ + - 
HIST1H3B K27M ++ NR - - - - 
ACVR1 mutation ++ - - - - - 
NTRK SV + ++ + NR NR NR 
*Peak age 4-9years. Grade not specified; infratentorially located. #Supratentorially located. 
Abbreviations: - low; + moderate; ++ high; +++ very high; DIPG, diffuse intrinsic pontine glioma; 
HGG, high grade glioma; NR, not reported; ys, years; Amp, amplification; Del, deletion; Alt, 
alterations 
A study by Bax et al distinguished four different subclasses based on the pattern of different 
genomic profiles of paediatric GBM, described as Stable, Aneuploid, Rearranged or  
Amplifier genomes [59]. The Stable genome group has few, low level, focal changes, it 
occurs in 20.6% of cases and it is independent of histological grade or type, but seems to 
convey an improved survival in patients with HGG. This group appears to be unique to the 
paediatric setting. In contrast, the Aneuploid group comprises tumours with large, single 
copy alterations involving whole chromosomes or chromosomal arms, occurring in 34.9% of 
cases. The Rearranged group includes tumours with numerous, low level, intra-
chromosomal breaks resulting in multiple gains and losses. Finally, tumours with single or 
multiple high level amplification were part of the Amplifier group, that had a significantly 
worse clinical outcome.  
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In 2008, high-throughput molecular profiling studies of aHGG lead to the identification of 
three major intracellular signalling pathways which are commonly targeted by genetic 
alterations.  Later in 2013, TCGA initiative expanded the scope and depth of molecular data 
on GBM, incorporating next generation datasets available [56].  These studies showed that 
GBM has deregulation of growth factor signalling via amplifications and mutations of the 
RTK genes and the activation of the PI3K pathway; inactivation of the p53 pathway, often via 
direct mutation; and dysregulation of Rb tumour suppressor pathways via 
activation/inactivation of enhancers/repressors (Figure 1.5) [42, 44, 61]. Combining copy 
number and sequencing data, 79%, 86% and 90% of 251 samples harboured somatic 
alterations in core components of the RB, TP53 and RTK pathways [42, 56]. Contrary to 
adult GBM, alterations of the three core signalling pathways of HGG is seen in significantly 
lower frequency in children GBM: 25% RTK/PI3K, 19% p53 and 22% RB [59], at least at the 
copy number level. Genomic amplification of the EGFR gene is the most frequent genetic 
alteration in aHGG (>40%) but it is rarely seen in children HGG (0-11%) [38, 44, 55]. On the 
other hand, focal amplification at 4q12 encompassing the PDGFRA gene is the one focal 
alteration which is more commonly observed in children with HGG [58, 59]. PDGFRA is the 
most common event in paediatric setting and it leads to PDGFR signalling activation which is 
augmented by rare findings of PDGFA, PDGFB, and PDGFRB gain or amplification [38, 58, 
59, 62]. Several studies have also suggested that PDGFRA is the key oncogenic event in 
DIPG and that this alteration is more commonly observed in radiation-induced gliomas [58]. 
Additionally, aHGG also harbour CDKN2A and CDKN2B deletions in 53% of cases, yet 
these events are rarely seen in pHGG [56]. The G1 checkpoint regulators CCND1, CCND2, 
CCND3, CDK4 and CDK6 are predominantly amplified in DIPGs, whereas CDKN2A 
homozygous deletions are restricted to supratentorial pHGG [63]. Other genes that are less 
frequently targeted by homozygous deletion in adult GBM (1-10%) include PTEN, RB1, 
CDKN2C, FAF1 (FAS-associated factor 1), QKI (QKI KH domain containing), NF1, NPAS3 
(neuronal PAS domain protein 3) and TP53 [60]. Focal amplification of PDGFRA, MDM2 
(mouse double minute 2 homolog), MDM4, MET often co-occur in various combinations in 
aHGG (1.5-13%) [56]. Nevertheless, amplification of genes such as MYC (v-myc 
myelocytomatosis viral oncogene homolog), MYCN (v-myc myelocytomatosis viral oncogene 
homolog, neuroblastoma derived) and KRAS (vi-Ki-ras Kirsten rat sarcoma viral oncogene 
homolog) and deletion of CDKN2C occur at low frequencies in pHGG [38, 58, 59, 64]. 
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Figure 1.5. Landscape of core signalling pathway alterations in glioblastoma. Adapted from [56] 
Gene Mutations 
The most recent studies in both paediatric and aHGG aimed at full genome-wide 
characterization have led to the identification of novel recurrent mutations in both diseases. 
The availability of increasing number of samples for genome sequencing has now facilitated 
the detection of lower frequency events in well-known cancer genes and genes that were 
previously not associated with cancer.  The number of coding mutations per tumour sample 
is highly variable in the adult population (3-179) and considerably lower in the paediatric 
setting (15 per tumour sample) [56, 60, 65].  
pHGG present similar frequencies of TP53 mutations as aHGG (34-37% vs 20-29%, 
respectively) [60]. However, HGGs arising in infants (<3 years) have a better prognosis and 
a lower frequency (9%) of TP53 alterations [66], and in contrast, DIPGs present a higher 
frequency of these mutations (42-50%) [63, 67, 68]. Frequent somatic mutations are also 
found in NF1 (25%), similar to that of aHGG, and both PDGFRA (8%) and EGFR (4%) are 
also mutated in pHGG [63]. The frequent mutations observed in IDH1 and IDH2 in 
secondary adult GBM, can only be found in 8.6% of pHGG cases, and are restricted to 
patients >13 years of age [38]. 
The single most important mutations found in pHGG which clearly distinguish these tumours 
from their adult counterparts are the recently discovered histone H3 mutations [65, 69]. 
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These mutations occur on the histone tail, at or near important modification sites, are 
restricted to ~38% of childhood and young adults (<30 years) HGGs [60] and are mutually 
exclusive with recurrent point mutations in IDH1 [69]. Heterozygous mutations in H3F3A (H3 
histone, family 3A) result in amino acid substitutions at positions K27 and G34. Additionally, 
K27 is also found to be mutated in the H3.1 histone genes HIST1H3B (histone cluster 1, 
H3b) and HIST1H3C [65, 70]. The H3F3A p.27 lysine-to-methionine substitution occurs in 
midline GBM and DIPG cases in younger children (70-88% cases [65, 67]), though the same 
substitution in HIST1H3B is specific to DIPG and it occurs at lower frequency (11-31%). 
Moreover, recurrent activating mutations in the ACVR1 (activin A receptor, type I) gene were 
exclusively found in DIPG, and were strongly associated with younger age, longer survival 
time and the presence of HIST1H3B p.Lys27Met as well as wild-type TP53 [63, 67]. The 
K27M mutation confers a reduction of the global trimethylation at this site (downregulation of 
the repressive mark), which dramatically alters gene expression leading to overexpression of 
PRC2 (polycomb repressive complex 2) target genes [71]. H3F3A p.Glycine-to-
Arginine/Valine at residue 34 occurs in adolescents which present supratentorial HGG. This 
mutation interferes with the regulation of H3K36me3 active mark, but contrary to H3K27M 
does not lead to a global downregulation of the trimethylation at this residue [72]. A study by 
Bjerke et al [72] showed that in a G34V mutant paediatric GBM cell line (KNS42) MYCN is 
the gene that is most strongly enriched for H3K36me3 marks, and is also associated with 
transcriptional upregulation of this locus. Furthermore, the H3K36 trimethyltransferase 
SETD2 (SET domain containing 2) is also mutated in children and young adults, and these 
mutations are mutually exclusive with H3F3A G34 mutations [73], which may be an 
alternative mechanism to deregulate the active mark. Moreover, it has been shown by Li and 
colleagues that SETD2 downregulation, followed by depletion of H3K36me3 leads to an 
increased spontaneous mutation frequency and chromosomal depletion [74]. In addition, the 
G34 tumours also harbour mutations in H3.3 chaperone complex ATRX/DAXX (alpha 
thalassemia/mental retardation syndrome X-linked / death-domain associated protein), which 
is responsible for depositing the histone H3 at telomeres, pericentric heterochromatin and 
actively transcribed regions. The mutations in ATRX and DAXX contribute to the ALT 
(alternative lengthening telomeres) phenotype commonly seen in pGBM, which maintains or 
increases telomere length [69] in the absence of TERT promoter mutations. In addition, 
these tumours normally present a pattern of hypomethylation [57, 69]. 
In addition to recurrent histone H3, ATRX/DAXX and SETD2 mutations, frequent mutations 
in other histone writers and erasers and in chromatin-remodelling genes have also been 
recently described (eg. MLL, KDM5C, KDM3A, JMJD1C) [63]. These mutations are often 
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concurrent with the mutations in H3 genes, with 91% of DIPG and 48% of hemispheric  HGG 
containing mutations in histone genes and/or this group of epigenetic regulators [63].  
1.3. Somatic structural variation in cancer 
Cancer is a genetic disease that occurs at the cellular level with two dominating types of 
initiating events: the inactivation of genes by deletion, mutation or epigenetic mechanisms, 
and the activation or deregulation of genes as a consequence of point mutation, 
amplification or cytogenetic abnormality [75]. These events occur gradually and cumulatively 
in a cell, enhancing a cell’s evolutionary fitness, promoting outgrowth and progression 
towards cancer [76, 77]. One of the most difficult forms of genetic variation to interpret with 
respect to functional consequences are structural variants (SV). These may involve equal 
exchange of material between two chromosomal regions – balanced rearrangements – or 
lead to loss or gain of portions of the genome – unbalanced rearrangements (leading to copy 
number variation). Balanced rearrangements include inversions and reciprocal 
translocations; unbalanced rearrangements include deletions, duplications, insertions, 
amplifications and non-reciprocal translocations [78] (Figure 1.6). SVs are commonly 
classified as sequence variants of at least 50 base pairs (bp) in size, therefore discriminating 
them from smaller variants, such as single-nucleotide variants (SNV) and short insertions 
and deletions (indels) [79, 80].  Furthermore, it has been hypothesized that the primary 
pathogenic changes in cancer result from balanced rearrangements, while the secondary 
changes that occur during cancer progression are from unbalanced changes [81]. The early 
chromosomal alterations give the cell a proliferative advantage, and alter the normal cellular 
environment by disrupting proto-oncogenes and tumour suppressor genes, leading to 
additional changes in the genome. The importance of chromosomal aberrations in tumour 
development varies substantially between and within tumour types; some undergo marked 
genome rearrangement, whereas others may evolve by alternative mechanisms [54, 59, 82]. 
The number of aberrations is normally small in pre-malignant, hyperproliferative lesions and 
substantially greater in more advanced tumours. Among these rearrangements, balanced 
chromosomal translocations are considered as the primary cause for many cancers like 
lymphoma, leukaemia and some solid tumours [75, 83, 84]. 
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Figure 1.6. Structural variants: classes and formation mechanisms. A) Structural variants comprise 
unbalanced copy-number variation (a), insertions (b) and duplications (c), as well as balanced 
variants such as inversions (d) and translocations (e). B) Molecular mechanisms leading to structural 
variant formation a. Recurrent structural variants often result from non-allelic homologous 
recombination (NAHR) which involves recombination between long highly similar low-copy-number 
repeats (blue and orange segments). b. Novel genomic insertions can involve mobile element 
insertion of transposable elements by retrotransposition. c. DNA-replication-associated template-
switching events, involving the fork-stalling and template switching (FoSTeS) and microhomology-
mediated break-induced replication (MMBIR) mechanisms. d. Many structural variants in humans 
are attributed to non-homologous end joining (NHEJ) which is often accompanied by the addition or 
deletion of several nucleotides in the form of a ’repair-scar’ (small red bar). e. Chromothripsis —a 
phenomenon that involves chromosome shattering leading to numerous breakpoints, followed by 
error-prone DNA repair. Adapted from [79] 
1.3.1. Mechanisms of structural variation 
For a rearrangement to occur, several criteria need to be fulfilled. First, the sequences 
undergoing rearrangement need to be in close spatial proximity. Secondly, there needs to be 
a DNA break or a switch in the template strand used during DNA replication. Finally, some 
sequences are more prone to rearrangements owing to their structure and epigenetic 
modifications [85]. Double-strand DNA breaks (DSB) are known to play the essential role in 
the occurrence of SVs, irrespective of the origin and cell type, and are thought to be the pre-
requisite for any chromosomal aberration to occur, though the exact mechanism is mostly 
unclear. Mutagens of both internal and external origins continuously damage normal DNA 
causing these DSBs. Direct exposure to harmful exogenous agents, like ionizing radiation or 
drugs may cause DSBs, but they can also occur as a product of a normal aerobic 
metabolism which creates oxygen free radicals that damage DNA. There are also several 
cellular processes that generate and repair DSBs as part of normal programmed genomic 
rearrangements: V(D)J recombination and class switch recombination, both related to 
antibody  generation [83, 86]. 
Changes in the structure of chromosomes are repaired by two general mechanisms: 
homologous recombination and non-homologous recombination (Figure 1.6) [87]. A highly 
conserved non-homologous DNA repair pathway, Non-Homologous End Joining (NHEJ), 
repairs DSBs in the absence of extensive sequence homology and is often accompanied by 
the addition or deletion of several nucleotides in the form of a “repair scar” [79]. NHEJ events 
sometimes have some degree of microhomology (2-25 bp of similarity) at their breakpoints 
[88]. On the other hand, non-allelic homologous recombination (NAHR) involves 
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recombination of homologous sequences at regions of repetitive sequences on the genome, 
known as low-copy-repeats (LCRs) [87, 88]. Other mechanisms, such as fork stalling and 
template switching (FoSTeS) and microhomology-mediated break-induce replication 
(MMBIR) have also been proposed as mechanisms that lead to simple or complex SVs, 
frequently involving duplicative events [87, 88]. Moreover, Stephens and colleagues reported 
that there is another mechanism that leads to genetic instability, mutated, amplified and 
rearranged genes, a one-off cataclysmic event in which chromosomes are shattered and 
then stitched back together, a phenomenon termed chromothripsis [76]. Chromothripsis 
seems to be a rare event, only seen in 2-3% of all cancers and also in some congenital 
diseases [76, 89, 90] but it is significantly higher in adult GBM (>30%) and in pHGG (31%) 
[63, 91]. The DSBs caused by chromothripsis are repaired by NHEJ mechanism, and when 
these repair systems fail chromosomal aberrations occur [83, 92].  
1.3.2. Biological impact of structural variants 
The molecular consequences of SVs are relatively easy to predict when the variant involves 
entire genes – the expression of which is assumed to vary accordingly – or when the 
breakpoints of the rearrangements intersect with coding regions, hence leading to gene 
fusions or truncations. It is considerably more problematic when SVs occur kilobases (kb) 
upstream of genes and yet may still result in gene expression changes [87].  
1.3.3. Technologies for measurement of structural variation 
SVs have been thoroughly studied using a variety of methods. The first technique used  to 
reliably discriminate between chromosomes and identify translocations, inversions and 
CNVs larger than 5Mb was the Giemsa staining of condensed chromosomes (G-banding) 
[93]. The discovery of the Philadelphia chromosome in chronic myeloid leukaemia (CML) in 
1960 [94] was the first consistent chromosomal change to be seen in human cancer and it 
was discovered using G-banding [75].  Complementary to this low-resolution method, a 
targeted and more sensitive method was developed, FISH (fluorescent in situ hybridization). 
FISH allows the precise detection of abnormalities of a few hundred kb based on 
hybridization of fluorescently labelled probes to specific complementary sequences in the 
chromosome. When visualising FISH under the microscope, detection of deletions (missing 
signals), amplifications (extra signals) or translocations (relocated signals) is possible [93].  
The approach of identifying novel candidate fusions by 1) detecting a consistent 
chromosomal aberration using molecular cytogenetic techniques, 2) examining the SV at 
higher levels of resolution using appropriate molecular techniques until the gene fusion in 
question is finally identified, and finally 3) the sequence being determined and the case-to-
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case variability in terms of precise breakpoint sites being established has been used for 
several years [95, 96].  Though important, this approach is limited and these cytogenetic 
techniques do not allow the detection of small SVs. Nevertheless, the recent improvement in 
genome-wide techniques allowed us to identify the extent of CNVs and also to have a more 
complete measurement of SVs of all types [97].   
Microarray-based techniques – aCGH (array comparative genomic hybridization) and SNP 
array (single nucleotide polymorphism array) – were the first genome-wide survey of SVs in 
the human genome. The discovery of the BRAF (v-raf murine sarcoma viral oncogene 
homolog B) tandem duplication at chromosome 7q34 present in 66% pilocytic astrocytomas 
was first discovered using these microarray based techniques [98, 99]. In addition, due to its 
affordability, microarrays permitted a comprehensive picture of all CNVs across several 
types of tumours. However, the information that arrays can reveal about SVs is limited. They 
can only detect sequences that match the oligonucleotide probes used to make them, which 
lie in non-repetitive regions, making it difficult to detect SVs with breakpoints in repetitive 
regions, such as NAHR events or indels of repetitive sequences [88, 97, 100]. Furthermore, 
microarrays can only detect differences in number of copies, being blind to copy-neutral, or 
balanced variants, such as inversions or reciprocal translocations [88]. 
DNA sequencing technology has advanced dramatically and has allowed researchers to 
simultaneously infer information of both structural and single nucleotide variants. One 
strategy for genome-wide high-resolution identification of fusion genes and other large scale 
SVs is paired-end sequencing of genomic DNA or RNA from tumour samples or tumour-
derived cell lines [101]. First, the genome is precisely divided into fragments of known size 
(~500bp) and instead of sequencing the entire piece of DNA, reads are taken only from 
either end. The resulting paired reads are mapped back to the reference human genome 
sequence and if they do not match, then a genomic rearrangement is inferred [102]. 
Algorithms for detection of SVs from next generation sequence data normally rely on 
discordant paired-end reads or depth of coverage. Read-depth indicates how many copies 
are present of each gene and if a region is amplified it will show higher read depth, and if 
deleted, low read depth (less reads). Many algorithms, including Breakdancer and TopHat 
[103, 104] used to detect SVs rely on the presence of discordant paired reads. In the case of 
inter-chromosomal translocation, one member of the pair will map to one chromosome and 
its mate to another. When inversions or intra-chromosomal translocations occur, the two 
ends map to the same chromosome but in the wrong orientation or the wrong distance apart. 
These methods can normally detect the breakpoints but with low resolution and normally 
have low specificity, when one of the paired ends maps to a repetitive region or a high 
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homology region [105]. In addition, paired-end analysis methods rely on cut-offs to filter out 
false positives which are normally based on the number of supporting reads. In order to 
avoid the high-false positive rates inherent to most paired-end approaches, and to better 
localize the breakpoints, PCR-based validation followed by first generation sequencing 
(Sanger sequencing) is important.  
Current paired-end sequencing can obtain an extremely high probability of breakpoint 
detection with a very low number of reads. Array CGH can be used by itself to identify the 
breakpoints involved in deletions and amplifications, using algorithms to analyse CNAs, but 
when combined with next-generation end sequencing data, breakpoint resolution can 
improve even more. As the cost of next-generation end sequencing declines and its 
technology is improved, paired-end sequencing of cancer genomes (both tumour samples 
and cell lines) will provide reliable and precise detection of fusion genes [101, 106]. 
1.3.4. General overview of fusion genes in cancer 
Translocations are generally classified as reciprocal and non-reciprocal. Reciprocal 
translocations occur when segments between two chromosomes are exchanged. This can 
happen between any two chromosomes and at various sites along the length of the 
chromosome. Non-reciprocal translocations occur when a chromosomal segment is 
transferred to a non-homologous chromosome (one-way transfer). The juxtaposition of the 
coding region of a gene near the transcriptionally active promoter/enhancer region of 
another gene, leading to over-expression of the former gene, is a functionally important 
outcome of translocations. They can also result in the formation of a unique fusion or 
chimeric gene, which can be used as a marker for the malignant cells [83]. 
At present, more than 300 different fusion genes have been identified [75]. Fusion genes 
can be used as diagnostic markers and most importantly as specific therapeutic targets, 
leading to the development of successful cancer drugs [107]. Although gene fusions are 
typically associated with haematological malignancies, rare bone and soft-tissue tumours, 
they have been also described in solid tumours, namely in prostate, ovarian, brain and lung 
cancers [108-112]. The development of cutting edge technology for DNA sequencing that 
has been developed in the past few years has led to an enormous number of publications 
where novel and recurrent rearrangements are described in numerous different cancers. 
Up to 2007 (the latest review documenting fusion genes in cancer) 264 gene fusions, 
involving 238 different genes, had been identified in haematological disorders and these 
represented 75% of all fusion genes known in human neoplasia at the time [75]. The  first 
  24 
consistent chromosome change to be seen in human cancer was observed in CML in 1960 
[94]. The Philadelphia chromosome is the result of a reciprocal translocation, 
t(9;22)(q34.1;q11.23), in which a portion of the BCR (breakpoint cluster region) gene is 
joined to the cytoplasmic ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase) tyrosine 
kinase, generating a constitutively active enzyme. The resulting chimeric protein contains the 
catalytic domain of ABL fused to a domain of BCR that mediates constitutive oligomerization 
of the fusion protein in the absence of physiologic activating signals, thereby promoting 
aberrant tyrosine kinase activity [113]. This discovery lead to the development of the first 
small molecule inhibitor imatinib, which inhibits the fusion kinase activity [107, 114-116].  
Other well-known specific changes seen in practically 100% of a particular leukaemia or 
lymphoma type are the immunoglobulin heavy locus (IGH):CCND1 that occurs in mantle cell 
lymphoma, the MYC deregulation in Burkitt lymphoma and PML:RARA (promyelocytic 
leukaemia / retinoic acid receptor, alpha)  in acute promyelocytic leukaemia.  
Only more recently have fusion genes in other solid tumours started to be described as 
novel techniques have made such discoveries possible. Some of the first and most important 
of these have been identified in prostate cancer. Tomlins and colleagues described a fusion 
between the 5’ untranslated region of a prostate-specific and androgen-inducible gene, 
TMPRSS2 (transmembrane protease, serine 2) and the 3’ end region of different genes in 
the ETS (erythroblastosis virus E26 transformation-specific) family of transcription factors 
(eg. ERG, ETV1) [108]. The TMPRSS2:ERG fusion can occur either through inter-
chromosomal insertion or through deletion of the intervening region on chromosome 21 
(reviewed in [117]). This alteration has been observed in 50–60% of prostate tumours [118], 
and leads to increased cell migration [119] and proliferation [120], although the prognostic 
implications of TMPRSS2:ERG have not yet been fully elucidated. Currently, there is 
evidence that this fusion can be used as potential biomarker for prostate cancer, using non-
invasive screening techniques [117].  
Bone and soft tissue sarcomas, as in haematological malignancies, have gene fusions that 
occur more often in some subtypes than in others. There are 41 known gene fusions in 17 
different sarcoma types [75]. Close to 100% of Ewing sarcomas, myxoid liposarcomas and 
synovial sarcomas harbour chimeric genes EWSR1, DDIT3 and SSX1 (2 and 4), 
respectively [75].  
In 2007, a study to isolate novel transforming genes in non-small-cell lung cancer (NSCLC) 
reported the presence of a fusion gene that contains the N-terminal portion of the protein 
encoded by the echinoderm microtubule-associated protein-like 4 (EML4) gene and the 
intracellular signaling portion of the TK encoded by anaplastic lymphoma kinase (ALK) gene, 
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giving rise to a novel kinase that confers a proliferative advantage to cancer cells. Five out of 
75 (~7%) of patients with NSCLC were positive for this fusion, and were distinct from those 
harbouring EGFR mutations, another hallmark of this type of cancer [112]. In just 4 years 
since the discovery of this novel kinase, a new drug – Crizotinib – has been approved by the 
US Food and Drug Administration (FDA) [121]. Treatment of 82 patients with advanced ALK 
rearrangement-positive NSCLC resulted in tumour shrinkage in 57% of patients and 
stabilized disease in a further 33% [122].  
These results show that fusion genes are potential druggable alterations and they can help 
to distinguish different subtypes within the same disease.  
1.3.5. Gene fusions in brain tumours 
As recently as 2008, Jones and colleagues reported the first recurrent rearrangement in 
brain tumours [98, 99]. This involves a gene fusion involving the BRAF gene, a key 
component of the MAPK pathway, a commonly deregulated pathway in paediatric low grade 
astrocytomas. A KIAA1549–BRAF fusion was found in 80% of sporadic pilocytic 
astrocytomas [98, 99, 123], with the KIAA1549 gene replacing the auto-inhibitory domain of 
the RAF molecule, leading to constitutive activation of the kinase activity [98]. Recently, 
other fusion partners for BRAF have been described, including interstitial deletion of a ~2.5 
megabase (Mb) segment that leads to the fusion of BRAF gene with an uncharacterized 
gene located on 7q34, FAM131B. This deletion removes the BRAF N-terminal inhibitory 
domains, giving a constitutively active BRAF kinase [124]. BRAF and other family members 
(eg. RAF1) fusions have also been described in a small percentage of prostate and gastric 
cancer, and melanoma [125]. Furthermore, in 2013, Jinghui Zhang and colleagues 
sequenced 39 paediatric LGGs and reported the present of intragenic duplications of the 
portion of the FGFR1 (Fibroblast growth factor receptor 1) encoding the tyrosine kinase 
domain, as well as rearrangements of MYB (v-myb avian myeloblastosis viral oncogene 
homolog) which lead to activation of the same pathway as BRAF fusions [126].  
In HGG, to date only few fusions have been described in the literature. In 2003, Charest and 
colleagues described the first fusion gene found in an adult GBM cell line, an intra-
chromosomal homozygous deletion on chr6q21 that leads to the formation of FIG (Fused in 
GBM):ROS (c-ros oncogene 1, receptor tyrosine kinase) fusion, which displays a constitutive 
TK activity in the GBM cell line U118MG [127]. ROS is a proto-oncogene highly expressed in 
a variety of tumour cell lines, and belongs to a subfamily of T insulin receptor genes. The 
second fusion to be described in GBM involves genes LEO1 (Leo1, Paf1/RNA polymerase II 
complex component) and SLC12A1 (solute carrier family 12, member 1), but no further 
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studies have been done to explore the oncogenic characteristics of this fusion [128]. In 
addition, a study by Ozawa T. and colleagues described a fusion involving PDGFRA and the 
gene encoding for the vascular endothelial growth factor receptor – 2 (VEGFR-2) [129]. The 
resulting fusion protein has constitutive PDGFRA kinase activity and oncogenic transforming 
potential and occurs in HGG with amplified PDGFRA.  
Moreover, in 2012, Singh and colleagues identified a tandem duplication on chromosome 
4p16.3 which creates a fusion transcript, FGFR3:TACC3 (transforming, acidic coiled-coil 
containing protein 3) [130]. This structural variant leads to loss of the 3’-UTR of FGFR3, 
blocking gene regulation of miR99a and enhancing expression of the fusion gene [131]. The 
chimaera occurs in 3% of adult GBM, displays oncogenic activity and is associated with 
amplification of both genes [130]. EGFR was also found to be fused with SEPT14 (septin 14) 
in 7% of adult GBM, and almost always occurred within amplified regions of the fusion 
partner genes [47]. This fusion gene gives the ability to glioma cells to self-renew and 
constitutively activate STAT3 signalling, also conferring sensitivity to EGFR inhibition [47].   
The recent sequencing initiatives of pHGG tumours led to the discovery of the first fusion 
gene in this type of tumour [63]. Gene fusion involving the kinase domain of each of the 
three NTRK (neurotrophin receptor) genes and five different N-terminal fusion partners were 
identified in 4% of DIPG and 10% of non-brainstem HGGs. Interestingly, 40% of non-
brainstem HGGs occur in infants (<3 years old). NTRK fusions drive glioma formation in vivo 
and lead to activation of the PI3K/MAPK signalling [63]. 
All fusion genes occurring in brain tumours until now seem to use the same strategy, the 
replacement of the regulatory domain of a kinase gene by a constitutively active regulatory 
domain of another gene. This mechanism leads to a constitutively active kinase, which gives 
growth advantage to the cells that harbour the fusion. The low frequency of gene fusions in 
malignant brain tumours can lead to the idea that they play a minor role in the disease 
pathogenesis, nevertheless fusion genes that have not yet been identified, might 
characterize the different subtypes of this broad disease and the eventual goal is that novel 
drugs are developed acting specifically against the alteration. 
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2. AIMS 
The main goal of this thesis was to better understand the molecular mechanisms underlying 
the most malignant form of paediatric brain tumours, high grade gliomas (HGG). I decided to 
study the structural chromosome rearrangements that lead to the occurrence of gene fusions 
in pHGG. This was an understudied topic in childhood brain tumours and its investigation 
could lead to the discovery of novel targets for the treatment of this lethal disease.  
This objective encompasses the following specific aims: 
• Characterize the presence and frequency of PDGFRA molecular alterations – 
mutations and structural rearrangements – in pHGG. 
• Investigate novel structural rearrangements associated with copy number alterations 
in pHGG. 
• Utilise whole genome sequencing approaches to identify novel structural 
rearrangements that lead to fusion genes in paediatric malignant gliomas. 
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3. PDGFRA ALTERATIONS IN PAEDIATRIC HIGH GRADE GLIOMA 
3.1. INTRODUCTION 
RTKs are important mediators of signalling networks that transmit extracellular signals into 
cells and activate various cascades of intracellular processes that control cell growth, 
proliferation, differentiation, survival and metabolism [1]. Stimulation of these RTKs either by 
autocrine/paracrine secretion and binding of growth factors or by genetic alterations in the 
genes encoding the receptors themselves (amplifications, indels, fusions, mutations) are 
commonly found in cancer. These alterations result in RTKs with a constitutive or strongly 
enhanced signalling capacity, which provides rationale for the development of small 
molecules that selectively inhibit RTK activity and downstream signalling [1, 2]. 
The PDGFR/PDGF system includes two receptors (PDGFRA and PDGFRB) and four 
ligands (PDGFA, PDGFB, PDGFC, and PDGFD) which belong to the type III family of RTKs 
[3]. Receptor dimerization is triggered by ligand binding, enabling autophosphorylation of 
multiple tyrosine residues and subsequent recruitment of a variety of signalling transduction 
molecules. Activated PDGFRs transduce signals via numerous downstream pathways 
including PI3K/Akt, RAS/MAP kinase, Src kinase family and PLC/PKC pathways, which have 
all been implicated in tumourigenesis [3-5]. PDGFR regulates normal cellular growth and 
differentiation [6], and expression of activated PDGFR promotes oncogenic transformation. 
PDGFRA is the predominant target of focal amplification in pHGG including DIPG (12% and 
30%, respectively), in contrast to the disease in adults, where EGFR is the most common 
target (43% - Classical Subgroup) [7-10]. However, the Proneuronal adult GBM subgroup is 
also driven by PDGF signalling, with approximately one third of the Proneuronal/PDGF 
tumours harbouring amplification of the PDGFRA locus, while the remainder shows 
overexpression of the PDGF ligand [10-12]. Furthermore, the gene expression signature 
associated with PDGFRA is significantly overexpressed in pHGG, even in tumours that do 
not harbour the RTK amplification. Besides PDGFRA itself, PDGFB ligand is also commonly 
amplified and/or overexpressed in paediatric GBM, indicating a potential for autocrine-
paracrine loops boosting oncogenic signalling pathway through the PDGF network [8, 13]. 
Abnormally activated PDGFRA signalling driven by viral expression of PDGFB ligand is 
sufficient to induce glioma formation in vivo, indicating that activation of PDGFR pathways is 
potentially an early event in tumourigenesis [14-16]. Furthermore, simultaneous 
overexpression of PDGFB and loss of TP53 induced murine HGG with increased incidence 
and shorter latency indicating cooperativity between these pathways [17, 18]. However, 
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these studies focused on autocrine and paracrine activation of PDGFR signalling pathways 
by PDGFB ligand overexpression. 
Activating mutations in PDGFRA have been previously reported in gastrointestinal stromal 
tumours (GIST) [2, 19, 20]. GIST mutations occur in 6-7% of cases and are mainly located in 
the TK domain of PDGFRA (exons 12 and 18), leading to a constitutive phosphorylation of 
PDGFRA and ligand-independent kinase activity when expressed in vitro [21, 22]. On the 
other hand, TK domain PDGFRA mutations reported in GBM are only sporadic. Rand and 
colleagues reported a 2-bp deletion in exon 23 (the final exon) within the C-terminus of 
PDGFRA which results in an alternate, shorter C-terminus [19]; four GBM missense 
mutations (I1050T, W349C, C235Y, V536E) have been reported in the extracellular and TK 
domain of PDGFRA [9, 23]. The functional consequences of these mutations were not 
analysed. Interestingly, mutations in the extracellular domain of EGFR have been detected 
in 13.6% of cases in a series of 132 adult GBM [24]. These mutations are associated with 
EGFR copy number alterations and with an increased sensitivity to targeted inhibitors of 
EGFR kinase domain and they are oncogenic in a fibroblast cell line [24]. 
Larger structural rearrangements involving PDGFRA are a more common event in adult 
GBMs. Ozawa and colleagues reported an in-frame deletion of 81 amino acids (aa) in the 
immunoglobulin-like (Ig-like) domains of PDGFRA (termed PDGFRA Δ8,9) to be present in 
40% of adult GBM with PDGFRA amplification (Figure 3.1) [25-27]. 
The mutant PDGFRA has the deletion in the extracellular domain with retention of normal 
transmembrane and intracellular domains. This produces a novel transcript fusing exons 7–
10 resulting in loss of coding regions for part of the fourth and fifth Ig-like domains due to a 
complete loss of PDGFRA gene exons 8 and 9. Interestingly, this type of deletion is 
reminiscent of the oncogenic deletion frequently observed in human GBMs, which generates 
a constitutively active EGFRvIII protein [28-34]. Moreover, a gene fusion between the kinase 
insert domain receptor (KDR) TK domain (VEGFRII) and PDGFRA extracellular domain was 
identified the same study. The KDR:PDGFRA (KP) fusion protein consists of an extracellular 
domain containing the first to sixth Ig-like domain of KDR and the disrupted fifth Ig-like 
domain of PDGFRA, followed by the intact transmembrane domain and TK domain of 
PDGFRA (Figure 3.1). Both PDGFRA rearrangements showed constitutively elevated TK 
activity and transforming potential that is reversed by PDGFR blockade [27].  
To explore the possibility that PDGFRA might be a preferential target of oncogenic mutations 
in the paediatric setting, we screened a large series of cases for single base changes and 
small indels, as well as the Δ8,9 and KP fusion, informing two studies in collaboration with 
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colleagues at the Institut Gustav Roussy, Paris, and St Jude Childrens Research Hospital, 
Memphis. 
	  
Figure 3.1. Schematic of PDGFRA, PDGFRAΔ8,9 and KDR:PDGFRA. PDGFRA is constituted by 
five immunoglobulin-like (Ig-like) domains and two tyrosine kinase (TK) domains. PDGFRAΔ8,9 
has an in-frame deletion of exons 8 and 9 resulting in the deletion of 81 amino acids. This deletion 
results in loss of approximately half of Ig-like domain 4 and half of Ig-like domain 5. KDR:PDGFRA 
results from the fusion of the extracellular domain of KDR (Ig-like domains 1-6) with half the Ig-like 
domain 5 and the TK domain of PDGFRA. 
3.2. MATERIALS AND METHODS 
3.2.1. Patient samples 
A total of 306 tumour samples were included in this study. Both formalin-fixed, paraffin-
embedded (FFPE) and snap-frozen HGG specimens from children, young adult (<23 years) 
and older adults were obtained from the following institutions: King’s College Hospital (UK), 
St George’s Hospital (UK), Newcastle Royal Infirmary (UK), Nottingham University Hospital 
(UK), St Jude Children’s Research Hospital (US) and Institut Gustave Roussy (France).  
(Appendix I). 
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3.2.2. DNA and RNA extraction 
DNA from both frozen and FFPE specimens was extracted using the DNeasy Tissue Kit 
(Qiagen, Manchester, UK). RNA was extracted from the FFPE samples using the 
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Life Technologies, Paisley, UK) and 
cDNA was synthetized using the SuperScript system (Life Technologies) according to the 
manufacturer’s protocol.  Nucleic acids were quantified using a ND-1000 Nanodrop (Thermo 
Scientific, Loughborough, UK). 
3.2.3. Screening of novel PDGFRA mutations 
All coding exons of PDGFRA were PCR amplified from genomic DNA in the tumours listed in 
Appendix I. Each reaction contained 20ng of genomic DNA and was carried out using Taq 
DNA Polymerase (Life Technologies) in a final volume of 25 µl. The following program was 
used: Initial denaturation at 94°C for 3min, followed by a 2-Step-Touchdown: 1. (94°C 30 
sec, 68°C 45 sec, 72°C 1 min) 18 cycles, 2. (94°C 30 sec, 50°C 45 sec, 72°C 1 min) 30 
cycles; followed by an additional cycle of 72°C 10 min. The primers used are listed in Table 
3.1. DNA sequencing of the PCR products was performed by DNA Sequencing & Services 
(MRCPPU, College of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) 
using Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer. Sequences were analysed using Mutation Surveyor 
(SoftGenetics, US) and Chromas Lite 2.1 (Technelysium, Australia).  
3.2.4. Screening of PDGFRAΔ8,9 and KDR:PDGFRA fusion gene 
83 paediatric plus 75 adult cases were screened by RT-PCR for the 243 bp deletion in exons 
8 and 9, and 83 samples were screened for the KP fusion (Appendix I). The KDR-Exon9-F 
(K9) / PDGFRA-Exon12-R (P12) primer pair was used for the detection of the KP fusion. The 
screening of the PDGFRAΔ8,9 was performed with PDGFRAdel8,9 Ex7_ Fwd1/ Ex10_ Rev1 
and PDGFRAdel8,9 Ex9_Fwd1/ Ex10_Rev2 primer pairs for detection of both wild type and 
mutant allele (Table 3.1). PCR was performed as described in the previous section using 
20ng of cDNA. 
3.2.5. Statistical analysis 
Association between histological tumour type and the presence of PDGFRA mutation in 
pHGG was assessed by exact chi-square test for independence 
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Table 3.1. Primers sequences used in PDGFRA mutations screen. 
Primer Sequence 
PDGFRA Ex2 Fwdb CTAGGCTCCAGGGTTGTTTCT 
PDGFRA Ex2 Revb AGGAACTCAGAGAGGACTGGG 
PDGFRA Ex3a Fwdb AGACTGTCCTTTCTGACTGCATC 
PDGFRA Ex3a Revb CATTTCTGATTTCCACATCGG 
PDGFRA Ex3b Fwdb CCGATGTGGAAATCAGAAATG 
PDGFRA Ex3b Revb CAGGAAGAGGAGAAGAAGCTTGGT 
PDGFRA Ex4a Fwdb CTGGATTTATGTGTAAAGGTGAAAT 
PDGFRA Ex4a Revb TTGTGTAAGGTTACAGGAGTCTCG 
PDGFRA Ex4b Fwdb ACTGATCCCGAGACTCCTGTAA 
PDGFRA Ex4b Revb GCACCTTATGATTTTGCCTGTT 
PDGFRA Ex5 Fwdb CCTGTGGATTTTTAGGCCCTT 
PDGFRA Ex5 Revb AAGCCATTGCACGTTTTGA 
PDGFRA Ex6 Fwdb TTCACTCCTAGGAGCGAGCT 
PDGFRA Ex6 Revb GAGCAGCATGGACAACTGAC 
PDGFRA Ex7 Fwdb CGGGATCCATATGTGGTAATC 
PDGFRA Ex7 Revb TGGGCAGAGAGTTTCTTTACCT 
PDGFRA Ex8 Fwdb GGAACTTACTTAGCTACTGCTTGTT 
PDGFRA Ex8 Revb CCTTGGAAGACACTCATCTACAGA 
PDGFRA Ex9 Fwdb CACGAGCTATTCCATTCTGACTT 
PDGFRA Ex9 Revb ACCACGAAAGAAGAAGACACATC 
PDGFRA Ex10 Fwdb GAATTGGCCCTATACTTAGGCC 
PDGFRA Ex10 Revb GTTGTCCTGACTGTTGAGGAACT 
PDGFRA Ex11 Fwdb TTTCATTGTGCCTCTCTCTCTTG 
PDGFRA Ex11 Revb GCTATGCTTGTTCTCATTGGC 
PDGFRA Ex12 Fwdb CTGGGACTTTGGTAATTCACCA 
PDGFRA Ex12 Revb AGTCTTGGGAGGTTACCCCAT 
PDGFRA Ex18 Fwdb GATGGCTTGATCCTGAGTCA 
PDGFRA Ex18 Revb GCCTGACCAGTGAGGGAA 
PDGFRA Ex23 Fwdb GCAGGAGTTGTAATATTTGCTCTTC 
PDGFRA Ex23 Revb CAGTTACAGGAAGCTGTCTTCCA 
PDGFRAdel8,9 Ex7 Fwd1 TGAGATCACCACTGATGTGGA 
PDGFRAdel8,9 Ex9 Fwd1 CATCCATTCTGGACTTGGT 
PDGFRAdel8,9 Ex10 Rev1 TGGCCAAAATAGTCCAGGAA 
PDGFRAdel8,9_Ex10_Rev2 CTGTCTCGGGAGTGGATCTC 
KDR-Exon9-F (K9)  CCCTTGAGTCCAATCACACA 
PDGFRA-E12-R (P12)  GGTATGAAATTCGCTGGAGG 
KDR-Exon13-F (K13) AATCCATGTGGGAGAGTTGC 
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3.3. RESULTS 
Encouraged by the fact that PDGFRA plays an important role in pHGG and that oncogenic 
alterations in PDGFRA have been previously reported in other cancers including adult GBM, 
we decided to sequence all coding exons of PDGFRA in pHGG samples and screen for 
previously reported structural rearrangements (Figure 3.1). Two different cohorts of samples 
were used in this study. The first cohort (cohort 1) consisted of a series of 34 DIPGs 
biopsies. The biopsy material was obtain at the Neurosurgery Department of Necker Sick 
Children’s Hospital in Paris and after DNA and RNA extraction, was also used for aCGH and 
gene expression profile at the Institut Gustave Roussy, France. The second cohort (cohort 2) 
contained 133 (90 pHGGs outside the brainstem and 43 DIPGs) samples that were obtained 
from St Jude Children’s Research Hospital, USA and the Royal Marsden Hospital, UK. Both 
cohorts were sequenced for novel mutations in PDGFRA and a broad spectrum of 
alterations was discovered in both: novel missense mutations, small structural 
rearrangements (in-frame indels) and two previously reported large structural 
rearrangements – KP and PDGFRAΔ8,9.  
Overall, 18 cases as well as further two pHGG established as primary xenografts with 
altered PDGFRA were identified. All alterations were confirmed by independent PCR 
reactions and were validated as somatic, found only in the tumour and not matching 
germline DNA where a matched normal sample was available. In cohort 1, novel missense 
mutations were only observed in the PDGFRA extracellular domain in 3/34 (8.8%) cases, 
and in 2 additional primary xenografts. 66% (2/3) of the mutations were heterozygous and 
were also amplified. All mutations were found in DIPG cases. In cohort 2, 15/123 (12.2%) 
cases carried PDGFRA alterations, of which 60% (9/15) were present as heterozygous 
alleles, and 40% (6/15) occurred in cases with PDGFRA amplification. SNP array analyses 
previously showed copy number imbalances for the majority of the samples, demonstrating 
sufficient tumour purity to detect clonal alterations [8, 35]. Importantly, all mutations reported 
were readily detected by Sanger sequencing, indicating clonal expansion of the population 
containing the mutation, particularly in the cases in which PDGFRA was not amplified. In 
cohort 2, there was no association between the presence of PDGFRA mutation and 
histopathological features (p=0.26). Three mutations were found in anaplastic astrocytomas, 
one in an anaplastic oligodendroglioma, and the remaining mutations in grade IV GBMs, 
including two DIPGs. 
The coding mutations (G79D, E229K, C235R, C235Y, T276P, Y288C, C290R, T345H, 
W449C, R479Q, N659K, D842V) were located in the extracellular, transmembrane and TK 
domains of PDGFRA (Figure 3.2). The mutations found in the kinase domain, N659K and 
	  49 
D842V, were previously reported in GIST but not in gliomas [20, 36]. One of the mutations in 
the IGR-G82 paediatric glioma xenograft has been previously described in adult GBM 
(C235Y) [9]. In addition, 2 of the DIPG biopsy samples mutated in cohort 2 were included in 
a gene expression profile study, as referred before. Both mutant-positive cases were part of 
the group 1 DIPG which is characterized by a Proneural phenotype, oligodendroglial 
features (Appendix II Figure 4A) and is largely driven by PDGFRA, either by amplification 
(Appendix II Figure 5D) and/or these novel missense mutations (Figure 3.2, Appendix II 
Figure 5G).  	  
Moreover, 6 small structural rearrangements were identified in the extracellular domain of 
PDGFRA across 8 different patients. Three in-frame insertions (C450ins, A491ins and 
V544ins) and 3 in-frame deletions (E7del, E10del and E10del2) (Figure 3.3) not found in 
previous studies of a large collection of pHGGs and aHGGs [37, 38]. Three of the identified 
rearrangements (E7del, E10del2 and N659K) were recurrent, each of them found in 2 
different HGG cases. Analysis of cDNA showed that one of the somatic point mutations, 
N468S, generated a new splice site that removed 13 amino acids (E10del2) (Figure 3.3). 
We also evaluated whether activating PDGFRA alterations previously shown in aHGG occur 
frequently in our series of pHGG. PDGFRAΔ8,9, an in-frame deletion of 243 base pairs is a 
known transforming oncogene due to ligand-independent receptor activation [26, 27].  
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Figure 3.2. Missense mutations in PDGFRA. Cartoon showing missense mutations in PDGFRA 
overlaid with functional protein domains and exon boundaries. Chromatograms of three non-
brainstem high grade glioma (HGG) cases - RMH3499 (E229K), RMH3500 (C235R) and RMH3496 
(C290R) and three brainstem HGG cases – RMH 6974 (T276P), RMH3957 (W449C) and 
RMH6987 (R479Q). Ig-like: Immunoglobulin-like. 
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Figure 3.3. Structural rearrangements in PDGFRA. Cartoon showing small insertions and 
deletions present in PDGFRA overlaid with functional protein domains and exon boundaries. 
Sequencing chromatograms are shown for HGG028 for genomic DNA and cDNA. Sanger 
sequencing of PDGFRA from tumour and normal reference sample identified a heterozygous 
somatic missense mutation in genomic DNA from HGG028 and 2HGG171T (N468S). 
Subsequent validation of expression of the mutated allele by sequencing cDNA amplified by RT-
PCR revealed deletion of 13 amino acids, indicating that this point mutation lead to generation of 
an alternative splicing site and subsequent deletion of amino acids 456-468 within exon 10 
(E10del2) rather than encoding an amino acid substitution.  
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We used RT-PCR to screen for PDGFRAΔ8,9 mutant in pHGG and in an extended series of 
aHGGs (Appendix I). All adult cases harboured PDGFRA amplification. Two cases of 
PDGFRAΔ8,9 transcripts were identified in the adult group but none were found in the 
paediatric samples (Figure 3.4). Both mutant tumours expressed wild-type and deletion 
mutant transcripts. A gene fusion involving PDGFRA and KDR (Figure 3.1), which rendered 
a fusion transcript receptor constitutively active and tumorigenic in vivo, that has been 
reported in 1 out of 215 cases of adult GBMs [27]. Since PDGFRA is a common target in 
pHGG, we sought to use RT-PCR to screen for the KP fusion in pHGG. We found 1 case of 
KP in 83 non-brainstem pHGG analysed (Figure 3.5). In contrast to the case found in the T. 
Ozawa study, PDGFRA was not amplified (Figure 3.5), thus the mechanism driving the 
rearrangement was not associated with copy number alteration. However, the exact same 
gene regions were involved in the fusion, creating the same KP transcript as reported before 
(Figure 3.5). 
 
	  
Figure 3.4. Identification of the PDGFRAΔ8,9 fusion in two adult high grade glioma tumours. 
Cartoon showing PDGFRAΔ8,9  gene structure. Sequencing chromatograms are shown for 
RMH5685 and RMH6674 illustrating the sequence fusion of exon 7 and exon 10 in PDGFRA. 
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Figure 3.5. Identification of the KDR:PDGFRA (KP) fusion in one paediatric high grade glioma 
tumour. Schematic diagram showing the formation of the KP fusion transcript, as well as the gene 
structure of PDGFRA and KDR. Partial sequence of KP fusion transcript found in case HGG031.  
3.4. DISCUSSION 
The study described in this chapter contributed to two publications, Puget S et al PlosOne 
2012 (Appendix II) and Paugh S. et al Cancer Research 2013 (Appendix III). The former was 
focussed on DIPG, and provided evidence that PDGFRA amplification/mutation was 
associated with a specific subgroup of tumours, whilst the latter demonstrated that the novel 
mutations identified in pHGG were constitutively activating and tumourigenic. 
Aberrations of PDGFRA signalling via amplification and/or mutation and/or structural 
rearrangement are a frequent event in pHGG. In adult GBMs, the frequency of PDGFRA 
amplification and mutations is lower than in paediatric tumours and PDGFRA mutations 
comprise a distinct set of alterations compared to childhood disease (PDGFRAΔ8,9). In this 
study we identified novel somatic mutations and small indels in pHGG, as well as a case 
with a previously reported fusion gene, KP. A recent study reported PDGFRA mutations in 
pHGG, but none of the described mutations overlapped with our findings [37]. Interestingly, 
the novel mutations were not represented by a single hotspot as observed in GIST, but 
mainly spread across the extracellular domain of PDGFRA.  
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The mutations found in Cohort 1 were reported in Puget S et al study and contributed to the 
characterization of two molecularly distinct subgroups of DIPG (Appendix II Figure 2B).  
Group 1 DIPG was characterized by a Proneural phenotype, an oligodendroglial 
differentiation, and PDGFRA amplification/mutation, whereas group 2 DIPG exhibited a 
mesenchymal and pro-angiogenic phenotype. The gene expression profile of group 1 DIPG 
was significantly enriched with genes describing the signature of PDGFRA amplified gliomas 
[39, 40] supporting the hypothesis that PDGFRA amplification/mutation is associated with a 
robust gene expression profile across tumour location and patient’s age (Appendix II Figure 
5A). It is now known that the different gene expression profile is driven by the recently 
discovered mutations in the histone genes, H3.3 (H3F3A) and H3.1 (HIST1H3B), which are 
unique to DIPG tumours [41, 42]. This PDGFRA gene expression signature has also been 
previously described in adult tumours [11, 43-45], and includes the expression of genes 
involved in neurogenesis and oligodendrocyte development, such as Olig transcription 
factors, PDGFRA and SOX10 [46]. DIPG with oligodendroglial phenotype and Olig2 
overexpression exhibited an even worse evolution and resistance to radiation than the other 
DIPG in this series (Appendix II, Figure 4F). This could be explained by the fact that the 
CNS-restricted transcription factor Olig2 opposes p53 response to genotoxic damage in 
neural progenitors and malignant glioma [47]. In addition, Group I is linked with the K27M 
mutation in the H3.3 variant which is also associated with a worst outcome [48]. 
Interestingly, this is in contrast to the adult gliomas where oligodendroglial differentiation and 
proneural phenotype are linked with a better prognosis [10]. Moreover, we did not observe 
IDH1/2 mutations in 10 DIPG, while in adult Proneural gliomas IDH1 mutations are frequent. 
Furthermore, a recent study by K. Taylor et al has also confirmed that IDH1 mutations are 
absent in a large series of DIPG biopsies [49]. Integrative genomics showed that the gene 
expression profiles of this group of DIPG were driven by copy number changes, in contrast 
to the other group, suggesting that chromosomal instability plays an important role in the 
phenotype of these tumours. We found 28% (9/32) of PDGFRA gains or amplifications, all 
but one being included in the group 1 defined by unsupervised gene expression clustering. 
In addition, the PDGFRA amplified cases are also associated with H3.3 K27M mutation, but 
not H3.1 K27M (J. Grill unpublished observations). The PDGF autocrine/paracrine loop has 
been frequently implicated in oligodendrogliomas [50] and has been used to create 
preclinical models of glioma [16, 51], including brainstem tumours [52, 53]. PDGFRA 
amplification has been shown to be more frequent in pHGG than in adult , and a recent 
report found PDGFRA gain or amplification in four out of eleven post-mortem samples of 
DIPG [39, 54].  
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Cohort 2 PDGFRA missense mutations and structural rearrangements were reported in the 
Paugh S et al. study (Appendix III). Contrary to the previous study, several in-frame indels 
were detected in this series and these were distributed among different regions of the 
PDGFRA protein, including the kinase domain. On the other hand, only 1 case of pHGG 
carried the KP fusion and none harboured the PDGFRAΔ8,9, a recurrent alteration in adult 
GBM [25, 27]. Thus alternate mechanisms are used to generate oncogenic mutations of 
PDGFRA in childhood and adult HGGs. The role of six of the novel PDGFRA variants 
described in this chapter was explored. The PDGFRA mutants analysed represented 
alterations in different functional domains, and all were constitutively active and 
tumourigenic. In a p53-null background the D842V, V544ins, C450ins, E10del, E10del2 and 
E7del PDGFRA mutants showed ligand-independent phosphorylation while wild-type 
receptor activation required ligand stimulation (Appendix III Figure 3A), suggesting lack of 
sufficient ligand, or different selective advantage conferred by wild-type PDGFRA alteration 
versus mutation with or without amplification. Both wild-type and mutant PDGFRα conferred 
a proliferative advantage to p53-null primary mouse astrocytes in vitro, with all 6 mutants 
inducing HGG with an activated PDGFRA signalling (Appendix III Figure 4D. In contrast to 
the previous study, the tumours arising from PDGFRA mutants were not associated with a 
specific gene expression signature, instead they displayed a range of gene expression 
signatures similar to the spectrum seen in human HGG (Proneural, Proliferative and 
Mesenchymal) (Appendix III Figure 5).  When mutant cells were treated with small molecule 
inhibitors including dasatinib a potent multi-TK inhibitor, and crenolanib, a more specific 
PDGFRA inhibitor, PDGFRA signalling was abrogated (Appendix III Figure 3A) and 
proliferation was inhibited (Appendix III Figure 3B). In contrast to PDGFRA D842V, a 
recurrent hotspot mutation in GIST that confers resistance to imatinib [20], the mutations 
found in this study do not confer resistance to available small molecule PDGFR inhibitors, 
although these compounds induced a cytostatic, but not cytotoxic response. The 
resistance/sensitivity to certain inhibitors is mainly dependent on the specific mutation rather 
than the therapeutic target, as illustrated by the different spectrum of EGFR mutations in 
adult GBM that are not sensitive to the small molecule inhibitors that work well in lung cancer 
[55]. This data suggests that clinical use of PDGFR inhibitors as a single agent may not be 
sufficient to cause regression of pHGG, but could be a useful addition to other therapeutic 
approaches. 
In summary, this chapter demonstrated that PDGFRA alterations are a common event in 
both non-brainstem and brainstem pHGG. These alterations range from missense mutations 
to small indels and are important for tumour development.  Moreover, they have helped 
characterize two biologically and clinically different subgroups of DIPG. 
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4. INTRAGENIC COPY NUMBER BREAKPOINT ANALYSIS IDENTIFIES A NOVEL 
COMPLEX FUSION DHX57:TMEM178:MAP4K3 IN PAEDIATRIC HIGH GRADE 
GLIOMA  
4.1. INTRODUCTION 
DNA copy number and gene expression studies have highlighted key distinctions between 
HGG arising in childhood and far more commonly, much later in adult life [1-4]. Indeed, 
recent exome-level sequencing initiatives have conclusively shown the existence of 
subgroups of HGG marked by distinct driver mutations [5], which are significantly enriched in 
young children (H3F3A K27M), teenagers and young adults (H3F3A G34R/V), and middle-
aged adults (IDH1/2) [6]. Specific driving events for infants and elderly patients remain to be 
elucidated, however they too represent biological sub-entities, with infants having few 
genomic alterations [2], and elderly patients harbouring frequent amplification of EGFR and 
other genomic events [3, 4]. 
The identification of driving genetic alterations at the DNA copy level are necessarily most 
commonly focussed on assessing the amplification/deletion of genes in their entirety, and 
approaches to ascribe significance to genomic events make use of overlapping regions 
across multiple samples to find genes consistently within regions of gain/loss [7]. This 
approach has the result of ignoring genes for whom the breakpoint, i.e. the specific location 
of copy number change, is found within the coding regions. Such events may be more than 
mere bystanders of the “driving” aberration, and may themselves play significant roles in 
tumour initiation and maintenance.  
One key implication of copy number breakpoints occurring within genes is the possibility of 
generating novel fusions. Gene fusions can occur through both intra- and inter-chromosomal 
translocations, bringing together coding regions from two or more genes within a single 
reading frame allowing expression of a novel protein. Such gene fusions are common in 
cancer, but have historically been thought to be largely restricted to haematological 
malignancies and selected solid tumours such as sarcomas. Recent evidence has 
overturned this, with numerous novel gene fusions being discovered in a wide range of 
cancer types, exemplified by the identification of common TMPRSS2:ERG fusions in 
prostate cancer [8] and the EML4:ALK fusion in NSCLC [9]. 
The first fusion gene found in GBM was the rearrangement located at an amplified region at 
chromosome 4q12, resulting in the fusing of the kinase domain of PDGFRA with the 
regulatory domains of KDR (VEGFR2) [10]. This KDR:PDGFRA was found to be activating 
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and tumourigenic, however to date only a single additional case has been found, in a pHGG 
[11], and thus these fusions do not represent a common event. Another low frequency fusion 
has more recently been identified in approximately 3% of adult HGG, involving FGFR1 or 
FGFR3 partnering with TACC1 or TACC3 [12]. These FGFR:TACC fusions have been 
shown to localize to mitotic spindle poles, have constitutive kinase activity and induce mitotic 
and chromosomal segregation defects and aneuploidy [12]. The types of integrated analysis 
that identified these mutations have also begun to identify more common rearrangements, 
such as numerous fusions involving EGFR, the most frequently seen partner producing the 
EGFR:SEPT14 fusion demonstrated to activate STAT3 signalling and confer mitogen 
independence and sensitivity to EGFR inhibition [13]. 
Such analyses are clearly proving extremely valuable in furthering our understanding of 
HGG biology and generating novel targets for therapeutic intervention. As similar 
approaches are yet to be undertaken in the paediatric setting, we have applied an algorithm 
designed to identify intragenic copy number breakpoints in our previously published study of 
DNA copy number [2]. We identify numerous potentially functional gene disruptions and a 
novel validated complex fusion, DHX57:TMEM178:MAP4K3. 
4.2. MATERIALS and METHODS 
4.2.1. Published DNA copy number data 
Our lab previously carried out a DNA copy number profiling study of 100 pHGG cases on 
Affymetrix 500K SNP arrays [2]. The data have been deposited at the Gene Expression 
Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) with accession number GSE19578. Copy 
number assignment was carried out as per the original publication, using Affymetrix 
Genotyping Analysis Software (GTYPE version 4.s) improved using Bayesian Linear Model 
with Mahalanobis distance classifier algorithm (BRLMM) and standard dChipSNP 
normalization and model-based expression algorithms [2]. Log2-transformed data was used 
for all subsequent analysis in the present study. 
4.2.2. iCNA algorithm 
We implemented the iCNA algorithm developed as part of the GTS package under R2.11.0 
(cbio.mskcc.org/~brennan) [14]. Breakpoints are calculated according to user-defined ‘delta’ 
values representing shifts in log2 ratios between two contiguous genomic regions after 
segmenting the copy number data using circular binary segmentation (cbs) [15]. Using a 
delta of 0.4, breakpoint boundaries are identified and errors estimated by permutation-based 
calculations of neighbouring probe data. Confidence intervals are assigned and those falling 
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within the 95% window considered ‘high confidence’. An estimate is calculated for the 
expected rate of breaks for each gene based upon gene size and rate of breaks per sample, 
with a p value obtained based upon (observed-expected)/standard error. A corrected p value 
of < 0.05 is considered significant. Manual inspection of copy number plots was undertaken 
to ensure sufficient probe coverage was present at identified loci in order to prioritize the 
most convincing breakpoints. Those with substantial gaps at either side of the break were 
excluded. 
4.2.3. Custom oligonucleotide aCGH 
We designed two fine-tiling oligonucleotide microarrays to cover the specific amplicons 
observed at chromosomes 2p22.1 and 10q11.21 This was undertaken using the Agilent 
custom array design tool e-Array (Agilent, Santa Clara, CA, USA; 
https://earray.chem.agilent.com/ ), and comprised 700 probes covering 43.56–43.70Mb on 
chromosome 10 and 5000 probes covering 39–40Mb on chromosome 10 with a median 
probe interval of 200bp on 2x105K microarray. Due to limited amount of material, DNA was 
whole genome amplified (WGA) using the GenomePlex® Complete Whole Genome 
Amplification Kit (Sigma, Gillingham, UK) starting with 10ng of sample and control DNA, and 
following the manufacturer’s protocol. WGA DNA was labelled using the Agilent Genomic 
DNA ULS labelling kit, hybridised as per manufacturer’s instructions, and scanned on the 
Agilent 2505B Microarray Scanner System. Data has been submitted to ArrayExpress with 
accession number E-MTAB-2340. 
4.2.4. siRNA knockdown 
siRNA was carried out using a Dharmacon SMARTpoolTM (Dharmacon, Lafayette, CO, USA) 
against MAP4K3 [#003588] with paediatric glioma cells SF188, KNS42, UW479, Res259 
and Res186 [16] and a panel of breast carcinoma lines. Cells were plated and transfected 
24 hours later with siRNA using Lipofectamine RNAiMaxTM (Invitrogen, Paisley, UK) as per 
manufacturer's instructions, alongside transfections of siControl. Twenty four hours following 
transfection, cells were trypsinised and media replenished after 48 hours and 96 hours, with 
cell viability assessed after seven days using CellTiter-GloTM Luminescent Cell Viability 
Assay (Promega, Madison, WI, USA) as per manufacturer's instructions.  
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4.3. RESULTS 
We have previously carried out DNA copy number profiling of a large series of pHGG 
samples using Affymetrix 500K SNP arrays, and reported numerous genes encompassed 
within areas of focal amplification and deletion [2]. We now applied an algorithm (iCNA [14]) 
designed to identify copy number breakpoints contained within the sequence of known 
genes. A full schema of the analytical process is given in Figure 4.1.  
This algorithm was applied to 100 pHGG and 26 matched normal DNA samples, resulting in 
the identification of 1099 unique DNA copy number breaks contained within gene sequences 
across all tumour samples (Appendix IV - Supplementary Table S1). Of these, 479 were 
found to map to known regions of copy number variations found commonly in the germlines 
of the general population by cross-referencing the breakpoints with The Centre for Applied 
Genomics Database of Genomic Variants [17], leaving a total of 620 events.  
These were filtered to 500 after excluding those with p values > 0.05, and further reduced to 
388 with at least one sample harbouring a given aberration at ‘high confidence’. A further 
100 of these were excluded as they were also found in at least one of the normal samples 
profiled, representing either technical artefacts associated with the array platform used, or 
low frequency normal copy number polymorphisms. A final list of 288 iCNA is provided in 
Appendix IV - Supplementary Table S2.  
Most pHGG samples harboured at least one iCNA (median=3), although seven cases were 
found to contain none. Several cases were found to contain many more aberrations 
(maximum=19), though these were in the minority (Figure 4.2a). The number of iCNA events 
per sample was found to be prognostic in this multi-institutional series of cases, with pHGG 
containing more than 10 iCNA (n=9) found to have a significantly poorer survival 
(median=7.8 months), and those with no iCNA a better survival (median=24 months) than 
the rest of the tumours (median=13.2 months) (p=0.026, log-rank test) (Figure 4.2b).   
There were no differences in the number of iCNA between grade III (n=20, median=3, range 
0-7) and grade IV tumours (n=58, median=3, range 0-19) (p=0.456, t-test), though the cases 
with the highest number of iCNA were all grade IV GBM (Figure 4.2c). Similarly, there were 
no differences between primary tumours (n=68, median=3, range 0-19) and those which 
arose as secondary malignancies after cranio-spinal irradiation (n=10, median=2.5, range 0-
11) (p=0.698, t-test) (Figure 4.2d). Infants (less than 3 years at diagnosis) had significantly 
fewer iCNA (n=10, median=2.5, range 0-6) than older children (n=68, median=4, range 0-19) 
(p=0.050, t-test) (Figure 4.2e). Tumours with the K27M mutation in the gene encoding the 
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histone variant H3.3, H3F3A, harboured significantly more iCNA (n=5, median=6, range 1-
16) than either G34R/V mutant tumours (n=4, median=4.5, range 3-7) or wild-type (n=14, 
median=3, range 0-11) (p=0.043, ANOVA) (Figure 4.2f). This was independent of location of 
tumour, with no differences in number of iCNA between supratentorial GBM (n=51) and 
DIPG (n=7, p=0.684, t-test). 
 
Figure 4.1. Schema of iCNA algorithm applied to paediatric high grade glioma. 1099 intragenic 
breakpoints were initially identified in a published series of 100 pHGG. From these, known copy 
number polymorphisms were excluded, as were these seen in a series of 26 matched normal DNA 
samples. After filtering for statistical significance and manual inspection of copy number plots, a 
series of 19 intragenic deletions, 18 amplicons, and 2 candidate fusions were identified. 
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Figure 4.2. Clinicopathological correlates of intragenic copy number breaks in paediatric high 
grade glioma. (a) Number of intragenic breaks per sample in a series of 100 pHGG. (b) Kaplan-
Meier plot of overall survival stratified by number of intragenic breaks per sample. Pink: no breaks; 
Red: more than 10 breaks per sample; Grey: rest. (c-f)  Boxplot of number of intragenic breaks per 
sample separated by – (c) WHO grade. Orange: grade III; Brown: grade IV. (d) Previous radiation 
treatment for an earlier malignancy. Grey: primary pHGG; Purple: post-irradiation; (e) Age at 
diagnosis. Yellow: infant (<3 years old); Dark yellow: older children (>3 years old). (f) H3F3A 
status. Blue: G34R/V; Green: K27M; Grey: wild-type 
The 288 iCNA were further subjected to individual manual inspection of the data plots in 
order to identify the most robust copy number shifts associated with intragenic breaks. This 
resulted in a list of 39 unique events in 51 samples (Table 4.1). The recurrent changes 
included copy number loss, resulting primarily in either the absence of the 3’ end of a gene 
or small deletions wholly within the coding sequence. These intragenic deletions included 
those targeting known tumour suppressors in GBM such as NF1 (17q11.2, n=2) (Figure 
4.3a) and RB1 (13q14.2, n=1) (Appendix IV - Supplementary Figure S3), as well as putative 
novel GBM-associated genes including FAF1 (1p33, n=2) and MTAP (9p21.3, n=2) 
[Appendix IV - Supplementary Figure S3). In addition, there were novel deletions in the 
protein phosphatase PTPRE (10q26.2, n=2) (Figure 4.3b) and recurrent internal 
microdeletions in the gene CSMD3 (CUB and Sushi multiple domains 3) (8q23.3, n=3), all of 
which overlapped to result in the loss of exon 4 (Appendix IV - Supplementary Figure S3).  
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Table 4.1. Nominated intragenic copy number aberration candidates. 39 unique intragenic 
breakpoints found within 51 cases of paediatric high grade glioma. Direction of copy number shift 
(gain/loss) is reported, as well as candidate fusion events found within 51 cases of pHGG. 
Direction of copy number shift (gain/loss) is reported, as well as candidate fusion events. 
Cand.ID Gene Chromosome Sample Copy number change Comments 
1 FAF1 1 HGG091 Deletion   
  FAF1 1 HGG140 Deletion   
2 CD84 1 HGG088 Amplification   
3 LGAL
S8 
1 HGG070 Deletion   
4 KIDIN
S220 
2 HGG077 Amplification   
5 DHX5
7 
2 HGG063 Amplification Fusion 
candidate 6 TME
M178 
2 HGG063 Amplification Fusion 
candidate 7 WDR
49 
3 HGG010 Amplification   
8 PDC
D10 
3 HGG157 Deletion   
9 CHIC
2 
4 HGG077 Amplification   
10 ITGA
1 
5 HGG029 Deletion   
11 EPHA
7 
6 HGG139 Deletion   
12 LANC
L2 
7 HGG060 Amplification   
13 ECO
P 
7 HGG060 Amplification   
14 KCN
D2 
7 HGG152 Amplification   
  KCN
D2 
7 HGG162 Amplification   
14 SND1 7 HGG090 Deletion   
15 CSM
D3 
8 HGG054 Deletion   
  CSM
D3 
8 HGG140 Deletion   
  CSM
D3 
8 HGG153 Deletion   
16 SLC2
4A2 
9 HGG151 Deletion   
  SLC2
4A2 
9 HGG011 Deletion   
17 MTA
P 
9 HGG022 Deletion   
  MTA
P 
9 HGG007 Deletion   
18 ANK
RD26 
10 HGG068 Deletion   
19 RET 10 HGG139 Amplification Fusion 
candidate 20 CSG
ALNA
CT2 
10 HGG139 Amplification Fusion 
candidate 21 PTPR
E 
10 HGG086 Deletion   
  PTPR
E 
10 HGG145 Deletion   
22 RAB6
IP1 
11 HGG092 Amplification   
23 PSM
A1 
11 HGG092 Amplification   
24 TMT
C1 
12 HGG010 Amplification   
  TMT
C1 
12 HGG068 Amplification   
25 LRRK
2 
12 HGG068 Amplification   
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26 MYO
1A 
12 HGG029 Amplification   
27 XRC
C6BP
1 
12 HGG029 Amplification   
28 OSB
PL8 
12 HGG065 Amplification   
  OSB
PL8 
12 HGG162 Amplification   
29 RB1 13 HGG154 Deletion   
30 PCD
H17 
13 HGG059 Deletion   
31 CD27
6 
15 HGG006 Deletion   
32 MEF2
A 
15 HGG011 Deletion   
33 DNA
H2 
17 HGG143 Amplification   
34 NF1 17 HGG154 Deletion   
  NF1 17 HGG140 Deletion   
35 BRIP
1 
17 HGG077 Deletion   
36 KCN
B1 
20 HGG139 Amplification   
37 SYN3 22 HGG017 Deletion   
  SYN3 22 HGG146 Deletion   
38 TIMP
3 
22 HGG146 Deletion   
39 PHF2
1B 
22 HGG072 Deletion   
39 unique intragenic breakpoints found within 51 cases of paediatric high grade glioma. Direction of 
copy number shift (gain/loss) is reported, as well as candidate fusion events. 
Copy number gains within gene coding regions tended to be associated with regions 
flanking known oncogenic amplicons. These included amplification of the MYCN locus at 
chromosome 2p24.3, which in case HGG077 breaks within the coding region of the kinase 
D-interacting substrate KIDINS220 (Figure 4.4a); amplification of PDGFRA at 4q12, 
harbouring an iCNA in CHIC2 in the same case (though only covered by two probes); and 
recurrent breakpoints in the gene encoding the potassium voltage-gated channel KCND2 at 
7q31.31 in association with amplification of MET, though curiously this targeted either 5’ or 
3’ ends in two different cases (Figure 4.4b). Similarly, common amplification events 
encompassing EGFR (7p12) and CDK4 (12q14) had intragenic breakpoints at both ends in 
cases HGG060 (LANCL2 and ECOP) and HGG029 (MYO1A and XRCC6BP1), respectively 
(Appendix IV - Supplementary Figure S4). 
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For the most part, iCNA events resulted in an imbalance of certain regions of coding genes 
in isolation, with the predicted consequence a disruption of full-length gene expression. For 
certain events however, a 5’ end of one gene was found amplified at a similar copy number 
to a 3’ end of a second gene within the same case. We reasoned that such instances may 
represent candidate fusion genes, and we identified two such examples in our cohort. 
 
Figure 4.3. Intragenic deletions in paediatric high grade glioma. (a) Recurrent copy number 
breakpoint within NF1 on chromosome 17q11.2 in two cases of pHGG. (b) Recurrent copy number 
breakpoint within PTPRE on chromosome 10q26.2 in two cases of pHGG. Dark pink: confirmed 
region of loss; Light pink: region within which breakpoint lies, as defined by the resolution of probes 
on the array. 
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The first was at chromosome 10q11.21 and reflected a single amplicon, breaking within the 
genes RET and CSGALNACT2 such that we propose a hypothetical fusion gene 
encompassing the 5’ regulatory regions of CSGALNACT2 and the 3’ kinase domain of RET. 
In order to determine the precise breakpoints to allow validation of this novel fusion, we 
designed custom oligonucleotide arrays spanning the amplicon in order to carry out high-
resolution aCGH on the reference case HGG139, a relapse sample of GBM in which this 
genomic event was not present in the primary tumour. Although the breakpoint for 
CSGALNACT2 was identified within intron 2, leaving the catalytic domains intact, the 
breakpoint within RET could not be accurately determined to closer than 10kb between 
introns 1 and 2 (Appendix IV - Supplementary Figure S5).. 
 
Figure 4.4.  Intragenic amplifications in paediatric high grade glioma. (a) Copy number breakpoint 
within KIDINS200 on chromosome 2p25.1, flanking the MYCN amplicon in a case of pHGG. [b] 
Recurrent copy number breakpoint within KCND2 on chromosome 7q31.31 in two cases of pHGG, 
in both cases part of the MET amplicon, though targeting either the 5’ or 3’ end of the gene. Dark 
green: confirmed region of gain; Light green: region within which breakpoint lies, as defined by the 
resolution of probes on the array. 
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As material was limited for this case, we were unable to confirm the precise nature of the 
putative CSGALNACT2:RET fusion by PCR-based techniques  
The second fusion candidate was located at an amplified region of chromosome 2p22.1 in 
case HGG063, an anaplastic astrocytoma. At Affymetrix 500K SNP resolution, this appeared 
to be a single amplicon with breaks within the coding regions of the RNA helicase DHX57 
and the transmembrane protein TMEM178 (Figure 4.5a). Applying the same approach as 
above, using custom-designed oligonucleotide arrays for high-resolution aCGH revealed two 
amplicons within this structure, with further intragenic breakpoints within the mitogen-
activated protein kinase MAP4K3 (Figure 4.5b). Designing PCR primers to amplify across 
the highly specific breakpoints confirmed the presence of the fusion, which was further 
validated by direct sequencing (Figure 4.6). 
The resultant fusion gene, DHX57:TMEM178:MAP4K3, is a complex three gene fusion 
formed from a series of intragenic breaks, amplifications and inversions to produce a 
sequence comprising exons 1-12 of DHX57, exons 2-4 of TMEM178 and exons 13-34 of 
MAP4K3, associated with regions of microhomology (Figure 4.6). This would produce a 
protein with the zinger finger and DEAD-like helicase domains of DHX57, the claudin family 
transmembrane domains of TMEM178 and the citron domain of MAP4K3. Selective 
knockdown of MAP4K3 by siRNA leads to a significant reduction in cell viability in five 
paediatric glioma cell lines as assayed by CellTiter Glo, an effect not seen in 18/20 breast 
cancer cells (p=0.0017, pHGG vs breast cancer, t-test) (Appendix IV - Supplementary Figure 
S6).
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Figure 4.5. Identification of a novel complex fusion DHX57:TMEM178:MAP4K3.  (a) Affymetrix 
500K SNP array of chromosome 2, highlighting two amplicons, the most telomeric encompassing 
MYCN, the more centromeric as 2p22.1 involving intragenic breakpoints in DHX57 and TMEM178 
(green). (b) Custom oligonucleotide array of the 2p22.1 amplicon, revealing two amplified 
structures and three intragenic breakpoints, in DHX57, MAP4K3 and TMEM178 (green). 
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Figure 4.6. Cartoon depicting the structure of the DHX57:TMEM178:MAP4K3 fusion. A complex 
microhomology-mediated rearrangement of exons 1-12 of DHX57 (blue), exons 2-4 of TMEM178 
(green) and exons 13-34 of MAP4K3 (orange) was confirmed by direct sequencing. Regions of 
microhomology are highlighted in grey. 
4.4. DISCUSSION 
Comprehensive copy number profiling of adult and pHGGs was among the first data to 
demonstrate the biological differences between these similar-looking histological 
malignancies [18]. In this context, the focus has been on large-scale genomic copy number 
changes. A more refined analysis of copy number and exon-level expression data has 
identified new insights into genomic architecture and novel fusion proteins in adult GBM [12, 
13]. Here we leverage a large dataset we have previously generated [2] in the paediatric 
disease to carry out a scan of intragenic breakpoints, leading to the identification of novel 
gene disruptions and candidate gene fusions. 
The presence of intragenic copy number aberrations was confirmed in the vast majority of 
pHGG cases, and was itself prognostic, with an absence of iCNAs conferring a longer 
overall survival in paediatric patients. This was associated with the infant age group, known 
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to have a better clinical outcome than older children [19], and further highlights the biological 
distinctiveness of this age group. By contrast, the presence of large numbers of intragenic 
breaks conferred a shorter survival time, but was not a result of the grade of the tumour, nor 
associated with a second malignancy due to radiation treatment for an earlier cancer. We 
had previously reported an association of post-irradiated HGG with PDGFRA amplification 
and chromosome 1q gain [2], so it appears these are relatively selective radiation-induced 
changes, rather than reflecting a generalised genomic instability in secondary tumours from 
these patients. Importantly, we identified an increased number of iCNA in tumours 
harbouring an H3F3A K27M mutation, regardless of anatomical location. This is a group of 
thalamic and pontine HGG associated with a particularly dismal prognosis [18], for whom 
understanding the mechanisms of genomic instability and the identification of novel gene 
disruptions is of considerable interest.  
The majority of intragenic breakpoints we identified were associated with gene disruption. 
This includes deletions of known tumour suppressors such as RB1 and NF1, but also more 
novel GBM associated genes. FAF1 and MTAP were both recurrently targeted by intragenic 
deletion events in pHGG. These genes are localised close to known cyclin-dependent 
kinase inhibitors and tumour suppressors CDKN1C and CDKN2A/B, respectively, but both 
FAF1 and MTAP have recently been proposed to harbour tumour suppressor activity in their 
own right. FAF1 is associated with a FAS-mediated apoptosis response and restoration of 
the FAF1 protein in adult glioma cell lines significantly increases cell death [20], whilst in 
MTAP-deficient cells, methylthioadenosine, generated during polyamine biosynthesis, is not 
cleaved and the salvage pathway for adenine and methionine is absent.  It seems that such 
mechanisms are also likely in a subset of paediatric tumours.  
Of note we identified novel deletions in the protein phosphatase epsilon, PTPRE. This has 
not been reported previously, although there are several reports of the tumour suppressive 
capacity of the related PTPRD [21, 22]. This gene also appears targeted by intragenic 
deletions, and human astrocytes lacking PTPRD exhibited increased growth, as it is thought 
the protein usually functions to dephosphorylate the oncoprotein STAT3 [21]. The wholly 
intragenic microdeletions observed in CSMD3 in four cases may represent another novel 
mechanism of gene disruption. CSMD3 encodes a gene with multiple CUB and Sushi 
domains whose function is poorly understood. Recently, CSMD3 was identified as the 
second most frequently mutated gene (next to TP53) in lung cancer, where it was 
demonstrated that loss of CSMD3 results in increased proliferation of airway epithelial cells 
[23]. 
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Gene disruption may also play a significant functional role when known gain-of-function 
oncogenes are amplified. We report numerous intragenic breakpoints which may have been 
overlooked in the context of identifying the ‘driver’ event within a common amplicon, but 
which may themselves be tumourigenic. These include disruptions of KIDINS220, a 
functional mediator of multiple receptor signalling pathways and essential for cortical 
development [24, 25]; CHIC2, frequently deleted/rearranged in myeloid malignancies [26]; 
and KCND2, encoding a potassium voltage-gated channel, which is expressed in both 
neuronal and glial cells and has been shown to regulate ERK signaling in ganglioglioma [27]. 
All of these gene disruptions represent novel avenues for understanding the underlying 
biology of pHGG. 
Of most interest was the use of the iCNA algorithm to identify potential novel fusion genes, 
as was demonstrated in adult GBM with the identification of the KDR:PDGFRA fusion [10], 
which we also found in a case of pHGG [11]. Our analysis nominated two potential 
candidates – the first we were unable to conclusively validate, CSGALNACT2:RET. Such a 
putative fusion would retain the kinase domain of the RET oncoprotein, but would lose the 
autoregulatory portion of the protein, instead fusing it to the N terminal of chondroitin sulfate 
N-acetyl-galactosaminyltransferase 2. Although a precise cancer-related function has not 
been ascribed to the latter enzyme, it is thought to play an important role in morphogenesis 
in zebrafish models [28, 29]. Whilst not validated, oncogenic RET rearrangements and 
fusions are common in thyroid and lung cancer [30, 31], and the presence of infrequent 
activating fusions in HGG do not seem unlikely. 
We were able to validate a novel complex fusion involving three genes with intragenic 
breakpoints and amplification/rearrangement on chromosome 2p22.1. The resulting fusion 
gene, DHX57:TMEM178:MAP4K3 encompasses key regulatory domains from all three 
proteins, though a specific function is hard to predict. The  helicase properties of the DHX57 
component may be a candidate for oncogenicity, with numerous other DEAD-box helicases 
appearing to play a role in regulation of DNA repair, apoptosis and drug sensitivity [32]. 
MAP4K3 has been associated with several malignancies in both an oncogenic and tumour 
suppressor capacity [33, 34]. In particular, one function that has been ascribed includes 
activation of mTOR signalling via the TORC1 complex [35], a pathway commonly activated 
by diverse mechanisms in pHGG [18]. 
In the context of pHGG, although the kinase domain is not retained in the fusion, MAP4K3 
plays some functional role as selective knockdown by siRNA leads to a significant and 
selective reduction in cell viability in paediatric glioma cell lines. Thus we hypothesise that 
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the DHX57:TMEM178:MAP4K3 is activating as disruption of the protein would otherwise 
seem incompatible with tumour cell growth and proliferation. 
In summary these data represent a key addition to our understanding of the genomic 
alterations driving pHGG and provide novel avenues for developing sorely-needed novel 
therapeutic strategies for children with these otherwise incurable tumours. 
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5. INTEGRATED WHOLE GENOME AND TRANSCRIPTOME SEQUENCING IDENTIFIES 
NOVEL EXPRESSED FUSION TRANSCRIPTS IN PAEDIATRIC HIGH GRADE GLIOMA 
5.1. INTRODUCTION 
GBM is a highly aggressive brain tumour with a dismal clinical outcome, and though less 
common in the paediatric setting than in adults, it remains one of the biggest reasons for 
loss of life due to cancer in children. Recent genomic studies have profiled large numbers of 
GBM samples, leading to characterization of core pathogenic pathways and enabling 
molecular sub-classification [1-5]. Nevertheless, despite this exhaustive characterization, 
only few fusion genes have been reported in adult GBM and one in paediatric GBM.  Singh 
and colleagues have recently identified tandem duplication on 4p16.3 which creates a fusion 
transcript, FGFR3:TACC3 [6]. The fusion occurs in 3% of adult GBM, displays oncogenic 
activity and is associated with amplification of both genes [6]. In addition, a less frequent 
fusion involving PDGFRA, a gene commonly mutated in GBM, and KDR, the gene that 
encodes for the VEGF receptor, was found 1 out of 215 cases [7]. The KP fusion renders a 
receptor constitutively active and tumourigenic in vivo [7].  
Over the past few decades, genomic rearrangements and the creation of fusion genes have 
been reported to contribute to tumourigenesis in various malignancies, especially 
leukaemias and sarcomas [8, 9]. More recently, several reports have demonstrated that 
common epithelial cancers, such as carcinoma of the breast, prostate and lung, may also be 
the target of fusion genes [8, 10]. Gene fusions can lead to the production of oncogenic 
fusion proteins, such as the first to be discovered, the BCR:ABL1 kinase in chronic 
myelogeneous leukaemia [11]. Alternatively, fusion genes can lead to an enhanced 
expression of oncogenes via promoter switching, as seen in the TMPRSS2:ERG fusion in 
prostate cancer [12]. In addition to creating fusion genes, genomic rearrangements in these 
cancers break many other genes, affecting gene function and leading to gene inactivation 
[13].  
The recent development of high throughput sequencing technologies has enabled the 
detection of structural alterations in cancer DNA in a systematic way [14].  Most solid 
tumours fusion transcripts, like the recurrent VTI1A:TCF7L2 fusion in colorectal 
adenocarcinomas, were identified using paired-end whole genome or whole transcriptome 
sequencing. Moreover, very complex rearrangements like chromothripsis [15] and 
chromoanasynthesis [16] have been identified with these methods. The first is a cellular 
crisis that leads to chromosome shattering and the second comprises local rearrangements 
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with altered gene copy numbers produced by serial, microhomology-mediated template 
switching during DNA replication. 
Fusion transcripts found in patient samples have also been observed in several cell lines 
such as prostate cancer [17, 18], breast cancer [19] and NSCLC [20]. KNS42, SF188 and 
UW479 are pHGG cell lines extensively used as models to carry out preclinical and 
functional work. KNS42 and SF188 were derived from WHO grade IV paediatric GBMs in 
male patients aged 16 and 8 years old, respectively [21, 22].  UW479 was derived from a 
grade III anaplastic astrocytoma of a 13 year old female [23]. All three high grade lines have 
highly complex genomic profiles and harbour amplifications and deletions at several known 
cancer genes dysregulated in paediatric glioma, including CCND1, MYC, CDK4, PIK3CA, 
CDKN2A/B, and RB1 [24]. SF188 harbours an amplifier phenotype, with coordinated 
amplification of CCND1 and CDK4. By contrast, KNS42 cells achieves a similar end through 
direct deletion of RB1 itself. Further disruption to the p53 pathway (through point mutations 
of TP53 in both lines), and the RTK/PI3K/AKT pathway via NF1 deletion in SF188 and 
PIK3CA copy number gain in KNS42. Interestingly, UW479 cells also harbour numerous 
high level amplifications, including 3p11-p12, 6p21, 18p11 and 19q12 and an homozygous 
deletion at the CDKN2A/B locus [24].  
To examine whether SVs that lead to the production of oncogenic fusion proteins are 
present in pHGG, we used whole genome and transcriptome paired end sequencing to 
detect novel gene fusions in pHGG model cell lines – KNS42, SF188 and UW479. 
5.2. MATERIAL AND METHODS 
5.2.1. Cell lines  
Paediatric GBM cell line KNS42 was obtained from the JCRB (Japan Cancer Research 
Resources) cell bank. Paediatric SF188 cells were provided by Dr Daphne Haas-Kogan and 
UW479 were kindly provided by Dr Michael Bobola. These cell lines have been previously 
characterised [24]. They were grown as monolayers in DMEM F12-HAM complete media 
(Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS), incubated at 37°C with 
5% CO2. DNA was extracted from all the cell lines, and samples screened for mycoplasma 
at Surrey Diagnostics (Cranleigh, UK). 
5.2.2. DNA and RNA extraction 
Genomic DNA was extracted from pHGG cell lines using the DNeasy Blood & Tissue Kit 
(Qiagen, Manchester, UK), and the quantity and quality of the DNA was assessed with 
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Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies, Paisley, UK) and ND-1000 
Nanodrop (Thermo Scientific, Loughborough, UK). Total RNA was extracted using the 
Absolutely RNA Miniprep Kit (Agilent, Wokingham, UK), and the quantity and quality of the 
RNA was assessed on the 2100 Bioanalyzer (Agilent, Wokingham, UK), using the Agilent 
RNA 6000 Nano Kit (Agilent, Wokingham, UK), according to manufacturer instructions. 
cDNA was synthetize using the SuperScript II system (Life Technologies, Paisley, UK) 
according to manufacturer’s protocol.   
5.2.3. Whole genome sequencing  
Sequencing was performed at the Tumour Profiling Unit, Institute of Cancer Research, 
London, UK. KNS42, SF188 and UW479 were sequenced using the Illumina HiSeq2000 
sequencer. Briefly, 2.5-5 micrograms of DNA from each cell line were used to prepare the 
sequencing library through shearing of the DNA using Covaris S2 followed by ligation of 
sequencing adaptors according to the Illumina protocol. Fragments sized 00-766bp were 
extracted from the gel using the MinElute Gel Extraction Kit (Qiagen, Manchester, UK) to 
prepare 500bp insert libraries. Each sample was sequenced on multiple Illumina flow cells 
using the TruSeq Paired-End Cluster Kit v3-cBot-HS (Illumina, Little Chesterford, UK) with 
paired 100-bp reads to achieve ~30X coverage. 
5.2.4. Transcriptome sequencing 
RNA sequencing was performed at Source Bioscience, Nottingham, UK. 3 micrograms of 
total RNA from each cell line were prepared for high-throughput sequencing using the 
Illumina TruSeq RNA sample preparation Kit v2, according to manufacturer’s protocol.  
Sequencing produced roughly 74-92 million paired reads,  
5.2.5. Copy number analysis 
The copy number analysis uses the cell lines Affymetrix 500K SNP array data previously 
published by our lab [24]. The copy number data was re-processed using the Aroma 
Affymetrix package in R based upon the log ratio of each sample against a pool of 30 
European Hap Map mothers and smoothed by standard circular binary segmentation in the 
DNA copy package. Gains and losses were defined with a threshold of ±0.1 and 
amplifications and deletions with a threshold of ±0.5. Only regions of 10 or more contiguous 
probes were included in copy number analysis. 
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5.2.6. Bioinformatic analysis 
Raw sequencing data was aligned to the human genome (version hg19, Ensembl56) with 
the BWA v0.5.10 using default parameters [25]. BAM files were analysed by the 
BreakDancer v1.1.2 [26] with default parameters to characterize the structural 
rearrangements present in each line – deletions (DEL), insertions (INS), inversions (INV) 
and intra-chromosomal (ITX) and inter-chromosomal (CTX) translocations. The filtering 
process was based on sequence depth and retained rearrangements supported by at least 
ten paired reads. For ITX rearrangements, insert size should be greater than 1Kb, according 
to the variability in the insert size produced by the technique. As no matched constitutional 
DNA is available from the original patient from whom these cell lines were derived, we used 
publicly available normal genomes, and manually checked all regions involved in order to 
exclude those regions showing sufficient homology to represent a strong possibility of being 
false positives due to misalignments.  
Fusion gene detection was run on RNA Sequencing data using the Chimerascan pipeline 
v0.4.5 [27]. This relies upon Bowtie alignments [28] of paired end reads and the identification 
of mismatched pairs surrounding putative breaks encompassing reads containing the 
breakpoint sequence. Filtering of the Chimerascan output included steps to annotate each 
breakpoint for the longest Ensembl transcript covering the region and identifying candidate 
fused exons either side, as well as the predicted phase of the two partner exons (in-house 
script), intergenic fusions, readthroughs and those nominating SVs breakpoints smaller than 
10kb apart. Junctions were filtered to remove highly promiscuous partner reads with 
nominations to more than two distinct genomic loci and those representing multi-mapping 
genomic regions.  
Overlay of DNA and RNA sequencing levels fusions was based upon the intersection of 
gene annotations and genomic loci of the two partner genes in each case. 
Sequenced Variants were called using GATKv2.3-9 variant calling. Variants were filtered for 
depth, allele fraction, and minor allele frequency (MAF) in 1000 genomes of less than 5%. 
Genes which had more than 100 variants per Mb sequenced and which carry more than two 
coding variants in each individual cell lines were removed 
5.2.7. PCR validation 
Four PCR primers (IDT Technologies, Coralville, US) were designed using Primer3 [29, 30] 
for each pair of genes involved in the predicted SV (Table 5.1). These primers were 
designed ±200bp apart from the breakpoints to generate amplicons spanning the breakpoint-
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junction-sequences of predicted SVs. In addition to fusion gene amplification, we amplified 
both partner genes involved. DNA from the cell line carrying the fusion and normal control 
DNA (Promega, Southampton, UK) were used. PCR was carried out with Platinum® Taq 
DNA Polymerase High Fidelity (Life Technologies, Paisley, UK) in a 25 μl volume and with 
100 nanograms of genomic DNA or cDNA as template. The following program was used: 
Initial denaturation at 94°C for 3min, followed by a 2-Step-Touchdown: 1. (94°C 30 sec, 
68°C 45 sec, 72°C 1 min) 18 cycles, 2. (94°C 30 sec, 50°C 45 sec, 72°C 1 min) 30 cycles; 
followed by an additional cycle of 72°C 10 min. Fusions PCR products were extracted by gel 
purification (Qiagen, Manchester, UK) or cleaned up with the Illustra™ ExoStar™ 1-STEP kit 
(VWR, Lutterworth, UK). Sanger DNA sequencing of the PCR products was performed by 
DNA Sequencing & Services (MRCPPU, College of Life Sciences, University of Dundee, 
Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer.  
5.2.8. Metaphase slides 
KNS42, SF188 and UW479 were grown to 70-80% confluency and incubated with colcemid 
(Life Technologies, Paisley, UK) (1:100) for 1-3h. pHGG cells were harvested and treated 
with an hypotonic solution of 0.075M KCl for 5-8min at 37˚C. After this treatment, cells were 
pre-fixed with an ice-cold 3:1 methanol:acetic acid solution. The cells were collected by 
centrifugation, the supernatant was removed completely and the cell pellet was resuspended 
in 1 ml of fresh fixative (3:1 methanol:acetic acid solution) and stored at -20C until use. The 
nuclear suspensions were dropped onto clean slides and dried at room temperature prior to 
use. Control metaphase slides were kindly provided by John Swansbury (Clinical 
Cytogenetics, Royal Marsden Hospital, Sutton, UK). 
5.2.9. Fluorescent in-situ Hybridization 
Fusion genes were either detected using break-apart FISH probes for one of the genes 
involved in the fusion or using fusion probes, where a probe for each gene involved was 
selected and differentially labelled. Centromere probes were used as chromosome-specific 
controls. BAC clones were obtained from 32K re-array BAC collection distributed by CHORI 
and housed by the Breakthrough Microarray Facility (Institute of Cancer Research, London, 
UK) and FISH-mapped onto control metaphase slides to ensure specificity. BAC clones used 
are listed in Table 5.2. BAC DNA was amplified from 10 nanograms starting material using 
the IllustraTM GenomiPhiTM V2 DNA amplification kit (GE Healthcare, Little Chalfont, UK) 
according to manufacturer’s instructions. Probes were labelled with biotin, dioxigenin (DIG) 
or Aqua using the BioPrime® DNA Labeling System (Life Technologies, Paisley, UK).  
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Table 5.1.  Sequence of primers used for the screen of structural variants involving genes at either side in KNS42, SF188 and UW479 cell lines. The first column corresponds to 
the fusion ID which contains the cell line in which the fusion is present, followed by the chromosomal location of the partner gene 1 and partner gene 2.  
Cell Line Fusion ID Gene 1 Gene 1 Primer Forward Gene 1 Primer Reverse Gene 2 Gene 2 Primer Forward Gene 2 Primer Reverse 
KNS42_1_156051752_3_189542047 MEX3 CTTTGTAGAGAGCGCAGAGCTT AGATCTGCTTTCTTGGTTTTGC TP63 CGGATAGAGGCAGCAGGTAT TTGGAAAAGTCCAGGCTAGG 
KNS42_2_171814878_13_49848076 GORASP2 TCTCATCCCAGCTCTTTAGTCC CACAGCTACTTGGTTAGGCTGA CDADC1 CTTGCATTCTTTTTCCCTCAAG GATTTCCCTTCTGCCCAAAT 
KNS42_1_58802590_10_74176383 DAB1 AGCTGCAAGACTTCAATCCTTT AACCACCACGTTACTCCAATTT MICU1 TTATGGCCACATTTCACACG TGGGAATGCAGTAGTGAGCA 
KNS42_2_43437013_6_45891802  CTCCCATGATGGTTAGAACACC CCAGCTGTCTCTGTCTCTCTCA CLIC5 CATCGGATCGTGAACTGATTT AGGGTATCCAGGGAACTGCT 
KNS42_6_14261299_8_8718282  CTGAAGCTGACAAACACAAAGC AACCTCCCACTATGATTCTGGA MFHAS1 AGAACGCCCTCTGTTCCTTT TTACCTCAGCCCAAGAAACG 
KNS42_6_15532273_8_8667072 DTNBP1 ATCTCAGCTCACTGCAACCTCT ATTCCACCAGTTTTCCTAGCTG MFHAS1 GCTCCCACTGATTCCACATT GCCGTCTGCAGTAACCTCTC 
KNS42_1_152387895_11_132713260  CACACATGTTTTTGTGGTGATG GTGATGTTCATAAGGTGCCAAA OPCML CATCAGCCTAAGATGCTTGC GCTCTGTTTCAGATGCCAAG 
KNS42_12_96967216_X_100735303 c12orf63 CGAGGAAGGATATGTCTCCAAA CTAGAGCCTGCATACCAGTCCT  TGCCCAAGGATATCCAAAAA AGACAGGGTTTCGCTGTGTC 
KNS42_7_103159742_12_98598388 RELN GTGTTTCTTTGCTTTCCAGTCC AGCCTAGGTGACAGAGCAAGAC  CACAGACTGGCAAAATTGGAT TTCAGGAGCAGGTTGTTCG 
KNS42_3_164722685_5_57093054 SI CTGCTGAATATGCATCCAAAAG ATTGACTCACAGTTCTGCATGG  CCCATCTTGTTTGCCATTGT TAACAGCAGGCTTCCCAAAA 
KNS42_12_96977487_X_98569531 c12orf63 TGATCTTGACCTTGGAGACTGA GTGAACTTCATTTCCCCTTCAC  CAAGCCAGTCAAAGCAGACA TCTGATTCTTTGCCATTGGTC 
KNS42_5_64964650_5_65433006 SGTB ACTTGAGGTCAGGAGTTCGAGA GGAGAAAAGGGGCATTAGGTAT  TTCCACATTTTTGGGCATCT CCACCAGGATTGTGATAGGG 
SF188_20_4895215_20_25459154 SLC23A2 ATCCCTGAGAGGCCTAAGGA CTGCCTCAGCCTCCTGAGTA  GCCTCCCAAAGTGCTGATTA TCAAGTCTGGGGTTTCTTGC 
SF188_6_158783682_17_78736108 TULP4 TGCGCTTGTTGTTTGTTCAT CAATCTTGGCTCACTGCAAA RPTOR CAATCTTGGCTCACTGCAAA AGGGCGGTAGGACAAACTCT 
SF188_1_144680231_1_144954567  CAGGATTCAAATGCCACAGA TCCCCTCTCACCTTAAGCAA PDE4DIP CGTGTTAGCCAGGATGGTTT GGGAAAATGGGCACTCTCAT 
SF188_11_88909186_15_27561047  TCCGGCATCATCGAAATAGT TGAGGCCTCCACACATCATA GABRG3 GGCAAATTGGACCCTGAATA CTCAGCCTCCCAAGTAGCTG 
SF188_20_278393_21_17652744  AAAAACCAAACCCACACAGC ATCTGGATGACCGCGTAGAT c21orf34 TTGTGGAGAGGAATGGGGTA GATGTTGTTCTGGCCTCTCC 
SF188_16_542305_16_542428 RAB11FIP3 GGGTTTGTAAAGGTGGCAGA AAGTCTCTGCGTGGGAAGAA  GGGTTTGTAAAGGTGGCAGA AAGTCTCTGCGTGGGAAGAA 
SF188_11_57812425_20_3753964 OR9Q1 CGACATCTGTGCAGTCAGGT TCCCTTATCCGAATTGCTTG  TTCAAAGACCACCAGGCAAT TTGCCTGTAACCCCAGCTAC 
UW479_8_137751825_17_49361503  CTGCAACATGCAATTCATCA CTTTCCCCTGCAGAGACTTG UTP18 CACGCCCAGCTAATTTTTGT GATCCAGAACACGGGAATTT 
UW479_8_117230013_17_49354767  AGCCATGTGGGACTGTGAGT TACCTTTCCCCTCACAATGG UTP18 GGTTGATGGGAAAACAAATCC TGGGTATGGTAGAGGGCAGA 
UW479_8_141832537_15_42650218 PTK2 CATGCAGATTGGACATGGAG ATGCTCCCTTATCACCAACG CAPN3 TTTGCGTCAGCGAGTAAATG GGGATGTCACACCTGGTTTC 
UW479_3_47028066_22_19936322 NBEAL2 AGGGTGTGGTTCTAGGGACA GGAGCCCAAAATACCCAGAT  AAAATTAGCTGGGCATGGTG TCTCACCACTGCACTCCATC 
UW479_3_55024288_19_47734383 CACNA2D3 GGATCAGAAGTCATGCACCA AGAATGGTCAGGGGAGAGGT  CTGCACTCCTGTCACCTCCT GTCGGTCGGTCTGTGTACG 
UW479_9_32381210_9_33849115  GCGTATAGCAGGTGTGGTGA TGATGTGGGTGGTCAAAAGA UBE2R2 CATGCATGAGCTACCACACC ACAGGCGTCCATCCATACTC 
UW479_1_113149456_20_3902968 ST7L TACAGTGGCACCCCACTTCT GCCCCATATCTAGGCCCTTA  CGAAGTGCTGGGTTACCTGT AAGAGGTGTGGAGAGCAAGG 
UW479_14_32066014_14_33251221 NUBPL TCTGACGCTGAGATGACTGG GGACGGAGGAAGAACAGGAT AKAP6 GGCAAGCATTACCCAGATGT AGCTGTGGATCCCCATTATT 
UW479_17_8745523_17_9557484 PIK3R6 AGTTGCTGTGCTGTTGCAGT TTGGGGAAACACTTGTGTGA  GCTGGGTCCCTCCTTAGGTA CTCAGCCTCCCAAGTAGCTG 
UW479_9_27945060_18_30711907  TTCAGATGCCACAGAATCCA TTCCACTCTGGTTTTGCTCA c18or34 CCCACCAACATTATGCCATT CATTTCAAAGAGGATATGCAGAGA 
UW479_9_102146807_18_30736184  AACGAGCAGGAGACAATGCT ATGAGTCCCAGGGAAAATCC c18or35 ACTGGGGGTATTTCATGGTG CCCAGAAGTGTCATGCAGAA 
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UW479_9_86638539_18_30729821  GGACCAGATGACCTCCAAGA AGACCAGTGGTTCCCAAGAA c18or36 GAAGCCTTTCCGTATCCACA CTACATGTGGCCTCCCAGTT 
UW479_1_82756062_14_67423798  AGGACACGACATTGGGTTTC TGAGCAGCTATTGCAGAGGA GPHN TTCTCTGATGGCCAGTGATG GGGAGGCTGAGGTAGGAGAA 
UW479_14_31036241_15_30984655 G2E3 TTGGTGCCAATTTTTCTTCA GAAATGAAAGTGGGACACTGC  CACCACCACACTTGGCTAAT AGCCCCAGAAACAGAAGGAC 
UW479_12_1695918_12_9246077 A2M TGAGCTCTGATCATGCCACT CTCCCAAAGTGCTGGGATTA  TAGAAAGGTGGTTGGGGTTG GCCTCTCCTGGCTTGTTAAG 
UW479_8_47159193_9_137280905 RXRA CCATGCAGAGCAAAGAAACA TCATGCCGCTTCTTCCTACT  CTTCGATGTCCTTCCTCTGC ATACCCCCAAAGTCCAAAGC 
UW479_12_3690145_20_62854780 PRMT8 GAAGGCCATGCTACACTGGT GTCCTGGCATCTCCAGTCAT MYT1 GCTGTCCTCCAAGGACTGAG GATCTTCAGGAGAGGCTGGA 
UW479_3_114154875_3_168102681 ZBTB20 CAACCTGAAGTTTGGCTTGG GGTTTTCTTCTGGGTCACCA  ATGGCATCTAAAGCCAGCAC GTTTCACGCAGACAGCAAAA 
UW479_20_15544438_22_35396912 MACROD2 CCTGGTCCATGCCCTTAATA GGCGACATGAGAAACCATCT  TGCAATCTCAGCCTACATCG GCCACATGGTCTCTGTAGCA 
UW479_5_93556435_22_35366567 c5orf36 ATGACTGGCAGCACACATTT GCTCTACCCCTGAGACCACA  CCAGAACCTCAGAATGTGACC CCTGGGGCTGCTATAACAAA 
UW479_1_47836334_14_53815391 CMPK1 TAACCCACGTCCCTCTCATC GGAGTACAATGGTGCGATCC  CTGGGTGTCTTCTTCCCTTG TGCAGGACACTTAAGGAGCA 
UW479_6_45229405_8_62847098 SUPT3H CAAAACCTGCCAGAGACACA TCAGCTTGGGCATTATTGGT  TTCAAGGTCACTCCAAAGCA TAGGTCATGGCTGCCAAACT 
UW479_8_62579337_8_62708134 ASPH GCAATGCCACATTTAAGCAG GGGCTTGGCATATTGTTTGT  TGCAAGTTGAGAGGATTCTTTG GGCAGAGATTGGAAGATTGAA 
UW479_8_57896780_19_31716239 IMPAD1 ATTTTGGGAAGAGGGGAAAA GGTGAGAGATGGTGGCCTAA  AAATCAGAAAAGGGGGCATT ATAAGGCAACAGCAGGAGGA 
UW479_7_71425213_7_99282578 CALN1 AATTCCTGGGCAAACCAAAT AACACGGATGGAAGTGGAAG  GCAATGGGCAAAGTCACAGT TTCAACCAGAAAAACCCATTG 
UW479_8_40433239_14_55716413 ZMAT4 CCACCCCAAGAAGATACAGC CATTGCCAAGATTTGTTTGG  GGAGACAAAAGGCCATCAAA CACATGTTTCCTGCATGTGG 
UW479_9_28000942_9_86632969 LINGO2 TCTCTGCATTCCTGACACCA CTTCTGTGGCATGTGGAAGA  CTTTTGCCCGGCTAATTTTT GGGCAACAGAGTGAGACTCC 
UW479_7_88827600_8_143781332 ZNF804B TCAATTGAGTAGCAAATTGGATG CAGGTAACCTCAAGGTCACATTATT  GCATGGAAATCCTCCAGTTC ATCTTCTCCGCTGAAGAGCA 
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Briefly, the metaphase slides were incubated in 70% acetic acid for 10min and washed in 
PBS 3x3min and 2XSSC 1x3min, prior to digestion for 5min at 37˚C with 0.01M HCl / 
0.02mg/ml Pepsin solution (Sigma, Gillingham, UK). The slides were washed in PBS 2x3min 
and PBS / 0.05M MgCl2 1x3min followed by fixation in 1%formaldehyde / PBS / 0.05M MgCl2 
for 5min. Dehydration was carried out with 3 min 70%, 90%, 100% ethanol and slides were 
air dried for 10min at room temperature. The slides were denatured at 75˚C and hybridised 
with the appropriate biotin and/or DIG and/or Aqua labelled probe overnight at 37˚C in a 
humidified chamber. Removal of the coverslips was carried out by soaking the slides in 
2xSSC / 0.1% Igepal for 2 mins at room temperature and immersing in 0.4xSSC / 0.3% 
Igepal at 73˚C for 2min. Slides were rinsed in 2xSSC / 0.1% Igepal for 1min and PBS for 
3min.  When dual FISH was performed, slides were first incubated in a humidified chamber 
at 37˚C with two layers of anti-DIG-fluorescein (Roche, Welwyn Garden City, UK) for 10min 
each, washed with PBS 3x3min and incubated with two layers of Streptavidin-cy3 (Sigma, 
Gillingham, UK) 10min each. Slides were soaked in PBS for 3min, dehydrated with 3min 
70%, 90%, 100% ethanol and left to dry at room temperature for 10min. Slides were finally 
mounted in Vectashield with DAPI (Vector Laboratories, Peterborough, UK), and captured 
on the Leica Ariol microscope (Wetzlar, Germany) at x20 using filters for DAPI, Cy3, FITC 
and Aqua.  
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Table 5.2. List of BAC clones of the 32K re-array BAC collection used for FISH 
Probe ID chrom start end bac.id Gene/chr/cent 
TP1708E04 17 78045988 78182971 RP11-334C17 RPTOR 
TP1709F04 17 78559488 78720126 RP11-317F05 RPTOR 
TP1707A07 17 78698182 78900648 RP11-812H19 RPTOR 
TP0613A07 6 158899201 159089502 RP11-654E18 TULP4 
TP0618H04 6 159060790 159272494 RP11-507C10 TULP4 
TP0619A11 6 159308756 159421507 RP11-589H21 TULP4 
TP0206C02                      2 171595376 171751356 RP11-164H08 GORASP2 
TP0206A10                                 2 88991806 89157237 RP11-157D12 cent 2(p) 
TP0222G01                                 2 89159257 89307765 RP11-294I20 cent 2(p) 
TP0225B01                                  2 89264572 89459196 RP11-631H05 cent 2(p) 
TP0218B05                                  2 89389635 89602031 RP11-685C07 cent 2(p) 
TP0228B08                                  2 89526216 89623186 CTD-2063D22 cent 2(p) 
TP1308G12                               13 49942118 50119412 RP11-767O08 CDADC1 
TP1305D11 13 49572364 49735007 RP11-446P06 CDADC1 
TP1306C04                               13 19398031 19540646 RP11-518D18 cent 13 (q) 
TP1306C02                                13 19501986 19679218 RP11-521I05 cent 13 (q) 
TP1302H02                                13 19697044 19857280 RP11-139J24 cent 13 (q) 
TP1304B12                               13 19845749 20046229  RP11-304L17 cent 13 (q) 
TP1306C09                               13 19909447 20076150 RP11-535A03 cent 13 (q) 
TP1402H07 14 31636363 31795856 RP11-200I02 NUBPL 
TP1402F05 14 32290056 32435545 RP11-159D23 NUBPL 
TP1103C02 11 55707995 55878656 RP11-129H09 cent 11q 
TP1103D04 11 55875895 56040558 RP11-138A07 cent 11q 
TP1202E10 12 33739612 33925027 RP11-102G23 cent 12p 
TP0806G06 8 47450712 47566922 RP11-445A15 cent 8 
TP0403E10 4 54072620 54226790 RP11-98L24 SCFD2 (4q2) 
TP0416F09 4 54252656 54420846 RP11-809N18 LNX1, FIP1L1 (4q12) 
TP0402E10 4 54576785 54759122 RP11-61P24 FIP1L1 (4q12) 
TP0411H12 4 55093276 55273379 RP11-626H04 PDGFRA (4q12) 
TP0813F05 8 128690817 128824097 RP11-237F24 MYC (8q24) 
TP1112D12 11 48449190 48603500 RP11-657L09 11p11.2  
TP1109F12 11 69409496 69572287 RP11-681H17 CCND1 (11q13.2)  
TP1108E01 11 118313325 118461726 RP11-606K01 MLL (11q23.3) 
TP1215E03 12 58002869 58210408 RP11-571M06 CDK4 (12q14) 
Cent: centromere; chr: chromosome 
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5.3. RESULTS 
To identify potential novel structural variants in pHGG, we performed whole genome 
sequencing of three cell line models - KNS42, SF188 and UW479, generating paired 100-
base reads with an average of 30X sequence coverage. The Breakdancer package was then 
applied to detect SVs [26], as it is considered to provide accurate and comprehensive 
predictions of SVs in genomes, and is routinely used to identify fusion genes [31]. It predicts 
individual genomic breakpoints by searching from clusters of abnormally mapped paired end 
reads [26]. We used a stringent filtering method that only identified rearrangements 
supported by at least ten reads, with a Breakdancer score of ≥80, with an even balance 
between positive and negative strands, and which was filtered against normal genomes. 
This approach identified 2646 genomic junctions (INS, DEL, INV, ITX, CTX) of which 303 
represented genic rearrangements: 76 in KNS42, 93 in SF188 and 134 in UW479 (Appendix 
V). These events were divided into two groups: CTX (n=216) and ITX (n=87). The genomes 
of the cell lines are represented as Circos plots in Figure 5.1, also annotated for known 
cancer-associated single nucleotide variants.  
As fusion genes are often associated with specific copy number breakpoints [32, 33], we 
interpreted our SV analysis in the context of a previously published 500K SNP array study 
carried out on the cell lines [24] (Appendix VI). 74/303 (24.4%) of the nominated SVs were 
associated with an intragenic copy number difference in at least one of the two breakpoints. 
SF188 showed the highest number of copy number-related breakpoints (n=34) due to the 
occurrence of a complex rearrangement that involves regions of chromosomes 4, 8, 11 and 
12 (see below). UW479 was also found to be highly rearranged (n=28), more so than KNS42 
(12 breakpoints associated with copy number).  
The predicted SVs were validated by PCR using genomic DNA, with 17/74 (23%) confirmed 
(though additional 27/74 (36.4%) correspond to the SF188 extra-chromosomal 
rearrangements which were subsequently validated by FISH) (Table 5.3).  Sanger 
sequencing of the detected SVs revealed sequence microhomology at the rearrangement 
breakpoints in 13/17 (76%) validated SVs (ranging from 1-7 nucleotides). Two SVs in 
UW479 (PRMT8:MYT1, ASPH:chr8) were separated by small genomic shards, 1 and 6 
nucleotides, respectively (Figure 5.2). A schematic representation of the predicted structures 
of each fusion validated is presented in Figure 5.3. 
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Figure 5.1. DNA structural rearrangements and copy number alterations detected in three paediatric high grade glioma cancer cell lines – KNS42, SF188 and 
UW479 – displayed as Circos plots. Each Circos plot depicts whole genome sequencing data from each cell line. Outer ring contains chromosomal 
ideograms, annotated for somatic single nucleotide variants in coding genes (black). Inner ring plots copy number derived from copy number data, dark 
orange=amplification, orange=gain, dark blue=deletion, light blue=loss. Inside the circle are drawn structural variants, blue=validated fusion genes, 
red=amplified breakpoints.  
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Table 5.3. List of fusion genes validated at the genomic level in each cell line. 
Cell line Fusion ID Gene 1  chr 1 Gene 2 chr 2 
UW479_14_32066014_14_33251221 NUBPL 14q12 AKAP6 14q12 
UW479_17_8745523_17_9557484 PIK3R6 17p13.1 USP43 17p13.1 
UW479_12_3690145_20_62854780 PRMT8 12p13.32 MYT1 20q13.33 
UW479_20_15544438_22_35396912 MACROD2 20p12.1  22q12.3 
UW479_1_47836334_14_53815391 CMPK1 1p33  14q22.1 
UW479_8_62579337_8_62708134 ASPH 8q12.3  8q12.3 
UW479_9_86638539_18_30729821  9q21.32 CCDC178 18q12.1 
UW479_8_47159193_9_137280905  8q11.1 RXRA 9q34.2 
KNS42_2_171814878_13_49848076 GORASP2 2q31.1 CDADC1 13q14.2 
KNS42_1_58802590_10_74176383 DAB1 1p32.2 MICU1 10q22.1 
KNS42_7_3023122_7_3359981 CARD11 7p22.2 SDK1 7p22.2 
KNS42_6_15532273_8_8667072 DTNBP1 6p22.3 MFHAS1 8p23.1 
KNS42_5_64964650_5_65433006 SGTB 5q12.3  5q12.3 
KNS42_12_96977487_X_98569531 c12orf63 12q23.1  Xq22.1 
KNS42_3_164722685_5_57093054 SI 3q26.1  5q11.2 
KNS42_2_43437013_6_45891802  2p21 CLIC5 6p21.1 
SF188_6_158783682_17_78736108 TULP4 6q25.3 RPTOR 17q25.3 
To determine whether the validated SVs resulted in expressed fusion transcripts at the 
mRNA level, we additionally performed paired-end whole transcriptome sequencing of the 
three cell lines and applied the Chimera Scan software package to identify chimeric gene 
sequences [27]. The predicted list of fusion transcripts was based on the overlay of DNA and 
RNA sequencing levels fusions through the intersection of gene annotations and genomic 
loci of the two partner genes in each case and it is represented as circos plots (Figure 5.4). 
Of the validated expressed fusions, we chose to focus on three for further study: 
RPTOR:TULP4 (SF188, described in detail in Chapter 6), NUBPL:AKAP6 (UW479), and 
GORASP2:CDADC1 (KNS42).  
The NUBPL:AKAP6 fusion transcript is derived from an intra-chromosomal rearrangement at 
14q12. The sequences of the DNA junction exhibited microhomology of two nucleotides, a 
characteristic of the non-homologous end joining (NHEJ) mechanism (Figure 5.2). Both 
Nucleotide Binding Protein-Like (NUBPL) and A Kinase Anchor-Protein 6 (AKAP6) are 
transcribed in the same direction, with the DNA copy number profile demonstrating 
amplification of regions preserving the 5’ end of AKAP6 and the 3’ end portion of NUBPL 
(Figure 5.5A), similar to the mechanism driving KIAA1549:BRAF, a fusion that results from a 
tandem duplication of 2Mb at 7q34 in LGG [34]. 
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Figure 5.2. Sanger sequencing validation of novel fusion genes in the paediatric high grade glioma 
cell lines – UW479, KNS42 and SF188. Sequence traces of eight novel fusion genes (two inter-
chromosomal and six intra-chromosomal) in UW479, eight inter-chromosomal fusions in KNS42 and 
one inter-chromosomal translocation in SF188.  
In order to determine whether the NUBPL:AKAP6 rearrangement was the result of a tandem 
duplication, we designed a break-apart FISH probe for NUBPL (Figure 5.6A), however we 
were unable to detect this using FISH, presumably due to the low resolution of this technique 
for such a small region (1Mb) (Figure 5.6C). Regardless, the pair of signals of the split 
NUBPL probe are separated at a relatively constant distance from each other Figure 5.6C 
(yellow arrow). Sanger sequencing of the RT-PCR product showed fusion of AKAP6 exon 12 
with exon 4 of NUBPL (Figure 5.5B). 
 96 
 
Figure 5.3. Schematic representation of each gene involved in fusion formation as well as the 
formation of the predicted fusion transcript for each validated (DNA level) translocation in the 
paediatric high grade glioma cell lines.  
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The fusion gene identified in KNS42 involved the genes encoding the Golgi reassembly 
stacking protein 2 (GORASP2) and the cytidine and dCMP deaminase domain containing 1 
(CDADC1) (Figure 5.7C). This rearrangement resulted from an inter-chromosomal 
translocation between 2q31 and 13q14, with the genes involved being transcribed in the 
same direction. Sequencing of the genomic breakpoint revealed a similar microhomology 
region to that described above with NUBPL:AKAP6 (Figure 5.2). We used two different FISH 
strategies to detect this rearrangement: a fusion probe for the GORASP2 and CDADC1 
regions involved in the fusion and a CDADC1 break-apart probe to determine if the gene 
was disrupted (Figure 5.8A). FISH confirmed that CDADC1 and GORASP2 are fused in 
KNS42 (Figure 5.8B). The CDADC1 split apart probe FISH indicated that part of this gene is 
deleted (5’end), since we can only detect two copies of the normal gene and one red signal 
for the 3’ end region of CDADC1, the part involved in the fusion (Figure 5.8C). Additional 
sequencing of the cDNA revealed the fusion junction to involve exon 7 of GORASP2 and 
exon 6 of CDADC1 exon, joining the 5’ end region of GORASP2 with the 3’ end of CDADC1 
(Figure 5.7B) Expression of the fusion gene was confirmed by assessment of exon coverage 
from the RNA sequencing data, demonstrating the predicted exon-specific expression 
pattern, restricted to KNS42 (Figure 5.7D).  
Paired end reads from the whole genome sequencing analysis suggested a complex 
rearrangement involving different chromosomes in the pHGG cell line SF188. Intra- and 
inter-genic breakpoints associated with highly amplified regions in chromosomes 4q12, 
8q24, 11p11, 11q13, 11p14, 11q23 and 12q14 (Figure 5.9) were detected by the 
Breakdancer package. The amplicon structures showed alternation of amplified and non- 
amplified segments, some with similar copy number, suggesting a bridging mechanism that 
connects the segments and enables co-amplification. Several oncogenes previously noted to 
be altered in GBMs were located in these amplicons: MYC (8q24), CCND1 (11q13) and 
CDK4 (12q14). Gene amplification at 4q12 has been previously reported in GBM cases and 
this region spans three neighbouring RTKs - PDGFRA, KIT and KDR. FISH on SF188 
revealed that PDGFRA was not amplified in SF188 and it is not involved in this complex 
structure (Figure 5.10A). Instead, the two focal amplifications at 4q12 are located at the 
SDCD2 (Figure 5.10A) and FIP1L1 (Figure 5.10B). loci, upstream of the 4q12 RTKs, and it is 
these genes which are found in the amplified structure (Figure 5.11). Additionally, the 
amplicon at 11q23 involves MLL, a histone 3 lysine 4 (H3K4) methylase frequently involved 
in translocation in human acute leaukaemias of myeloid and lymphoid lineages [35]. The 
amplified regions at 11p11 and 11p14 do not include any coding genes. 
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Figure 5.4. RNA structural rearrangements detected in three paediatric high grade glioma cancer cell lines – KNS42, SF188 and UW479 – displayed as 
Circos plots. Each Circos plot depicts an overlay of transcriptome sequencing with whole genome sequencing for each cell line. Green: expressed fusion 
genes; Grey: structural variants only detected in RNA sequencing.  
 99 
 
 100 
Figure 5.5. Identification of NUBPL:AKAP6 gene fusion in UW479 paediatric high grade glioma cell 
line.  A) UW479 500K Affymetrix aCGH copy number profile of NUBPL and AKAP6. B) PCR and RT-
PCR detection of NUBPL:AKAP6 in UW479 genomic DNA and cDNA. Ctl: normal human genomic 
DNA. Partial sequence of the NUBPL:AKAP6 fusion transcript identified in UW479. C) Schematic 
representation of NUBPL and AKAP6 genes as well as the formation of the fusion transcript involving 
exons 1-12 of NUBPL and exons 4-11 of AKAP6. D) Expression of NUBPL and AKAP6 exons in 
UW479 vs KNS42 and SF188 cell lines. NUBPL: Nucleotide Binding Protein-Like; AKAP6: A Kinase 
Anchor-Protein 6; NA: NUBPL:AKAP6; AAA: AAA ATPases domain used for ATP binding; ParA: 
ParA/MinD ATPase like domain; SPECT: spectrin repeats; PKA RII: ser/thr protein kinase A RII 
interacting domain 
.
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Figure 5.6. FISH of NUBPL:AKAP6 rearrangement in UW479. A) Region specific BAC probes used 
for break-apart FISH. Probes were selected according to hg19 build of the human genome to 
overlap with the region of NUBPL that is involved in the fusion (RP11-200I02; green bar) with 
AKAP6 and to the region of the same gene that it is not disrupted (RP11-159D23; red bar). B)  
Diagram of the FISH signals expected when using control tissue, followed by interphase and 
metaphase NUBPL FISH in control tissue. C) Representative cartoon of the expected signals in the 
positive fusion cell line followed by FISH on interphase and metaphase UW479 cells. Original 
magnification 1000X. 
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Figure 5.7. Identification of GORASP2:CDADC1 gene fusion in KNS42 paediatric high grade glioma 
cell line.  A) KNS42 500K Affymetrix aCGH copy number profile of GORASP2 and CDADC1. B) PCR 
and RT-PCR detection of GORASP2:CDADC1 in KNS42 genomic DNA and cDNA. Ctl: normal 
human genomic DNA. Partial sequence of the GORASP2:CDADC1 fusion transcript identified in 
KNS42. C) Schematic representation of GORASP2 and CDADC1 genes as well as the formation of 
the fusion transcript involving exons 1-12 of GORASP2 and exons 4-11 of CDADC1. D) Expression of 
GORASP2 and CDADC1 exons in KNS42 vs UW479 and SF188 cell lines. GORASP2: golgi 
reassembly stacking protein 2 cytidine; CDADC1: dCMP deaminase domain containing 1; GC: 
GORASP2:CDADC1; GRASP55/65: GRASP55/65 PDZ like domain; CD-like dom: cytidine deaminase 
like domain; Deoxy Dea: deoxycytidylate deaminase domain 
.
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Figure 5.8. FISH of GORASP2-CDADC1 rearrangement in KNS42. A) Region specific BAC probes 
used for FISH. Probes were selected according to hg19 build of the human genome to overlap with 
the region of CDADC1 that is involved in the fusion (RP11-767008; red bar) and to the region of the 
same gene that is not disrupted (RP11-446P06; green bar). Another probe covering the region of 
GORASP2 involved in the fusion was also selected (RP11-164H08; green bar). B)  Diagram of the 
FISH signals expected when using fusion probes for GORASP2 and CDADC1, followed by interphase 
and metaphase FISH in control tissue and in the positive fusion cell line, KNS42. The yellow arrows 
indicate the fusion in KNS42. C) Representative cartoon of the expected signals when using a 
CDADC1 break-apart probe. FISH onto interphase and metaphase cells of control tissue and KNS42, 
showing split of 1 CDADC1 signal (yellow arrow) which indicates the rearrangement of this gene. 
Original magnification X1000. 
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The phenomenon of gene amplification in cancer cells is often manifested either as extra-
chromosomal self-replicating double-minutes (DMs) or as uniformly staining, linearly 
integrated chromosomal segments called homogenously staining regions (HSRs) [36]. DMs 
have been previously reported in GBM and other cancer types as a mean of amplifying 
oncogenes [37-40].  In order to determine if the amplicons in SF188 were present as DMs or 
HSRs, we performed multi-coloured FISH in SF188 metaphase spreads. As shown in Figure 
5.10, all amplicons were present as DMs and all regions in these amplicons showed similar 
amplification levels as predicted by the aCGH data (Figure 5.9), apart from the 11p11 region 
where levels of amplification were considerably lower (Figure 5.10, suggesting the presence 
of different double minute structures. Interestingly, we found that some SF188 cells 
contained a high number of DMs with CDK4 (12q14) whereas other cells just harboured few 
DMs of the same amplicon, a result of an uneven cell division and heterogeneity within the 
cell line. The same was true for the CCND1 (11q13) amplicon (Figure 5.10). 
In order to resolve the structure of these complex rearrangements and understand if these 
DMs were present in more than one extra-chromosomal structure, we performed dual FISH, 
combining probes for each amplicon listed by Breakdancer. We found that SCFD2 (4q12), 
FIP1L1 (4q12), MYC (8q24), MLL (11q23) and CDK4 (12q14) were present in the same DM 
(Figure 5.11). Interestingly, we found that the DMs containing MYC (8q24) are sometimes 
isolated (Figure 5.11B, 5.11D) (yellow arrows) or in the same structure as SCFD2 (4q12) 
(Figure 5.11B). or CDK4 (12q14) (Figure 5.11D). Combination of FISH probes for 11p11 and 
11q13 (CCND1) with 4q12 (SCFD2) revealed that these exist in different DM structures 
(Figure 5.12A, 5.12B). Moreover, distinct subpopulations of cells were observed when 
combining CCND1 (11q13) with CDK4 (12q14) (Figure 5.12E). A population of cells 
harboured only CDK4 amplification (Figure 5.12E green arrow), a second population 
contained only CCND1 amplification (Figure 5.12E red arrow), and some cells contained 
both amplifications in the same DM (Figure 5.12E yellow arrow). To demonstrate which 
amplicons were present in the second DM structure, we then combined 11q13 (CCND1) with 
either 11p11 or 11p14 and observed that these are present in the same extra-chromosomal 
structure, as shown by FISH in Figure 5.13. To further confirm that these DMs were 
separated structures we combined FISH probes for 11p14 with either 4q12 (Figure 5.12C) or 
CDK4 (12q14) (Figure 5.12D) or MYC (8q24) (Figure 5.12F). This FISH demonstrated once 
more that the amplicons occur in different DMs. Though the rearrangements involving these 
four different chromosomes were too complex for all the fragments to be resolved, a possible 
structure for each DM based on the FISH and Breakdancer results is shown in Figure 5.14. 
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Figure 5.9. SF188 amplicons. Affymetrix 500K SNP array of chromosome 4, 8, 11 and 12 showing 
the genes involved in each amplicon. BAC clones selected for FISH validation are represented 
underneath each gene. 
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Figure 5.10. FISH validation of the 
amplification peaks in SF188. 
Specific BAC probes for 8q24 (MYC) 
(C), 11p11 (D), 11q13 (CCND1) (E), 
11q23 (MLL) (F), 11p14 (G), 12q14 
(CDK4) (H) were labelled with Cy3 
(red) and co-hybridized to SF188 
interphase and metaphase cells with 
chromosome specific control probes 
labelled with fluorescein (green). 
Centromere 4 was labelled with Aqua 
and 4q12 gene PDGFRA was 
labelled with Cy3 (A), SCFD2 with 
fluorescein (A) and FIP1L1 with both 
(B). FISH shows that all regions 
amplified are in double minutes 
structures (B-H). PDGFRA is not 
amplified in SF188 (A) and only one 
region of the FIP1L1 gene in the 4q12 
region is amplified (B). The levels of 
amplification of all regions are similar, 
with the exception of 11p11 (D) and 
11p14 (G) which appear to have 
significantly fewer copies. 
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Figure 5.11. Dual FISH for the different amplicons in SF188. SCFD2 (4q12), FIP1L1 (4q12) (A), MYC (8q24) (B), MLL (11q23) (C), CDK4 
(12q14) (D) are present in the same double minute structure. The yellow arrows show that MYC is not always amplified in the same double 
minute with SCFD2 and CDK4, but may be seen by itself. 
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Figure 5.12. Dual FISH on SF188 
showing that some regions are 
amplified in distinct double minute 
structures. 11p11 (A), 11q13 
(CCND1) (B) and 11p14 (C) are not 
amplified with 4q12 (SCFD2) and 
12q14 (CDK4) (D) in the same double 
minute structure. Dual FISH for 11q13 
(CCND1) and 12q14 (CDK4) (E) show 
a mixed population with cells 
harbouring CCND1 amplification, 
some only CDK4, and others both.  
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Figure 5.13. Dual FISH on SF188 showing that 11p11 (A), 11q13 (CCND1) (A and B) and 11p14 
(B) are amplified in the same double minute structure.  
.
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Figure 5.14. Double minutes structures present in SF188 paediatric high grade glioma cell line displayed as Circos plots (predicted structures). 
Chromosomes 4q12, 8q24, 11q23 and 12q14 are present in one double minute (A). The second double minute is constituted of chromosome 11p11, 11q13 
and11p14 (C).  MYC is sometimes present as an independent structure (B).  Outer ring contains copy number derived from whole genome sequencing data 
(green=gain), annotated for the genes involved in the amplicons, followed by DNA orientation (grey arrows) and chromosomal location in the inner ring.  
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5.4 DISCUSSION 
In this chapter we report the landscape of gene fusions from three pHGG cell lines analysed 
by whole genome and transcriptome sequencing. Integrative analysis of a panel of three 
pHGG cell lines identified 17 novel fusion genes, all of which were localized to regions of 
amplification. Several distinct types of SVs were identified, including a complex extra-
chromosomal rearrangement present in SF188 that leads to amplification of multiple 
oncogenes through the production of DMs 
The pHGG cell lines were derived from patient tumour samples many years previously, and 
as such lacked matched normal controls that could be used to determine germline variation. 
Even using a very stringent filtering method to filter Breakdancer output, the number of 
predicted rearrangements was very high.  The predicted rearrangements were spread 
throughout the genome and therefore reflect the patterns seen in other solid tumours [41-
43], rather than as hotspots of rearrangements observed in leukaemia. Only 23% (17/74) of 
the SVs that coincide with genic regions were validated by PCR, and further 36.4% of these 
were validated by FISH (SF188 DMs), which accounts for a total of 59.4% validated SVs 
across the three cell lines. Other studies show that even when patient matched normal 
samples are sequenced and used to remove false positives, the validation rate is never 
100%. Berger and colleagues showed that in prostate cancer 78% of candidate 
rearrangements were validated using multiplexed PCR followed by massively parallel 
sequencing, and in this case matched normal samples were used to remove the false 
positives [44]. Contrary to other cancers, e.g. breast [42] and colorectal cancer [45], the 
majority of rearrangements validated in pHGG cell lines were inter-chromosomal.  
Integrating relative copy number data with the breakpoints is an important approach to assist 
in filtering putative SVs, as it has been shown that repeated breaks and rejoining of 
chromosomes during chromosomal amplifications leads to the generation of amplicon-
associated fusion genes [33]. Furthermore, other studies have reported that focal 
amplifications of certain genes resulted in the creation of chimaeras, such as the 
FGFR3:TACC3 fusion described in adult GBM [6]. Some of the rearranged genes reported in 
this study have unknown function and/or have not been related to cancer before (eg. SI, 
ASPH).  Others have been reported in the literature as harbouring breakpoints in multiple 
cancer samples, such as the methylatransferase-encoding PRMT8, the O-acetyl-ADP-ribose 
deacetylase MACROD2, both disrupted in UW479, and the chloride ion channel CLIC5 
detected in KNS42 [45].  
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The intra-chromosomal translocation discovered in UW479 that creates the NUBPL:AKAP6 
fusion involves two genes that have been connected to a specific genetic disorder and to 
cancer, respectively. NUBPL is a gene required for the assembly of the respiratory chain 
NADH dehydrogenase (complex I), an oligomeric enzymatic complex located in the inner 
mitochondrial membrane. Little is known about its structure, but disruption of this gene 
through missense mutations leads mitochondrial complex I deficiency in humans [46]. A 
deletion of NUBPL exons 1-4 with duplication of exon 7, leading to inactive NUBPL, has 
been found in this disorder [46, 47], and corresponds to the same region in UW479. 
NUBPL:AKAP6 fusion loses an important functional domain of AKAP6, the Ser/Thr protein 
kinase A (PKA) RII interacting domain. AKAP6 is part of A-kinase anchoring proteins family, 
which are key components of signal transduction. AKAP family members are structurally 
different yet functionally related proteins that bind and anchor the PKA to specific subcellular 
sites, thereby confining PKA activity to potential substrates, such as cyclic adenosine 
monophosphate [48]. In addition, there is evidence that AKAP family members expression 
and gene variation are directly associated with cancer development. AKAP3 mRNA 
expression appears to be associated with poor prognosis in epithelial ovarian cancer [49], 
and genetic alterations of AKAP9, AKAP11, AKAP12, and AKAP13 are associated with the 
aetiology of colorectal and lung cancer [50, 51], prostate, and breast cancers [52-54]. 
Moreover, Ciampi and colleagues reported an in-frame fusion between the C-terminal 
catalytic domain (exons 9 – 18) of the Ser/Thr kinase BRAF and the N-terminus (exons 1 – 
8) of another member of the AKAPs family, AKAP9, leading to constitutive BRAF and MAPK 
pathway activation. AKAP9 which was normally located in the centrosome and Golgi, lacked 
the C-terminal centrosomal domain, losing its centrosome location in cancer cells [55]. 
Although the role of NUBPL:AKAP6 is unclear, one could speculate that both genes play 
important physiological functions and their disruption in UW479 can either inactivate a copy 
of AKAP6, by disruption of its important PKA RII interacting domain, or lead to an inactive 
NUBPL, which plays an important role in cell metabolism.  
The GORASP2:CDADC1 chimaera is differently expressed in KNS42 compared to the other 
lines, which argues for a functionally significant role. Though neither gene has previously 
been associated with cancer, it is known that GORASP2 plays an important part in the 
regulation of mitosis through Golgi fragmentation [56]. The GORASP2 domain involved in 
this fusion (N-terminal GRASP domain) is essential for protein oligomerization/dimerization 
and for maintaining the Golgi complex structure. GORASP2 forms a complex matrix with 
GRASP65 and GM130 which is essential for the structure and function of the Golgi complex. 
When these proteins are phosphorylated by ERK1/CDK1/PLK1, the Golgi is dissembled and 
cells enter mitosis [56].  Interestingly, it has been shown that the GRASP domain of 
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GORASP2 is necessary and sufficient for oligomerization, which leads to inhibition of Golgi 
fragmentation in living cells resulting in a delay of the G2/M transition [57]. There is only one 
report available on CDADC1 where this gene was first identified [58], with no further 
information available on its structure and function. This fusion may activate CDADC1 or 
create a functionally active GORASP2 protein independent of being regulated by mitosis.  
Recently, Siyuan Zheng and colleagues identified a complex structural rearrangement that 
occurred within the same chromosome. A breakpoint-enriched region was identified at 
12q14-15 with focal amplifications involving the CDK4 and MDM2 oncogenes. This pattern 
was identified in ~5% of GBM patient samples and is associated with poor survival [58]. It is 
evident that amplifications do not occur randomly throughout the genome, and regions that 
are amplified tend not to be deleted, and vice versa. The amplified loci normally contain 
oncogenes, as it is the case of the genes involved in the extra-chromosomal structures 
present in SF188: MYC on 8q24, CCND1 on 11q13 and CDK4 on 12q14. More importantly, 
even though SF188 is a cell line originated from one single clone, we observed selective 
heterogeneity within the line. Some cells contained DMs with CDK4 and other cells 
contained DMs with CCND1, with few cells containing both. This reflects the asymmetric 
segregation of the DMs during cell division as they do not align along the mitotic spindle. 
These type of complex co-amplifications have also been described in other cancer types, 
such as breast cancer samples and cell lines [59, 60].   
As well as the novel fusion identification described above, the data provided in this chapter 
will form a valuable reference for future functional studies of the disease, as these cell lines 
are part of a small number of available pHGG models, with KNS42 representing the only 
available model for the study of the H3F3A G34V mutation. 
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6. RPTOR REARRANGEMENTS IN PAEDIATRIC HIGH GRADE GLIOMA 
6.1. Introduction 
Many of the dysregulated signalling processes identified in both paediatric and adult GBM 
involve the mammalian target of rapamycin (mTOR), a PI3K-related protein kinase [1]. 
mTOR controls cell growth in response to energy, nutrients, growth factors and other 
environmental cues, and is also frequently deregulated in other cancers [2, 3]. In the 
previously described pHGG cell line sequencing study (chapter 5), we identified a novel 
gene fusion involving RPTOR in SF188, a cell line derived from an 8 year old boy with GBM.  
The mTOR kinase is the catalytic subunit of two multiprotein complexes, mTORC1 and 
mTORC2 (Figure 6.1A). mTORC1 is defined by its regulatory associated protein of mTOR 
(RPTOR) subunit [4-6], which is replaced by RICTOR (rapamycin-insensitive RPTOR 
independent companion of mTOR) in mTORC2 [7]. Both complexes contain mammalian 
lethal with sec-13 (mLST8; also known as GβL) [6] and the recently identified DEP domain-
containing mTOR-interacting protein (DEPTOR) [8], but differ in several subunits that 
interact with RPTOR and RICTOR [2]. Further unique components of mTORC1 include a 
negative regulator proline-rich AKT substrate 40 kDa (PRAS40) [9], whereas mTORC2 
contains protein observed with rictor-1 (Protor-1) and Protor-2, which probably help complex 
assembly [10], and mammalian stress-activated protein kinase interacting protein 1 (mSIN1), 
which may target mTORC2 to membranes [11, 12]. These complexes perform non-
overlapping functions within the cell. mTORC2 primarily responds to growth factors, 
promoting cell cycle entry, cell survival, actin cytoskeleton polarization and anabolic output, 
contrary to mTORC1, which regulates cell growth by prompting translation, ribosome 
biogenesis and autophagy [13].  
mTORC1 drives growth through two downstream substrates, eukaryotic initiation factor 4E 
binding protein 1 (4E-BP1) and the S6 kinase 1 (S6K1) (Figure 6.1B) [14, 15], which control 
cap-dependent translation initiation and elongation, respectively. The regulation of the 
activity of mTORC1 towards these downstream targets and yet unidentified substrates 
appears to be complex and is likely to be dependent on the organization of the various 
subunits in the mTORC1 complex. RPTOR functions as an essential scaffolding protein and 
it is indispensable for mTOR to phosphorylate 4E-BP1 and S6K1, and for mTORC1 complex 
formation and dimerization [4]. RPTOR consists of a conserved N-terminal region followed 
by three HEAT repeats and seven WD40 repeats.  
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Figure 6.1. (A), Mammalian target of rapamycin (mTOR) complexes (mTORC1 and mTORC2) 
contain in addition to mTOR, DEPTOR (DEP-domain-containing mTOR-interacting protein) and 
mLST8 (mammalian lethal with SEC13 protein 8; also known as GβL). Other protein partners differ 
between the two complexes. Whereas mTORC1 contains RAPTOR (regulatory-associated protein of 
mTOR) and PRAS40 (proline-rich AKT substrate 40 kDa), mTORC2 contains RICTOR (rapamycin-
insensitive companion of mTOR), mSIN1 (mammalian stress activated MAP kinase-interacting protein 
1) and PROTOR (protein observed with RICTOR). (B) The mTOR signalling network. Arrows 
represent activation, bars represent inhibition. mTOR signalling regulates multiple critical cellular 
processes by integrating energy and nutrient status and PI3K/Akt signalling induced by growth factors 
and insulin. Adapted from [16, 17]. 
 
The RPTOR-mTOR interaction is very dynamic, and is thought to require the HEAT repeats 
of mTOR. The strength of interaction between mTOR and RPTOR can be modified by 
nutrients and other signals that regulate the mTORC1 pathway, but how this translates into 
regulation of the pathway remains vague. It has been shown that when in the presence of 
nutrients and amino acids, mTORC1 is recruited to lysosomes and late endosomes, a 
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process mediated by RPTOR, and co-localizes with its activator, the small GTPase Ras 
homolog enriched in brain (RHEB). RHEB is predicted to bind to and activate the mTOR 
kinase domain, and displace the mTORC1 inhibitor PRAS40 from RPTOR, leading to 
phosphorylation of 4E-BP1 and S6K, and mRNA translation. RPTOR phosphorylation on 
S722/792 is mediated by AMP-activated protein kinase (AMPK) and is required for the 
inhibition of mTORC1 activity induced by energy stress, whereas phosphorylation on 
S719/721/722 is mediated by p90 ribosomal S6 kinases (RSKs) and contributes to the 
activation of mTORC1 by mitogen stimulation.  
Given our identification of the novel RPTOR:TULP4 fusion in SF188, we sought to  
determine if SVs frequently involve RPTOR in paediatric and adult HGG samples, and begin 
to unravel the biological consequences of such RPTOR disruptions.  
6.2. MATERIAL AND METHODS 
6.2.1. Patient samples 
A series of 213 (53 paediatric samples and 160 adult cases) (Appendix I) formalin-fixed, 
paraffin- embedded (FFPE) samples were retrieved after approval from Wandsworth 
Research Ethics Committee approval from 213 consecutive patients diagnosed with GBM 
(WHO grade IV), anaplastic astrocytoma (WHO grade III) or anaplastic oligodendroglioma 
(WHO grade III) within the last 5 years from the archives of King's College Hospital, with 
diagnosis confirmed by re-review (S. Popov and S. Al-Sarraj). 
1 mm diameter cores from each case were taken and constructed in 11 tissue microarrays 
(TMAs). In addition, a series of control tissues were included, comprising normal human 
brain, normal mouse brain, placenta and colon. 
6.2.2 Fluorescent in-situ hybridization 
FISH based on the break-apart or fusion probe strategy was used to validate the RPTOR 
gene aberrations. For the RPTOR:TULP4 fusion probe, the following BAC clones were used: 
RP11-317F05 (red) and RP11-819H19 (green). For the break-apart probe the following BAC 
clones were used: RP11-317F05 (red), RP11-334C17 (red), RP11-819H19 (green) and 
RP11-387C10 (green). The cell line FISH protocol is described in chapter 5. The following 
protocol was used for FISH in TMAs: BAC DNA was amplified from 10 nanograms starting 
material using the IllustraTM GenomiPhiTM V2 DNA amplification kit (GE Healthcare, Little 
Chalfont, UK) according to manufacturer’s instructions. Probes were labelled with biotin and 
dioxigenin (DIG) using the BioPrime® DNA Labeling System (Life Technologies, Paisley, 
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UK). Briefly, the FFPE tissue sections were deparaffinised in 3 changes of xylene, 10min 
each and hydrated with 3 min 100%, 90%, 70% and deionised H2O (dH2O). The slides were 
pre-treated with 0.2M HCl for 20min, washed in dH2O for 3min and incubated in 8% (w/v) 
sodium thiocyanate at 80°C for 30min.  Slides were washed in 2xSSC for 3min, prior to 
digestion for 20min at 37°C with 0.01M HCl/ 0.025% (w/v) pepsin (Sigma, Gillingham, UK) 
solution. Slides were washed in 2xSSC for 5min, dehydrated with 3min 70%, 90%, 100% 
ethanol and left to dry at room temperature for 10min. Denaturation was carried out for 5min 
at 75°C and hybridization with the appropriate biotin- and DIG-labelled probe was done 
overnight at 37˚C in a humidified chamber. Removal of the coverslips was carried out by 
soaking the slides in 2xSSC/0.1% Igepal for 2 mins at room temperature and immersing in 
0.4xSSC/0.3% Igepal at 73˚C for 2min. Slides were rinsed in 2xSSC/0.1% Igepal for 1min 
and PBS for 3min.  Slides were first incubated in a humidified chamber at 37˚C with two 
layers of anti-DIG-fluorescein (Roche, Welwyn Garden City, UK) for 10min each, washed 
with PBS 3x3min and incubated with two layers of Streptavidin-cy3 (Sigma, Gillingham, UK) 
10min each. Slides were soaked in PBS for 3min, dehydrated with 3min 70%, 90%, 100% 
ethanol and left to dry at room temperature for 10min. TMA slides were finally mounted in 
Vectashield with DAPI (Vector Laboratories, Peterborough, UK), and captured on the Ariol 
System (Leica Microsystems, Wetzlar, Germany) using filters for DAPI, Cy3 and FITC.  
6.2.3. Cell lines 
The cell line SF188 was previously described in chapter 5. Briefly, cells were grown in 
DMEM F12-HAM complete media (Sigma-Aldrich) supplemented with 10% foetal bovine 
serum (FBS), incubated at 37°C with 5%CO2. DNA was extracted from the cell line and 
samples screened for mycoplasma at Surrey Diagnostics (Cranleigh, UK). 
6.2.4. DNA and RNA extraction 
Genomic DNA was extracted from SF188 pHGG cell line using the DNeasy Blood & Tissue 
Kit (Qiagen, Manchester, UK), and the quantity and quality of the DNA was assessed with 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies, Paisley, UK) and ND-1000 
Nanodrop (Thermo Scientific, Loughborough, UK). Total RNA was extracted using the 
Absolutely RNA Miniprep Kit (Agilent, Wokingham, UK), and the quantity and quality of the 
RNA was assessed on the 2100 Bioanalyzer (Agilent, Wokingham, UK), using the Agilent 
RNA 6000 Nano Kit (Agilent, Wokingham, UK), according to manufacturer instructions. 
cDNA was synthesized using the SuperScript II system (Life Technologies, Paisley, UK) 
according to manufacturer’s protocol.   
 127 
6.2.5. PCR validation 
Four PCR primers (IDT Technologies, Coralville, US) were designed using Primer3 [18, 19] 
for RPTOR and TULP4. These primers were designed ±200bp apart from the breakpoints to 
generate amplicons spanning the breakpoint-junction-sequences of predicted SV. In addition 
to fusion gene amplification, we amplified both partner genes involved. The following primer 
combinations were performed for DNA: RPTOR Fwd [5’- AGTTTGTCCTACCGCCCTTG-3’] 
x RPTOR Rev [5’-CCTTTGGTGGGAACTCCTC-3’], TULP4 Fwd [5’- 
GTAGCATCAGCTCTTGCCCA-3’] x TULP4 Rev [5’-GCTGGACAATACTCCCTGGC-3’], 
RPTOR Fwd x TULP4 Rev, and for cDNA RPTOR Exon6 Fwd [5’-
GTAGCTGCAATCAACCCAAATC-3’] x TULP4 Exon2 Rev [5’- 
AGTTTCTGGTAGGGCTCATTCC - 3’]. DNA from SF188 and normal control DNA 
(Promega, Southampton, UK) were used. PCR was carried out with Platinum® Taq DNA 
Polymerase High Fidelity (Life Technologies, Paisley, UK) in a 25 μl volume and with 100 
nanograms of genomic DNA or cDNA as template. The following program was used: Initial 
denaturation at 94°C for 3min, followed by a 2-Step-Touchdown: 1. (94°C 30 sec, 68°C 45 
sec, 72°C 1 min) 18 cycles, 2. (94°C 30 sec, 50°C 45 sec, 72°C 1 min) 30 cycles; followed 
by an additional cycle of 72°C 10 min. The fusion PCR product was cleaned up with the 
Illustra™ ExoStar™ 1-STEP kit (VWR, Lutterworth, UK). Sanger DNA sequencing of the 
PCR products was performed by DNA Sequencing & Services (MRCPPU, College of Life 
Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied Biosystems 
Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer.  
6.3. RESULTS 
Analysis of the whole genome sequence and DNA copy number profile of the pHGG cell line 
SF188 identified a novel fusion preserving the 5’ end of RPTOR and the 3’ end portion of 
TULP4 (Figure 6.2A). This rearrangement results from an inter-chromosomal translocation 
involving chromosome 6q25 and 17q25, with only one of the alleles of each gene being 
disrupted (Figure 6.2B). The genomic breakpoint junction shows blunt ends, contrary to the 
majority of the other fusions described in the previous chapter, which revealed 
microhomology at the breakpoint site (Chapter 5 - Figure 5.1). The only double-strand break 
repair pathway that can join DNA ends with no homology at the repair site is the classical 
NHEJ [20]. Using two different FISH strategies we were able to validate in SF188 the 
RPTOR:TULP4 fusion (Figure 6.3B) and also the disrupted RPTOR gene (Figure 6.3C). 
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Figure 6.2. Identification of RPTOR:TULP4 gene fusion in SF188 paediatric high grade glioma cell 
line.  A) SF188 500K Affymetrix aCGH copy number profile of RPTOR and TULP4. B) PCR and RT-
PCR detection of RPTOR:TULP4 in SF188 genomic DNA and cDNA. Partial sequence of the 
RPTOR:TULP4 fusion transcript identified in SF188. C) Schematic representation of RPTOR and 
TULP4 genes as well as the formation of the fusion transcript involving exons 1-6 of RPTOR and 
exons 2-14 of TULP4, that leads to a truncation of RPTOR containing exon 1-6 plus four amino acids 
of TULP4. The translated amino acid sequence is shown below the cartoon, with RPTOR in pink. 
TULP4 in yellow and the STOP codon in blue. D) Expression of RPTOR and TULP4 exons in SF188 
vs KNS42 and UW479 cell lines. RPTOR: regulatory associated protein of mTOR; TULP4: tubby like 
protein 4; RT: RPTOR:TULP4; RNC: RPTOR N-terminal conserved domain; HEAT: Huntingtin, 
elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR1 repeats 
domain; WD40: ~40 amino acid motifs, often terminating in a Trp-Asp (W-D) dipeptide; SOCS: 
suppressor of cytokines signalling box; tub: tubby proteins domain.  
 
Sanger sequencing of the RT-PCR product confirmed the fusion of RPTOR exon 6 with exon 
2 of TULP4 (Figure 6.2B), which is predicted to lead to the expression of a truncated RPTOR 
(Figure 6.2C). The truncated form of RPTOR preserves the conserved N-terminal region and 
loses the domains that bind to mTOR (HEAT domain and WD40 repeats) (Figure 6.2C). 
When expression of the fusion gene was assessed by exon coverage from the RNA 
sequencing data, there was no exon-specific expression pattern restricted to SF188 (Figure 
6.2D).  
We next sought to screen for RPTOR rearrangements in our paediatric and adult HGG 
series using specific break-apart FISH probes (Figure 6.3A). We screened 11 adult and 
pHGG TMAs, of which only cores with 50 scorable cells were screened. The RPTOR FISH 
probe was also assessed in control tissue, and on the basis of non-specific signal patterns 
observed, a threshold of 10% positive cells was set for assessment of the glioma samples. 
For the first TMAs screened we used a break-apart probe containing only one BAC clone at 
either side of RPTOR (RP11-317F05 and RP11-819H19) in order to specifically detect the 
RPTOR breakpoint seen in SF188 (Figure 6.4). Using this probe we found an adult case 
(1/160), RMH5987 where 14% cells contained a disrupted RPTOR (Figure 6.4). We then 
decided to use a break-apart FISH probe containing two BAC clones at either side of the 
RPTOR breakpoint (RP11-317F05/RP11-334C17 and RP11-819H19/RP11-387L10) in order 
to cover a larger region of the gene in case the breakpoint is different from the one occurring 
in SF188, and also in order to have a stronger probe. (Figure 6.4A). We found 2/53 pHGG 
cases harboured a disrupted RPTOR (Figure 6.4).  
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Figure 6.3. FISH of RAPTOR:TULP4 rearrangement in SF188. A) Region specific BAC probes used 
for FISH. Probes were selected according to hg19 build of the human genome to overlap with the 
region of RAPTOR that is involved in the fusion (RP11-317F05; red bar) and to the region of the same 
gene that is not disrupted (RP11-819H19; green bar). A further probe covering the region of TULP4 
involved in the fusion was also selected (RP11-589H21; green bar). B)  Cartoon of the FISH signals 
expected when using fusion probes for RAPTOR and TULP4, followed by interphase and metaphase 
FISH in control tissue and in the positive fusion cell line, SF188. The yellow arrows indicate the fusion 
in SF188. C) Representative cartoon of the expected signals when using a RAPTOR break-apart 
probe. FISH on interphase and metaphase cells of control tissue and SF188, showing split of the 
RAPTOR signal (yellow arrows) which indicates the rearrangement of this gene. Original 
magnification X1000. 
 
Figure 6.4. Representative FISH images showing disrupted RAPTOR in high grade glioma cases 
RMH2466, RMH3967 and RMH5987. The yellow arrows indicate the split of the RAPTOR signal 
which shows the rearrangement of this gene. A RAPTOR break-apart probe was used. Original 
magnification X1000. 
Two cores were available for each case so a mean of the percentage of fusion positive cells 
screened was calculated. RMH3967, an anaplastic astrocytoma of 9 years old female 
contained a disrupted RPTOR in 36.5% (31% and 42% in each core) of cells. In RMH2466, 
a GBM of a 10 years old male, the percentage was lower, with only 11% of cells positive 
(12% and 20% in each core).  
We were next able to assess a series of pHGG samples for whole genome and RNA 
sequencing data was available [21], and identified a further 2/127 (1.6%) cases containing a 
rearranged RPTOR (Figure 6.5). In this study, structural variation in whole genome 
sequencing was analysed using CREST (‘Clipping Reveals Structure’), an algorithm that 
uses next-generation sequencing reads with partial alignments to a reference genome, to 
directly map SVs at the nucleotide level of resolution [21, 22]. RNA sequencing SVs were 
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detected using CICERO (‘Cicero Is Crest Extended for RNA Optimizations’) (unpublished), a 
novel algorithm that utilizes de novo assembly to identify SVs [21]. SJHGG137, a GBM from 
a 6 year old boy, harbours a translocation that fuses the first 6 exons of RPTOR (1-277 
amino acids) to the second exon of PRAME (preferentially expressed antigen in melanoma), 
an inter-chromosomal translocation involving chromosomes 17q25.3 and 22q11.22, 
respectively. The same region of RPTOR is present in the SF188 fusion (Figure 6.2C), and 
the net result is also predicted to be the truncation of RPTOR, with only 6 amino acids of 
PRAME being expressed (Figure 6.5). Secondly, case SJHGG102, a DIPG from a 5 year old 
girl, was found to harbour a truncation  more proximal in the gene when compared to SF188 
and SJHGG137 (Figure 6.5). Here, the first four exons of RPTOR are fused to an intergenic 
region located at chromosome 15q23. 
In total, we identified 4/180 (2.2%) paediatric and 1/160 (0.6%) adult HGG to harbour similar 
RPTOR truncations to that identified in SF188 cells. 
 
 133 
 
 
Figure 6.5. Schematic representations of the RPTOR rearrangements present in two paediatric high 
grade glioma cases. In SJHGG137 patient sample, the formation of the fusion transcript involves 
exons 1-6 of RPTOR and exons 2-5 of PRAME (Preferentially expressed antigen in melanoma), 
which leads to a truncation of RPTOR containing exon 1-6. In case SJHGG102, exons 1-3 of RPTOR 
are fused with an intergenic region of chromosome 15, that leads to the expression of a truncated 
form of RPTOR. The translated amino acid sequence is shown below the cartoon, with RPTOR in 
pink. TULP4 in yellow and the STOP codon in blue. 
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6.4. Discussion 
Using the sequencing strategy outlined in Chapter 5, we identified a novel fusion in SF188 
cells involving the mTORC1 complex member RPTOR. Whole genome sequencing revealed 
a t(6;17) resulting in the generation of the novel expressed fusion gene RPTOR:TULP4. To 
search for the relevance of this fusion in patient samples, we utilised published whole 
genome and transcriptome sequencing data along with FISH screening of HGG TMAs to 
further identify 4/180 (2.2%) paediatric and 1/160 (0.6%) adult HGG to harbour similar 
RPTOR truncations to that identified in the reference cell line. 
RPTOR encodes an important component of the mTORC1 complex which is essential for 
normal function and pathway activation. The discovery of RPTOR rearrangements is of 
particular interest, since oncogenic activation of the mTOR pathway has been described in 
different tumour types and also in HGG [2]. However, this usually results from point 
mutations rather than gene rearrangements, either in the mTOR complexes components, or 
upstream in the PI3K members which activate mTOR.  
In HGG, RPTOR is a promiscuous fusion partner found fused with TULP4, PRAME and an 
intergenic region in chromosome 15. Due to this, rather than focus on finding the same 
fusions in our TMA series, we designed break-apart probes to identify a further 3 cases with 
RPTOR truncation instead, regardless of fusion partner. Though the fusion partners of the 
positive cases found by FISH are unknown, it is likely that they also have different partners, 
as the fusions with both TULP4 and PRAME obtain a stop codon early in their sequence and 
are not expressed. Genes with different fusion partners are commonly seen in cancer, such 
as the recurrent fusion of TMPRSS2 with ETS transcription factor genes in prostate cancer 
[23]. This promiscuity indicates that the critical gene in this rearrangement is likely to be 
RPTOR.  
This structural rearrangement leads to the fusion of the N-terminal domain of RPTOR with 
the 3’ end region of another genomic region, resulting in the expression of a shorter form of 
RPTOR. Do-Hyung Kim and colleagues expressed the first 300 amino acids of RPTOR (N-
terminal domain) in HEK293 cells and observed that this isoform was unable to interact with 
endogenous mTOR [5], predicting for a loss of function, although activation of downstream 
targets were not evaluated.  
Given the necessity for RPTOR in oncogenic signalling through the mTORC1 complex, it is 
not immediately apparent how a loss of RPTOR function would play a tumourigenic role.  An 
alternative view of mTOR complex function and formation which is dependent on cell type 
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(reviewed in [24]) in the CNS has recently been proposed. NF1 is a common tumour 
suppressor in glioma, which primarily functions as a negative regulator of the Ras proto-
oncogene and when lost results in increased Ras activity due to the absent or decreased 
function of neurofibromin’s GTPase-activating protein. Da Yong Lee and colleagues showed 
that NF1 gene loss leads to increased neural stem cell proliferation and gliogenesis in the 
brainstem, but not in the cortex. RPTOR and RICTOR are responsible for this difference, as 
they are differently expressed in both regions of the brain. This results in unbalanced levels 
of mTOR/RPTOR (mTORC1) and mTOR/RICTOR (mTORC2) complexes, which lead to 
either a negative or positive regulation of Akt activity, depending on which complex is higher 
[25]. In the same way, the rearranged RPTOR in the HGG samples might yield a dominant-
negative action in mTORC1 complex, contributing to unbalanced levels of the two mTOR 
complexes, therefore contributing to tumourigenesis through RICTOR-activated phospho-Akt 
signalling. Moreover, AKT pathway activation is seen in all paediatric cell lines SF188, 
KNS42 and UW479 [26]. Additionally, when compared with KNS42 and UW479, SF188 
shows low levels of phosphorylated S6 [26]. This protein is a downstream target of the 
mTORC1 complex which contains RPTOR, therefore RPTOR truncation might contribute to 
this downregulation via mTORC1 and also to the upregulation of activated AKT via 
mTORC2. Interestingly, both the RMH2466 paediatric case and SF188 cell line harbour NF1 
loss.  
Our results provide evidence for a low-frequency recurrent translocation involving RPTOR, 
such as those seen in adult GBM (FGFR:TACC (3-8%) and EGFR:SEPT14 (3.2%)) and in 
pHGG (NTRK fusions (7%)) [21, 27-29]. The discovery of novel RPTOR rearrangements in 
2.2% of pHGG shows that functionally important fusion events occur in this disease and 
suggest further structural characterization will likely identify additionally new recurrent 
rearrangements. More importantly, RPTOR SVs constitute an alternative way of activating 
PI3K/mTOR pathway, which is commonly deregulated in HGG through other mechanism 
[30-34]. The function of the RPTOR rearrangements is still unclear and other studies will be 
needed to determine whether and how the fusion interacts with the function of mTORC1 and 
its pathway. Nevertheless, this study generated new insights into the molecular 
characterization of pHGG, and highlighted a potential therapeutic target for this disease. 
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
Although childhood and adult HGG share related histopathological features, recent 
molecular profiling studies have clearly demonstrated that they are distinct biological 
diseases [1-6].  The work described throughout this thesis was set out to explore the 
molecular mechanisms underpinning pHGG, and to further delineate the distinguishing 
features of the adult and paediatric diseases, with a view to identify novel targets for 
therapeutic intervention. The presence of structural rearrangements and fusion genes was 
chosen to be investigated in pHGG, as almost nothing was known at the start of this work. 
We sought to characterize the presence and frequency of PDGFRA molecular alterations – 
mutations and structural rearrangements, we explored novel structural rearrangements 
associated with copy number alterations, and finally, we utilised whole genome sequencing 
to identify novel structural rearrangements that lead to the occurrence of fusion genes in 
childhood HGG. 
7.1. PDGFRA alterations in paediatric high grade glioma 
PDGFRA is a receptor tyrosine kinase that triggers essential cellular responses such as 
proliferation, migration, and survival [7]. This gene is commonly altered in cancer, by 
mutation [8, 9] and/or amplification [5, 6]. More importantly, it is the most frequent target of 
focal amplification and overexpression in pHGG, including DIPG, playing an important role in 
this disease [1, 3, 5, 6, 10, 11]. We thus explored the possibility that PDGFRA might be a 
preferential target of other mechanisms of genetic alteration in pHGG: somatic mutations 
and structural variation. In order to investigate this, we screened a large series of cases for 
single base changes and small indels, as well as the PDGFRAΔ8,9 deletion and the KP 
fusion gene, previously reported in aHGG [12-14]. A summary of the main results described 
in this chapter are shown in Table 7.1. The results confirmed that childhood HGG harbour a 
distinct set of PDGFRA alterations when compared with their adult counterparts 
(PDGFRAΔ89, KP), and this is in agreement with previous reports [13, 15-17].  
In addition, our study revealed that PDGFRA is the target of several novel in-frame 
insertions and deletions, and mutations across all functional domains of the gene, contrary to 
what is observed in other cancers, such as GIST  and NSCLC, where mutations occur un 
hotspot locations like the TK domain [8, 18]. Interestingly, in our studies PDGFRA alterations 
(mutations and indels) are more common in pHGG arising outside the brainstem (14% vs 
6%), and 8/18 (44%) cases have concomitant amplification and mutation of PDGFRA. 
Recently, in a study by G. Wu et al, 16/112 (14.3%) pHGG analysed by next generation 
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sequencing harboured both PDGFRA alterations (amplification and/or mutation) and histone 
H3.3 mutations. More importantly, 12/16 cases were associated with H3.3 (H3F3A) K27M 
mutations, 3/16 with H3.3 (H3F3A) G34R and only 1/16 with H3.1 (HIST1H3B) K27M [2], 
which is in accordance with unpublished data by J. Grill et al. In the same study, additional 
alterations in PDGFRA were discovered, small indels and also a novel translocation 
involving chromosomes 4 and 10, which leads to DIP2C:PDGFRA fusion gene in one of the 
DIPG cases [2]. In addition, A. Fontebasso et al study revealed that 7.1% (3/40) paediatric 
midline high grade astrocytoma (mHGA) carry mutations in PDGFRA tyrosine kinase domain 
(c.983A>G, c.1021G>A, c.1630_1631_insCAG), and the same cases also contain H3.3 
K27M mutation.  These studies confirmed the results developed in this thesis, that PDGFRA 
is commonly altered in pHGG, and that these changes occur in all functional domains of the 
gene.
Table 7.1. – Summary of the findings from the studies of PDGFRA in paediatric high grade glioma. 
Tumour type PDGFRA Alteration 
PDGFRA 
Mutation 
PDGFRA 
SV 
Altered cases 
with PDGFRA 
Amplification 
NB-pHGG 13/90 (14%)* 6/13 (46%) 7/13 (54%) 6/13 (46%) 
DIPG 5/77 (6%) 4/5 (80%) 1/5 (20%) 2/5 (40%) 
Total 18/167 (11%) 10/18 (56%) 8/18 (44%) 8/18 (44%) 
NB-pHGG: non brainstem paediatric high grade glioma; DIPG: Diffuse Intrinsic Pontine Glioma; SV: 
Structural Variant; * 3 Anaplastic Astrocytomas, 1 Anaplastic Oligodendroglioma and 9 Grade IV 
Glioblastomas 
In our study, we further explored the role of six PDGFRA mutants in vitro and in vivo. All the 
mutations taken for functional analysis were located at the extracellular domain of PDGFRA, 
and were found to be constitutively active and tumourigenic. The same phenomenon has 
been observed in other TK receptors, such as EGFR and ERBB2, where mutations in the 
extracellular domain besides being tumourigenic, are also cause resistance to TK small 
molecule inhibitors [19, 20]. In contrast to PDGFRA D842V mutated GIST tumours [21], 
pHGG PDGFRA alterations (V544ins, C450ins, E10del, E10del2 and E7del) did not confer 
resistance to dasatinib, a PDGFRA small molecule inhibitor. 
Furthermore, the identification of the novel PDGFRA mutations contributed to the 
characterization of a subgroup of DIPG with oligodendroglial features, which is largely driven 
by both mutations and amplifications in PDGFRA. It is now known that the different gene 
expression profile is driven by mutations in the histone genes, H3.3 and H3.1 which are 
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unique to brainstem tumours [1, 3].  Given the clear importance of PDGFRA signalling on 
pHGG, it is unsurprising that there are multiple mechanisms active in driving tumourgenesis 
through a common pathway. Even though early-phase clinical trial observed thus far with 
PDGFRA inhibitors have been disappointing, the fact that PDGFRA represents one of the 
most frequently altered molecules in pHGG renders it an outstanding therapeutic target, not 
as single agent but as an addition other therapeutic approaches. Moreover, the molecular 
characterization of PDGFRA alterations presented in this thesis provide further evidence that 
PDGFRA mutated pHGG are characterized by altered RTK modifications.  
7.2. Intragenic copy number aberrations and structural variants in paediatric high 
grade glioma 
Comprehensive copy number profiling of adult and pHGG was among the first data to 
demonstrate the biological differences between these two similar diseases, but focuses only 
on amplification/deletion of genes in their entirety [5, 6, 22]. This method largely ignores the 
breakpoints that occur within the gene, which themselves may be functionally significant. 
Thus, we leveraged DNA copy number profiles to characterize the landscape of intragenic 
breakpoints in childhood malignant gliomas (summarized in chapter 4). This approach has 
been used before and it successfully identified a novel fusion in adult GBM, the 
KDR:PDGFRA fusion gene [13]. We analysed a large copy number dataset of 100 pHGG 
tumours, previously published by our group [6], and demonstrated the extent of iCNAs to be 
associated with age, type of histone mutation, and prognosis. Notably, in our study the 
presence of iCNAs was positively correlated with older paediatric patients, and younger 
patients (infant group >3 years) harboured less iCNAs. Other studies showed that children 
younger than 3 years of age, which have a paucity of chromosome instability and a lack of 
mutations, seem to be driven by a single potent driver oncogene recently discovered – 
NTRK fusion genes [2]. This fusion gene was not detected in our study, because it is a copy 
number silent event, highlighting one of the inherent limitations. Interestingly, a high number 
of iCNAs was found in tumours carrying the H3F3A K27M mutation. This mutation occurs in 
brainstem and other midline gliomas, and leads to a reduced trimethylation of the K27 
residue (H3K27me3), consequently less heterochromatin is formed, which may lead to 
increased genomic instability [23, 24].  
In our series of pHGG, we further confirmed genes that are known to be deleted in GBM 
(NF1 and Rb1), but we also identified potential tumour suppressor genes in pHGG, such as 
FAF1, PTPRE, PTPRD and CSMD3. Most importantly, we discovered and validated a novel 
complex gene fusion that involved three genes, DHX57:TMEM178:MAP4K3. After the 
PDGFRA rearrangements, this was the first chimaera to be described in a pHGG. Although 
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no functional assays were performed, this fusion gene might play an important role in 
childhood malignant gliomas, since pHGG cell lines were highly sensitive to MAP4K3 siRNA 
knockdown. We also identified a case that harboured a CSGALNACT2:RET  fusion, 
although due to limited amount of material validation was not possible.   
In order to further explore the occurrence of fusion genes in copy number altered loci, we 
carried out whole genome and transcriptome sequencing of pHGG cell line models. We used 
a similar approach to nominate novel SVs in pHGG by integrating algorithm predicted SVs 
(Breakdancer [25] and Chimera Scan [26]) identified by both WGS and whole transcriptome 
sequencing, with copy number data. We reasoned that the integration of these data would 
uncover novel pHGG fusion genes and would complement our study done in pHGG samples 
(chapter 4), as other fusion genes identified in brain tumours have been found to be 
associated with a copy number alteration, eg. BRAF rearrangements described in pilocytic 
astrocytomas [27], the KDR:PDGFRA [13] and the FGFR:TACC [28] seen in adult GBM. 
This work is described in chapter 5.  
At the start of this thesis next generation sequencing had not been yet performed in pHGG 
samples and cell line models, and most of the data available was based on aCGH and 
expression arrays [5, 6, 29]. Our study showed for the first time that glioma cell lines KNS42, 
SF188 and UW479 are highly rearranged and that they are characterized by several fusion 
genes. We validated 59.4% of the algorithm-predicted SVs, using both PCR and FISH, 
which is similar to other studies where matched normal samples were also used [30]. 
Besides identifying novel fusion genes, we also discovered three extra-chromosomal 
structural rearrangement structures in SF188, which involve chromosomes 4q12 (SCFD2, 
FIP1L1), 8q24 (MYC), 11p11, 11q13 (CCND1), 11q14, 11q23 (MLL) and 12q14 (CDK4). The 
amplified loci represented two very complex structures, which were present in the form of 
three DMs. Although the exact arrangement of the genes in the DMs was not possible to 
reconstruct, based on the FISH and sequencing results we were able to draw a predicted 
structure.  
We further characterized a fusion gene in each cell line: GORASP2:CDADC1 in KNS42, 
NUBPL:AKAP6 in UW479 and RPTOR:TULP4 in SF188.  Both GORASP2 and CDADC1 
have not been reported in cancer studies, so their role is KNS42 is unclear. Nevertheless, 
GORASP2 is involved in mitosis control [31], suggesting that this chimaera might help cells 
enter mitosis, therefore promoting tumourigeneis. Although no clear role has been given to 
NUBPL:AKAP6 fusion gene, AKAP family members have been directly associated with 
cancer development [32-34]. Recently, a study by Brett E. Johnson et al. on clonal evolution 
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in recurrent glioma showed that a late recurrence adult anaplastic astrocytoma harboured 39 
mutations in AKAP6, connecting for the first time this gene to glioma [35].  
The RPTOR:TULP4 fusion gene described in SF188 involves RPTOR, an important 
component of mTOR signalling. This fusion leads to the expression of a truncated form of 
RPTOR in SF188. We discovered that RPTOR was disrupted 2.2% of pHGG cases 
(described in chapter 6) and that patient samples harbour similar truncations to the SF188 
cell line. This finding suggests that structural variation is a different mechanism that pHGG 
use to alter the PI3K/mTOR pathway, which is commonly deregulated in glioma samples 
[36]. This has important implications for functional and preclinical studies, as it may underlie 
the high degree of sensitivity to PI3K/mTOR inhibitors seen with SF188 in vitro.  
As the roles of these fusion genes are still unclear, further studies need to be performed in 
order to better understand their role in pHGG.  Future experiments concerning RPTOR 
rearrangements should aim at the molecular mechanism of truncated RPTOR in mTORC1 
complex. In order to do so, a truncated RPTOR in vitro cell model could be used to access 
protein expression, both upstream and downstream of RPTOR, using both western blot and 
immunoprecipitation. In parallel, RPTOR siRNA knockdowns could be performed in SF188 in 
order to know if this fusion gene affects cell viability. Genetically engineered mouse models 
of RPTOR fusions would provide the ultimate validation of a key role in glioma development. 
In summary, our results establish that pHGG harbour unique SVs, many of which may play 
important roles in the disease. In our study, we generated a detailed catalogue of genomic 
abnormalities occurring in pHGG and uncovered novel potential therapeutic targets.  
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8. APPENDIX 
Appendix I.  
Table S3.1. Clinical sample information for cases used for PDGFRA and RPTOR screens 
Sample ID Cohort WHO grade Diagnosis 
Age at 
diagnosis 
(years) 
PDGFRA 
amplification* 
PDGFRA  
alteration 
2HGG169T Cohort 2 III AA 8     
2HGG170T Cohort 2 III AA 8     
2HGG171T Cohort 2 III AA 12   N468S/E10del2  
2HGG173T Cohort 2 III AA 15     
2HGG178T Cohort 2 III AA 13     
2HGG179T Cohort 2 III AA 17     
HGG024 Cohort 2 III AA 7.5     
HGG079 Cohort 2 III AA 22.75 Yes Y288C 
HGG082 Cohort 2 III AA 5     
HGG097 Cohort 2 III AA 9     
HGG156 Cohort 2 III AA 13.2     
RMH2460 Cohort 2 III AA 16.4     
RMH2480 Cohort 2 III AA 15.8     
RMH3552 Cohort 2 III AA 5.0     
RMH3558 Cohort 2 III AA 10.0     
RMH3565 Cohort 2 III AA 8.8     
RMH3568 Cohort 2 III AA 17.7     
RMH3570 Cohort 2 III AA 12.7     
RMH3943 Cohort 2 III AA 10.9     
RMH3945 Cohort 2 III AA 4.1     
RMH3946 Cohort 2 III AA 24.9     
RMH3950 Cohort 2 III AA 16.4     
RMH3951 Cohort 2 III AA 14.1     
RMH3968 Cohort 2 III AA 21.2     
HGG007 Cohort 2 III AO 16.7 Yes A491ins 
RMH2447 Cohort 2 III AO 13.8     
RMH3492 Cohort 2 III AO 21.1     
RMH3500 Cohort 2 III AO 9.0   C235R 
RMH3942 Cohort 2 III AO 11.3     
RMH3963 Cohort 2 III AO 21.5     
RMH2444 Cohort 2 III AOA 19.1     
2HGG172T Cohort 2 IV GB 3     
152 
2HGG174T Cohort 2 IV GB 16 Yes   
2HGG175T Cohort 2 IV GBM 4     
2HGG176T Cohort 2 IV GBM 4   N659K 
2HGG177T Cohort 2 IV GBM 0.8     
2HGG180T Cohort 2 IV GBM 9     
2HGG181T Cohort 2 IV GBM 3     
2HGG182T Cohort 2 IV GBM 1.4     
HGG001 Cohort 2 IV GBM 5.8     
HGG006 Cohort 2 IV GBM 6.3 Yes   
HGG008 Cohort 2 IV GBM 16.5     
HGG010 Cohort 2 IV GBM 17.8 Yes   
HGG014 Cohort 2 IV GBM 7   C450ins  
HGG019 Cohort 2 IV GBM 14.4   E7del 
HGG020 Cohort 2 IV GBM 13.8     
HGG022 Cohort 2 IV GBM 14.1     
HGG023 Cohort 2 IV GBM 9.9     
HGG026 Cohort 2 IV GBM 19.8   D842V 
HGG028 Cohort 2 IV GBM 19.8 Yes N468S/E10del2  
HGG086 Cohort 2 IV GBM 14     
HGG093 Cohort 2 IV GBM 11.3     
HGG152 Cohort 2 IV GBM 22.7     
HGG154 Cohort 2 IV GBM 3.8     
HGG157 Cohort 2 IV GBM 14.8 Yes E7del 
HGG158 Cohort 2 IV GBM 10.7     
HGG159 Cohort 2 IV GBM 13.1 Yes E10del 
HGG162 Cohort 2 IV GBM 13.5     
RMH2449 Cohort 2 IV GBM 11.0     
RMH2450 Cohort 2 IV GBM 0.5     
RMH2452 Cohort 2 IV GBM 3.8     
RMH2453 Cohort 2 IV GBM 11.9     
RMH2455 Cohort 2 IV GBM 17.0     
RMH2456 Cohort 2 IV GBM 13.3 Yes   
RMH2463 Cohort 2 IV GBM 12.0     
RMH2464 Cohort 2 IV GBM 9.2     
RMH2466 Cohort 2 IV GBM 9.7     
RMH2467 Cohort 2 IV GBM 10.3     
RMH2470 Cohort 2 IV GBM 14.3     
RMH2471 Cohort 2 IV GBM 12.4 Yes   
RMH2474 Cohort 2 IV GBM 15.4     
RMH2475 Cohort 2 IV GBM 15.2 Yes   
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RMH2477 Cohort 2 IV GBM 4.7     
RMH2478 Cohort 2 IV GBM 11.5     
RMH2479 Cohort 2 IV GBM 8.7     
RMH3491 Cohort 2 IV GBM 9.8     
RMH3498 Cohort 2 IV GBM 12.5   C290R 
RMH3499 Cohort 2 IV GBM 11.5 Yes E229K 
RMH3549 Cohort 2 IV GBM 6.3     
RMH3550 Cohort 2 IV GBM 10.0     
RMH3557 Cohort 2 IV GBM 5.8     
RMH3944 Cohort 2 IV GBM 10.4     
RMH3947 Cohort 2 IV GBM 6.7     
RMH3949 Cohort 2 IV GBM 5.5 Yes   
RMH3952 Cohort 2 IV GBM 14.5 Yes   
RMH3953 Cohort 2 IV GBM 21.4     
RMH3954 Cohort 2 IV GBM 20.2 Yes   
RMH3955 Cohort 2 IV GBM 19.8     
RMH3956 Cohort 2 IV GBM 6.1     
RMH3960 Cohort 2 IV GBM 11.3     
BSG001T Cohort 2 IV DIPG 11.8     
BSG003T(CB) Cohort 2 IV DIPG 7.9 Yes   
BSG004TD Cohort 2 IV DIPG 5.5     
BSG005T Cohort 2 IV DIPG 4.3     
BSG009T Cohort 2 IV DIPG 6.1 Yes   
BSG010T Cohort 2 IV DIPG 13.7     
BSG012T Cohort 2 IV DIPG 5.5     
BSG015T Cohort 2 IV DIPG 5.2     
BSG017T Cohort 2 IV DIPG 5.7     
BSG019T Cohort 2 IV DIPG 15.7 Yes   
BSG020T Cohort 2 IV DIPG 5.9     
BSG021T Cohort 2 IV DIPG 7.3     
BSG022TD Cohort 2 IV DIPG 5.3   V544ins  
BSG023T Cohort 2 IV DIPG 3.6 Yes   
BSG024TD Cohort 2 IV DIPG 14.9     
BSG025T Cohort 2 IV DIPG 3.9 Yes   
BSG026T Cohort 2 IV DIPG 6.4     
BSG027TD Cohort 2 IV DIPG 5.2     
BSG029T Cohort 2 IV DIPG 5.2     
BSG030T Cohort 2 IV DIPG 12.3     
BSG031T Cohort 2 IV DIPG 5.2     
BSG032T Cohort 2 IV DIPG 10.9     
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BSG033T Cohort 2 IV DIPG 3.7     
BSG034T Cohort 2 IV DIPG 8.9     
BSG035T Cohort 2 IV DIPG 13.2 Yes   
BSG037T Cohort 2 IV DIPG 15.7 Yes   
BSG038T Cohort 2 IV DIPG 6.9     
BSG039T Cohort 2 IV DIPG 6     
BSG040T Cohort 2 IV DIPG 12.5   N659K 
BSG042T Cohort 2 IV DIPG 10.2     
BSG044T Cohort 2 IV DIPG 9 Yes   
BSG045T Cohort 2 IV DIPG 5.6 Yes   
BSG046T Cohort 2 IV DIPG 3     
BSG047T Cohort 2 IV DIPG 8.4 Yes   
BSG509T Cohort 2 IV DIPG 5.6 Yes   
BSG529T Cohort 2 IV DIPG 6.1     
BSG900TD Cohort 2 IV DIPG 6.4     
BSG901TD Cohort 2 IV DIPG N/A     
BSG902TD Cohort 2 IV DIPG 9.8     
DIPG-WES001 Cohort 2 IV DIPG N/A     
DIPG-WES002 Cohort 2 IV DIPG N/A     
DIPG-WES003 Cohort 2 IV DIPG N/A     
HGG095 Cohort 2 IV DIPG 5     
RMH 3560 Cohort 1 N/A  DIPG 6.9     
RMH 3964 Cohort 1 N/A  DIPG 4.3     
RMH 3957  Cohort 1 N/A  DIPG 4.8 Yes W449C 
RMH 6962 Cohort 1 N/A  DIPG 8.03     
RMH 6963 Cohort 1 N/A  DIPG 4.46     
RMH 6964 Cohort 1 N/A  DIPG NA     
RMH 6965 Cohort 1 N/A  DIPG NA Yes   
RMH 6966 Cohort 1 N/A  DIPG 3.39     
RMH 6967 Cohort 1 N/A  DIPG 13.55     
RMH 6968 Cohort 1 N/A  DIPG 12.13     
RMH 6969 Cohort 1 N/A  DIPG NA     
RMH 6970 Cohort 1 N/A  DIPG NA     
RMH 6971 Cohort 1 N/A  DIPG 5.08     
RMH 6972 Cohort 1 N/A  DIPG 4.49     
RMH 6973 Cohort 1 N/A  DIPG 7.55     
RMH 6974 Cohort 1 N/A  DIPG 4.72 Yes T276P 
RMH 6975 Cohort 1 N/A  DIPG 6.26     
RMH 6976 Cohort 1 N/A  DIPG 4.75     
RMH 6977 Cohort 1 N/A  DIPG 9.41     
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RMH 6978 Cohort 1 N/A  DIPG 6.37     
RMH 6979 Cohort 1 N/A  DIPG NA     
RMH 6980 Cohort 1 N/A  DIPG 11.9     
RMH 6981 Cohort 1 N/A  DIPG NA     
RMH 6982 Cohort 1 N/A  DIPG 5.27     
RMH 6983 Cohort 1 N/A  DIPG 10.22     
RMH 6984 Cohort 1 N/A  DIPG 6.76     
RMH 6985 Cohort 1 N/A  DIPG 13.49     
RMH 6986 Cohort 1 N/A  DIPG 7.41 Yes   
RMH 6987 Cohort 1 N/A  DIPG 6.76   R479Q 
RMH 6988 Cohort 1 N/A  DIPG NA     
RMH 6989 Cohort 1 N/A  DIPG 11.03     
RMH 6990 Cohort 1 N/A  DIPG NA     
RMH 6991 Cohort 1 N/A  DIPG NA     
RMH 6992 Cohort 1 N/A  DIPG 6.22     
RMH5684 adult cohort IV GBM 41.97 Yes   
RMH5685 adult cohort IV GBM 76.49 Yes PDGFRA del8,9 
RMH5686 adult cohort IV GBM 63.17 Yes   
RMH5687 adult cohort III AA 65.18 Yes   
RMH 5688 adult cohort same case as above     Yes   
RMH 5689 adult cohort same case as above     Yes   
RMH5690 adult cohort IV GBM 70.49 Yes   
RMH5696 adult cohort IV GBM 57.1 Yes   
RMH5697 adult cohort IV GBM 75.96 Yes   
RMH5698 adult cohort same case as above     Yes   
RMH5701 adult cohort IV GBM 54.66 Yes   
RMH5707 adult cohort III AO 62.67 Yes   
RMH5714 adult cohort IV GBM 61.25 Yes   
RMH5716 adult cohort IV GBM 79.08 Yes   
RMH5724 adult cohort IV GBM 53.34 Yes   
RMH5725 adult cohort IV GBM 54.47 Yes   
RMH5966 adult cohort IV GBM 79.65 Yes   
RMH5978 adult cohort IV GBM 46.6 Yes   
RMH5981 adult cohort III AA 75.25 Yes   
RMH5982 adult cohort IV GBM 75.5 Yes   
RMH5984 adult cohort IV GBM 33.72 Yes   
RMH5986 adult cohort III AO 42.95 Yes   
RMH5989 adult cohort IV GBM 69.18 Yes   
RMH5991 adult cohort IV GBM 69.11 Yes   
RMH5998 adult cohort III AO 26.68 Yes   
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RMH6004 adult cohort IV GBM 79.96 Yes   
RMH6006 adult cohort IV GBM 38.15 Yes   
RMH6010 adult cohort IV GBM 62.88 Yes   
RMH6357 adult cohort IV GBM 59.71 Yes   
RMH 6375 adult cohort IV GBM 55.79 Yes   
RMH 6382 adult cohort IV GBM 61.47 Yes   
RMH 6388 adult cohort IV GBM 55.91 Yes   
RMH 6400 adult cohort IV GBM 49.87 Yes   
RMH 6416 adult cohort IV GBM 73.68 Yes   
RMH6417 adult cohort IV GBM 55.79 Yes   
RMH6427 adult cohort IV GBM 62.79 Yes   
RMH6433 adult cohort IV GBM 64.95 Yes   
RMH6440 adult cohort III AO 40.24 Yes   
RMH6620 adult cohort IV GBM 68.16 Yes   
RMH6621 adult cohort III AO 45.16 Yes   
RMH6625 adult cohort III AO 25.84 Yes   
RMH6628 adult cohort III AO 46.29 Yes   
RMH6634 adult cohort III AA 42.02 Yes   
RMH6636 adult cohort IV GBM 65.22 Yes   
RMH6641 adult cohort III AO 53.92 Yes   
RMH6645 adult cohort IV GBM 52.15 Yes   
RMH6646 adult cohort IV GBM 47.25 Yes   
RMH6653 adult cohort IV GBM 50.3 Yes   
RMH6665 adult cohort IV GBM 48.24 Yes   
RMH6666 adult cohort same case as above     Yes   
RMH6667 adult cohort IV GBM 55.98 Yes   
RMH6668 adult cohort IV GBM 55.96 Yes   
RMH6674 adult cohort IV GBM 78.13 Yes PDGFRA del8,9 
RMH6677 adult cohort IV GBM 48.88 Yes   
RMH6685 adult cohort IV GBM 45.78 Yes   
RMH6689 adult cohort IV GBM 51.85 Yes   
RMH6862 adult cohort IV GBM 67.45 Yes   
RMH6863 adult cohort same case as above     Yes   
RMH6872 adult cohort III AO 50.17 Yes   
RMH6873 adult cohort IV GBM 65.5 Yes   
RMH6874 adult cohort III AO 32.12 Yes   
RMH6881 adult cohort IV GBM 44.6 Yes   
RMH6887 adult cohort IV GBM 61.1 Yes   
RMH6888 adult cohort same case as above     Yes   
RMH6889 adult cohort IV GBM 51.83 Yes   
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RMH6891 adult cohort III AO 69.15 Yes   
RMH6892 adult cohort IV GBM 76.04 Yes   
RMH6893 adult cohort IV GBM NA Yes   
RMH6905 adult cohort IV GBM 43.68 Yes   
RMH6924 adult cohort IV GBM 52.02 Yes   
RMH6925 adult cohort IV GBM 54.91 Yes   
RMH6926 adult cohort IV GBM 76.07 Yes   
RMH6927 adult cohort IV GBM 66.83 Yes   
RMH6935 adult cohort IV GBM 45.36 Yes   
RMH6936 adult cohort same case as above     Yes   
Sample ID Cohort WHO grade Diagnosis 
Age at 
diagnosis 
(years) 
RPTOR  
Structural 
Variant  
RMH2445 paeds TMA III OAO 19.1    
RMH2452 paeds TMA IV GBM 3.8    
RMH2459 paeds TMA III AA 16.4    
RMH2462 paeds TMA same case as above        
RMH2465 paeds TMA IV GBM 13.9    
RMH2466 paeds TMA IV GBM 9.7 Yes  
RMH2468 paeds TMA IV GBM 10.3    
RMH2469 paeds TMA III GC 14.5    
RMH2473 paeds TMA IV GBM 15.4    
RMH3490 paeds TMA IV GBM 11.3    
RMH3492 paeds TMA II AO 21.1    
RMH3947 paeds TMA IV GBM 6.7    
RMH3952 paeds TMA IV GBM 14.5    
RMH3954 paeds TMA IV GBM 20.2    
RMH3955 paeds TMA IV GBM 19.8    
RMH3957 paeds TMA IV DIPG 4.8    
RMH3962 paeds TMA III AA 0.4    
RMH3963 paeds TMA III AO 21.5    
RMH3965 paeds TMA IV GBM 12.5    
RMH3967 paeds TMA III AA 9 Yes  
RMH4830 paeds TMA IV GBM 13    
RMH4833 paeds TMA IV GBM 18    
RMH4835 paeds TMA IV GBM 6    
RMH4839 paeds TMA IV GBM 16    
RMH4840 paeds TMA IV GBM 7    
RMH7062 paeds TMA IV GBM 13.9    
RMH7063 paeds TMA III PXA 13    
RMH7064 paeds TMA III AA 9    
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RMH7068 paeds TMA IV GBM 19.3    
RMH7069 paeds TMA IV GBM 20.3    
RMH7070 paeds TMA IV GBM 1.3    
RMH7072 paeds TMA IV GBM 12.9    
RMH7074 paeds TMA IV GBM 10    
RMH7077 paeds TMA III PXA 15    
RMH7342 paeds TMA III AO 13.2    
RMH7345 paeds TMA III AA 18    
RMH7351 paeds TMA IV GBM 9    
RMH7352 paeds TMA IV GBM 15    
RMH7358 paeds TMA III PXA 18    
RMH7359 paeds TMA same case as above        
RMH7472 paeds TMA N/A N/A N/A    
RMH7479 paeds TMA N/A N/A N/A    
RMH7501 paeds TMA N/A N/A N/A    
RMH7502 paeds TMA N/A N/A N/A    
RMH7503 paeds TMA N/A N/A N/A    
RMH7505 paeds TMA N/A N/A N/A    
RMH7721 paeds TMA N/A N/A N/A    
RMH7767 paeds TMA N/A N/A N/A    
RMH7768 paeds TMA N/A N/A N/A    
RMH7771 paeds TMA N/A N/A N/A    
RMH5684 adult TMA IV GBM 69.23    
RMH5687 adult TMA III AA 62.91    
RMH5688 adult TMA same case as above        
RMH5689 adult TMA same case as above        
RMH5690 adult TMA IV GBM 47.67    
RMH5691 adult TMA IV GBM 57.17    
RMH5692 adult TMA same case as above        
RMH5695 adult TMA III AO 60.28    
RMH5697 adult TMA IV GBM 68.16    
RMH5698 adult TMA same case as above        
RMH5699 adult TMA IV GBM 45.16    
RMH5700 adult TMA same case as above        
RMH5701 adult TMA IV GBM 63.12    
RMH5704 adult TMA IV GBM 72.65    
RMH5706 adult TMA IV GBM 52.63    
RMH5708 adult TMA IV GBM 66.46    
RMH5709 adult TMA IV GBM 58.34    
RMH5710 adult TMA III AA 56.76    
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RMH5713 adult TMA IV GBM 31.94    
RMH5714 adult TMA IV GBM 53.34    
RMH5715 adult TMA IV GBM 59.64    
RMH5716 adult TMA IV GBM 42.47    
RMH5718 adult TMA IV GBM 57.56    
RMH5719 adult TMA III AA 46.6    
RMH5720 adult TMA IV GBM 57.32    
RMH5722 adult TMA same case as above        
RMH5723 adult TMA IV GBM 45.49    
RMH5724 adult TMA IV GBM 47.09    
RMH5966 adult TMA IV GBM 25.84    
RMH5967 adult TMA IV GBM 47.25    
RMH5968 adult TMA same case as above        
RMH5969 adult TMA IV GBM 75.25    
TMH5970 adult TMA IV GBM 70.04    
RMH5972 adult TMA IV GBM 55.91    
RMH5973 adult TMA IV GBM 43.7    
RMH5974 adult TMA IV GBM 46.29    
RMH5976 adult TMA IV GBM 36.2    
RMH5978 adult TMA IV GBM 51.99    
RMH5980 adult TMA IV GBM 65.55    
RMH5981 adult TMA III AA 52.14    
RMH5982 adult TMA IV GBM 33.72    
RMH5983 adult TMA IV GBM 59.88    
RMH5984 adult TMA IV GBM 69.16    
RMH5985 adult TMA IV GBM 54.47    
RMH5986 adult TMA III AO 71.06    
RMH5987 adult TMA III AO 56.31 Yes  
RMH5988 adult TMA III AA 61.49    
RMH5989 adult TMA IV GBM 72.68    
RMH5990 adult TMA same case as above        
RMH5992 adult TMA III AA 42.09    
RMH5994 adult TMA IV GBM 67.45    
RMH5996 adult TMA IV GBM 65.22    
RMH5998 adult TMA III AO 42.95    
RMH5999 adult TMA IV GBM 60.18    
RMH6003 adult TMA IV GBM 42.97    
RMH6004 adult TMA IV GBM 51.86    
RMH6006 adult TMA IV GBM 66.06    
RMH6007 adult TMA IV GBM 49.13    
160 
RMH6010 adult TMA IV GBM 70.45    
RMH6011 adult TMA IV GBM 45.27    
RMH6341 adult TMA III AO 58.34    
RMH6343 adult TMA IV GBM 35.88    
RMH6345 adult TMA III AO 66.63    
RMH6346 adult TMA III AO 50.52    
RMH6347 adult TMA III AO 30.57    
RMH6354 adult TMA IV GBM 49.46    
RMH6356 adult TMA III AO 31.38    
RMH6362 adult TMA III AA 60.11    
RMH6365 adult TMA IV GBM 69.11    
RMH6370 adult TMA IV GBM 66.15    
RMH6372 adult TMA IV GBM 77.73    
RMH6373 adult TMA same case as above        
RMH6374 adult TMA IV GBM 58.62    
RMH6375 adult TMA IV GBM 51.35    
RMH6377 adult TMA IV GBM 60.13    
RMH6379 adult TMA III AO 62.67    
RMH6380 adult TMA IV GBM 39.01    
RMH6381 adult TMA III AO 63.09    
RMH6384 adult TMA IV GBM 62.65    
RMH6385 adult TMA IV GBM 26.68    
RMH6386 adult TMA IV GBM 70.82    
RMH6387 adult TMA IV GBM 46.8    
RMH6388 adult TMA IV GBM 68.75    
RMH6390 adult TMA III AO 50.11    
RMH6391 adult TMA IV GBM 40.53    
RMH6393 adult TMA IV GBM 67.07    
RMH6394 adult TMA III AO 70.4    
RMH6395 adult TMA IV GBM 64.27    
RMH6396 adult TMA IV GBM 65.7    
RMH6397 adult TMA IV GBM 69.78    
RMH6398 adult TMA III AO 80.83    
RMH6399 adult TMA III AO 60.49    
RMH6400 adult TMA IV GBM 45.83    
RMH6401 adult TMA IV GBM 43.07    
RMH6402 adult TMA III AO 50.17    
RMH6403 adult TMA IV GBM 69.45    
RMH6404 adult TMA IV GBM 82.42    
RMH6405 adult TMA IV GBM 51.6    
161 
RMH6409 adult TMA IV GBM 56.99    
RMH6411 adult TMA IV GBM 41.78    
RMH6412 adult TMA same case as above        
RMH6413 adult TMA IV GBM 65.95    
RMH6414 adult TMA IV GBM 45.76    
RMH6417 adult TMA IV GBM 36.04    
RMH6418 adult TMA III AO 57.4    
RMH6419 adult TMA IV GBM 32.12    
RMH6420 adult TMA IV GBM 71.32    
RMH6421 adult TMA IV GBM 56.86    
RMH6424 adult TMA IV GBM 46.44    
RMH6425 adult TMA IV GBM 67.56    
RMH6427 adult TMA IV GBM 55.96    
RMH6429 adult TMA IV GBM 71.91    
RMH6433 adult TMA IV GBM 41.91    
RMH6434 adult TMA IV GBM 59.89    
RMH6435 adult TMA IV GBM 62.15    
RMH6639 adult TMA IV GBM 70.92    
RMH6641 adult TMA same case as above        
RMH6650 adult TMA IV GBM 63.17    
RMH6651 adult TMA IV GBM 69.19    
RMH6652 adult TMA same case as above        
RMH6653 adult TMA IV GBM 65.18    
RMH6665 adult TMA IV GBM 51.15    
RMH6666 adult TMA same case as above        
RMH6676 adult TMA III AO 57.45    
RMH6685 adult TMA IV GBM 57.1    
RMH6687 adult TMA IV GBM 73.38    
RMH6689 adult TMA IV GBM 55.2    
RMH6691 adult TMA same case as above        
RMH6703 adult TMA III AA 69.21    
RMH6862 adult TMA IV GBM 28.66    
RMH6866 adult TMA IV GBM 56.01    
RMH6867 adult TMA III AO 47.38    
RMH6871 adult TMA III AO 65.91    
RMH6874 adult TMA III AO 69.32    
RMH6877 adult TMA IV GBM 76.04    
RMH6880 adult TMA same case as above        
RMH6881 adult TMA IV GBM 51.81    
RMH6884 adult TMA IV GBM 38.49    
162 
RMH6887 adult TMA IV GBM 37.02    
RMH6891 adult TMA III AO 73.74    
RMH6892 adult TMA IV GBM 37.78    
RMH6895 adult TMA IV GBM 72.62    
RMH6897 adult TMA III AO 41.84    
RMH6898 adult TMA III AO 49.43    
RMH6899 adult TMA IV GBM 38.42    
RMH6900 adult TMA IV GBM 67.21    
RMH6902 adult TMA IV GBM 37.33    
RMH6905 adult TMA IV GBM 54.85    
RMH6906 adult TMA IV GBM 43.68    
RMH6909 adult TMA III AA 67.69    
RMH6910 adult TMA IV GBM 46.97    
RMH6913 adult TMA III AA 58.56    
RMH6918 adult TMA IV GBM 55.88    
RMH6926 adult TMA IV GBM 39.3    
RMH6933 adult TMA IV GBM 66.83    
RMH6934 adult TMA III AA 57.12    
RMH6935 adult TMA IV GBM 60.87    
RMH6939 adult TMA III AO 60.68    
RMH6952 adult TMA III AO N/A    
RMH6959 adult TMA IV GBM N/A    
AA - non‐brainstem pediatric Anaplastic Astrocytoma 
GBM - non‐brainstem  glioblastoma 
DIPG - diffuse intrinsic pontine glioma (glioblastoma) 
GC - Gliomatosis cerebri 
PXA - Pleomorphic anaplastic xanthoastrocytoma 
N/A - data not available 
*accessed by FISH or aCGH 
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Appendix V 
Table S5.1. Structural variants (SV) predicted by the Breakdancer. All SVs listed involve genes at either side of the rearrangement. 
Breakdancer score is >99 for all SVs. Genes were annotated with Ensembl references (columns: “Gene 1 name” and “Gene 2 name”). 
Chr 1 Pos 1 Ori 1 Chr 2 Pos 2 Ori 2 Type Insert Size Reads Cell Line Gene 1 name Gene 2 name 
chr1 9121800 36+22- chr14 93712302 38+23- CTX -404 57 KNS42 ENSG00000142583|SLC2A5 ENSG00000011114|BTBD7 
chr1 28515580 22+0- chr19 24027536 22+0- CTX -404 22 KNS42 ENSG00000169403|PTAFR  
chr1 38433028 15+15- chr6 28863601 14+15- CTX -404 27 KNS42 ENSG00000183431|SF3A3  
chr1 58802590 1+16- chr10 74176383 0+15- CTX -404 15 KNS42 ENSG00000173406|DAB1 ENSG00000107745|MICU1 
chr1 59096783 10+1- chr2 32048657 1+12- CTX -404 10 KNS42 ENSG00000185839| ENSG00000242272|AK2P2 
chr1 109495128 30+28- chr3 110413045 28+30- CTX -404 58 KNS42 ENSG00000121940|CLCC1  
chr1 119401099 13+2- chr15 51189367 0+12- CTX -404 12 KNS42  ENSG00000247586| 
chr1 152276735 0+26- chr1 152281500 26+1- ITX 4064 26 KNS42 ENSG00000143631|FLG ENSG00000237975| 
chr1 152387895 37+0- chr11 132713260 2+43- CTX -404 37 KNS42 ENSG00000227415| ENSG00000183715|OPCML 
chr1 156051752 12+0- chr3 189542047 12+0- CTX -404 12 KNS42 ENSG00000254726|MEX3A ENSG00000073282|TP63 
chr1 168025506 22+0- chr19 24033172 2+24- CTX -404 22 KNS42 ENSG00000143164|DCAF6  
chr1 196735841 4+18- chr1 196745076 19+1- ITX 8434 18 KNS42  ENSG00000116785|CFHR3 
chr1 200067607 15+17- chr2 23697849 17+18- CTX -404 31 KNS42 ENSG00000116833|NR5A2 ENSG00000119771|KLHL29 
chr1 201070274 1+15- chr1 201210022 15+2- ITX 138949 14 KNS42 ENSG00000081248|CACNA1S  
chr2 43437013 0+20- chr6 45891802 2+19- CTX -404 18 KNS42 ENSG00000115970|THADA ENSG00000112782|CLIC5 
chr2 131096289 0+12- chr2 131110431 15+3- ITX 13271 12 KNS42 ENSG00000136710|CCDC115  
chr2 131778059 0+12- chr9 1407175 12+0- CTX -404 12 KNS42 ENSG00000136002|ARHGEF4  
chr2 132976153 1+12- chr14 19040918 10+1- CTX -404 10 KNS42 ENSG00000163046|ANKRD30BL  
chr2 132987650 27+0- chr15 20000010 31+14- CTX -404 26 KNS42 ENSG00000163046|ANKRD30BL  
chr2 133001848 3+34- chr14 19000141 0+33- CTX -404 32 KNS42 ENSG00000163046|ANKRD30BL  
220 
chr2 133005674 5+3- chr21 10707432 162+185- ITX -312 68 KNS42 ENSG00000163046|ANKRD30BL  
chr2 133006389 19+8- chr16 33970966 42+14- CTX -404 14 KNS42 ENSG00000163046|ANKRD30BL  
chr2 160149043 42+33- chr3 58772063 42+31- CTX -404 72 KNS42  ENSG00000163689|C3orf67 
chr2 171814878 21+1- chr13 49848076 1+18- CTX -404 18 KNS42 ENSG00000115806|GORASP2 ENSG00000102543|CDADC1 
chr2 172409811 2+18- chr13 32800774 18+1- CTX -404 18 KNS42 ENSG00000071967|CYBRD1 ENSG00000073910|FRY 
chr3 80325550 14+17- chr6 121481236 14+16- CTX -404 28 KNS42  ENSG00000146350|C6orf170 
chr3 84440279 2+21- chr4 190840980 1+22- CTX -404 21 KNS42  ENSG00000245685| 
chr3 111274477 0+29- chr8 128533826 0+29- CTX -404 29 KNS42 ENSG00000153283|CD96  
chr3 122653134 0+11- chr12 49892490 11+1- CTX -404 10 KNS42 ENSG00000082684|SEMA5B ENSG00000123352|SPATS2 
chr3 164722685 1+36- chr5 57093054 34+1- CTX -404 33 KNS42 ENSG00000090402|SI  
chr3 174480490 0+13- chr20 54946398 0+12- CTX -404 12 KNS42 ENSG00000177694|NAALADL2 ENSG00000087586|AURKA 
chr3 195729630 11+1- chr5 1623025 2+10- CTX -404 11 KNS42  ENSG00000188002| 
chr3 196625623 6+2- chr10 42597220 165+150- ITX -335 35 KNS42 ENSG00000119231|SENP5  
chr4 153556195 0+12- chr21 23045425 0+13- CTX -404 12 KNS42 ENSG00000170006|TMEM154 ENSG00000237527| 
chr4 160666229 5+12- chr21 17459342 6+12- CTX -404 17 KNS42 ENSG00000250488| ENSG00000215386|LINC00478 
chr4 175454371 22+41- chr11 127378377 22+13- CTX -404 12 KNS42 ENSG00000250596|  
chr4 175719343 0+21- chr4 176196699 20+0- ITX 476537 19 KNS42 ENSG00000145451|GLRA3  
chr5 159349918 0+31- chrX 66982460 31+0- CTX -404 31 KNS42 ENSG00000170214|ADRA1B  
chr6 14261299 16+0- chr8 8718282 0+16- CTX -404 16 KNS42  ENSG00000147324|MFHAS1 
chr6 15532273 0+11- chr8 8667072 11+0- CTX -404 11 KNS42 ENSG00000047579|DTNBP1 ENSG00000147324|MFHAS1 
chr6 20112705 2+11- chr9 117857639 2+21- CTX -404 10 KNS42 ENSG00000172197|MBOAT1 ENSG00000041982|TNC 
chr6 35754551 0+14- chr6 35766786 15+1- ITX 11406 14 KNS42 ENSG00000204140|C6orf127  
chr6 70386596 0+11- chr6 92147626 12+14- ITX 21759690 11 KNS42 ENSG00000168216|LMBRD1  
chr6 107307634 16+1- chr8 105231691 19+17- CTX -404 15 KNS42  ENSG00000176406|RIMS2 
chr6 119558597 7+18- chr8 82754452 7+8- CTX -404 11 KNS42 ENSG00000111885|MAN1A1 ENSG00000104497|SNX16 
chr6 134366639 2+15- chr22 24198439 16+71- CTX -404 15 KNS42 ENSG00000146411|SLC2A12  
221 
chr7 3023122 1+15- chr7 3359981 17+1- ITX 335662 15 KNS42 ENSG00000198286|CARD11 ENSG00000146555|SDK1 
chr7 21935990 5+8- chr22 22151474 8+5- CTX -404 13 KNS42 ENSG00000105877|DNAH11 ENSG00000100030|MAPK1 
chr7 99998836 11+0- chr11 74292835 0+11- CTX -404 11 KNS42 ENSG00000078487|ZCWPW1 ENSG00000077514|POLD3 
chr7 103159742 18+0- chr12 98598388 19+9- CTX -404 18 KNS42 ENSG00000189056|RELN ENSG00000258312| 
chr7 110756337 2+24- chr7 110757801 25+2- ITX 682 24 KNS42 ENSG00000173114|LRRN3 ENSG00000184903|IMMP2L 
chr7 136805167 0+21- chr7 136917293 22+2- ITX 111162 19 KNS42 ENSG00000234352| ENSG00000105894|PTN 
chr7 149736180 1+13- chr7 149739027 12+0- ITX 2081 11 KNS42  ENSG00000241449| 
chr8 15289742 21+14- chr13 74313749 21+15- CTX -404 35 KNS42 ENSG00000104723|TUSC3 ENSG00000118922|KLF12 
chr8 52730546 2+60- chr11 38812130 60+53- CTX -404 56 KNS42 ENSG00000168300|PCMTD1  
chr9 12681979 0+34- chr9 12686650 35+0- ITX 3470 34 KNS42  ENSG00000107165|TYRP1 
chr9 68434547 30+6- chr13 110874948 6+16- CTX -404 20 KNS42 ENSG00000215548| ENSG00000187498|COL4A1 
chr10 1114363 8+4- chr20 5020915 3+8- CTX -404 11 KNS42 ENSG00000047056|WDR37  
chr10 101588012 0+14- chr22 24606864 0+14- CTX -404 14 KNS42 ENSG00000023839|ABCC2  
chr10 127575298 4+89- chr13 20371183 88+2- CTX -404 84 KNS42 ENSG00000089876|DHX32  
chr10 127586269 25+4- chrY 59033113 23+1- CTX -404 23 KNS42 ENSG00000203780|FANK1  
chr10 127594410 3+28- chrY 59025715 8+31- CTX -404 27 KNS42 ENSG00000203780|FANK1  
chr11 49838891 1+21- chr11 49873934 21+0- ITX 33776 21 KNS42  ENSG00000254714| 
chr12 20704514 19+12- chr16 33963841 24+32- CTX -404 15 KNS42 ENSG00000172572|PDE3A  
chr12 69291843 13+1- chr14 59220388 10+1- CTX -404 10 KNS42 ENSG00000135678|CPM  
chr12 73239994 21+0- chr15 94888226 21+1- CTX -404 21 KNS42  ENSG00000140563|MCTP2 
chr12 96967216 0+14- chrX 100735303 1+15- CTX -404 13 KNS42 ENSG00000188596|C12orf63 ENSG00000196440|ARMCX4 
chr12 96977487 0+15- chrX 98569531 17+3- CTX -404 14 KNS42 ENSG00000188596|C12orf63  
chr12 127650496 6+14- chr17 31149593 7+12- CTX -404 10 KNS42 ENSG00000239776| ENSG00000176658|MYO1D 
chr13 23487887 1+17- chr13 24902264 18+2- ITX 1413472 16 KNS42 ENSG00000248788|  
chr17 39579140 1+11- chr17 39595475 9+0- ITX 14016 10 KNS42 ENSG00000108417|KRT37 ENSG00000171360|KRT38 
chr18 110103 174+139- chrX 29270354 10+14- CTX -404 10 KNS42  ENSG00000169306|IL1RAPL1 
222 
chr20 11281915 0+11- chrX 81651240 0+11- CTX -404 11 KNS42 ENSG00000230990|  
chr20 55038728 1+19- chr20 57284430 19+1- ITX 2244784 18 KNS42  ENSG00000215440|NPEPL1 
chr21 11054605 0+29- chrY 59001093 0+29- CTX -404 29 KNS42 ENSG00000187172|BAGE2  
chrX 1317601 1+29- chrX 1689918 31+2- ITX 371494 28 KNS42 ENSG00000205755|CRLF2  
            
chr1 28515699 12+1- chr19 24027616 10+0- CTX -406 10 SF188 ENSG00000169403|PTAFR  
chr1 38433053 12+20- chr6 28863616 12+20- CTX -406 32 SF188 ENSG00000183431|SF3A3  
chr1 91853069 4001+761- chr8 70602300 2+1060- CTX -406 1054 SF188 ENSG00000162669|HFM1 ENSG00000137571|SLCO5A1 
chr1 91853162 2939+753- chr12 127650866 734+3- CTX -406 731 SF188 ENSG00000162669|HFM1 ENSG00000239776| 
chr1 119401206 22+1- chr15 51189113 1+22- CTX -406 21 SF188  ENSG00000247586| 
chr1 153043779 0+16- chr1 153066681 15+0- ITX 22111 15 SF188 ENSG00000196805|SPRR2B ENSG00000203785|SPRR2E 
chr1 164240743 12+1- chr2 190999553 0+11- CTX -406 11 SF188  ENSG00000187699|C2orf88 
chr1 178665120 2+13- chr5 173541191 4+13- CTX -406 12 SF188  ENSG00000170091| 
chr1 225133401 6+12- chr1 225248304 12+1- ITX 114194 12 SF188 ENSG00000143799|PARP1 ENSG00000185842|DNAH14 
chr1 226056264 1+28- chr1 226058049 27+1- ITX 842 26 SF188 ENSG00000143799|PARP1 ENSG00000196187|TMEM63A 
chr2 3931958 12+0- chr12 124499519 12+1- CTX -406 11 SF188  ENSG00000179195|ZNF664 
chr2 11930066 11+21- chrX 42764633 0+16- CTX -406 13 SF188 ENSG00000134324|LPIN1  
chr2 28965181 1+20- chr2 29052473 22+0- ITX 86311 20 SF188  ENSG00000163806|SPDYA 
chr2 68914697 10+0- chr5 64467845 10+1- CTX -406 10 SF188 ENSG00000163219|ARHGAP25 ENSG00000049192|ADAMTS6 
chr2 132981508 15+10- chr14 19035116 30+4- CTX -406 15 SF188 ENSG00000163046|ANKRD30BL  
chr2 132987675 24+0- chr15 20000013 26+8- CTX -406 21 SF188 ENSG00000163046|ANKRD30BL  
chr2 133006034 19+2- chr16 33970522 44+10- CTX -406 16 SF188 ENSG00000163046|ANKRD30BL  
chr2 162139084 32+4- chr21 9829856 5+31- CTX -406 29 SF188 ENSG00000225813|  
chr3 66324954 0+12- chr3 94513880 14+1- ITX 28188174 12 SF188 ENSG00000144741|SLC25A26  
chr3 75722542 1+12- chr4 190935603 0+13- CTX -406 12 SF188 ENSG00000242516|  
chr3 75984130 1+19- chr19 33444289 0+28- CTX -406 17 SF188 ENSG00000185008|ROBO2 ENSG00000121289|CEP89 
223 
chr3 84440288 4+23- chr4 190840937 1+24- CTX -406 22 SF188  ENSG00000245685| 
chr3 111275066 25+1570- chr8 128488625 1254+3460- CTX -406 1555 SF188 ENSG00000153283|CD96 ENSG00000246228| 
chr3 124176062 10+0- chr7 63657750 1+11- CTX -406 10 SF188 ENSG00000160145|KALRN  
chr3 170340075 3+8- chr17 74374118 5+10- CTX -406 11 SF188 ENSG00000013297|CLDN11 ENSG00000161542|PRPSAP1 
chr3 196625619 16+6- chr10 42597278 261+215- ITX -341 55 SF188 ENSG00000119231|SENP5  
chr3 196625676 16+26- chr10 42390288 56+116- CTX -406 20 SF188 ENSG00000119231|SENP5  
chr4 1617097 0+13- chr20 9816311 15+1- CTX -406 13 SF188  ENSG00000101349|PAK7 
chr4 52798913 31+710- chr4 54214944 712+31- ITX 1408910 688 SF188  ENSG00000184178|SCFD2 
chr4 53474896 0+17- chr4 55131340 16+1- ITX 1655630 16 SF188 ENSG00000109189|USP46 ENSG00000134853|PDGFRA 
chr4 53503816 2+17- chr4 55608654 18+1- ITX 2104056 15 SF188 ENSG00000109189|USP46  
chr4 53882777 1+35- chr9 88287132 1+35- CTX -406 35 SF188 ENSG00000184178|SCFD2 ENSG00000135049|AGTPBP1 
chr4 54044675 28+670- chr8 128265420 1041+446- CTX -406 643 SF188 ENSG00000184178|SCFD2  
chr4 54127071 2+36- chr17 29741322 0+34- CTX -406 34 SF188 ENSG00000184178|SCFD2 ENSG00000131242|RAB11FIP4 
chr4 54165402 216+618- chr8 128043959 469+31- CTX -406 435 SF188 ENSG00000184178|SCFD2  
chr4 54211080 27+3- chr9 71691856 2+23- CTX -406 22 SF188 ENSG00000184178|SCFD2 ENSG00000165060|FXN 
chr4 54224715 0+15- chr4 55298688 17+1- ITX 1006086 16 SF188 ENSG00000184178|SCFD2  
chr4 54283618 56+743- chr11 118277406 99+788- CTX -406 692 SF188 ENSG00000145216|FIP1L1 ENSG00000167283|ATP5L 
chr4 54291376 661+75- chr8 128942087 1470+1485- CTX -406 585 SF188 ENSG00000145216|FIP1L1 ENSG00000249859|PVT1 
chr4 54327856 30+63- chr4 54561209 21+0- ITX 231409 21 SF188 ENSG00000072201|LNX1 ENSG00000145216|FIP1L1 
chr4 55045259 1+23- chr17 29881541 0+23- CTX -406 23 SF188 ENSG00000145216|FIP1L1  
chr4 55068948 0+25- chr4 55763485 25+0- ITX 693729 25 SF188 ENSG00000145216|FIP1L1  
chr4 55559032 1+36- chr17 29677191 0+35- CTX -406 35 SF188 ENSG00000157404|KIT ENSG00000196712|NF1 
chr4 80894424 14+1- chr5 21207753 0+14- CTX -406 13 SF188 ENSG00000163297|ANTXR2  
chr4 81060458 1+15- chr4 81190083 15+0- ITX 128524 15 SF188  ENSG00000138675|FGF5 
chr4 88186116 49+35- chr16 23176680 8+48- CTX -406 48 SF188 ENSG00000250572|  
chr4 172619946 21+1- chr7 23309549 15+21- CTX -406 21 SF188  ENSG00000136235|GPNMB 
224 
chr5 159350015 0+44- chrX 66982357 44+2- CTX -406 43 SF188 ENSG00000170214|ADRA1B  
chr5 160531888 9+3- chr10 96337717 3+7- CTX -406 10 SF188  ENSG00000119969|HELLS 
chr5 169544250 11+15- chr5 171214306 16+10- ITX 1668039 15 SF188  ENSG00000185662|C5orf50 
chr6 35754559 2+42- chr6 35766982 42+3- ITX 11404 41 SF188 ENSG00000204140|C6orf127  
chr6 36013499 10+0- chr11 107984106 2+11- CTX -406 10 SF188 ENSG00000112062|MAPK14 ENSG00000255467| 
chr6 132122317 0+17- chr6 154332127 16+10- ITX 22208698 16 SF188  ENSG00000112038|OPRM1 
chr6 158783682 22+35- chr17 78736108 35+24- CTX -406 52 SF188 ENSG00000130338|TULP4 ENSG00000141564|RPTOR 
chr7 111053658 12+8- chr12 108202919 8+14- CTX -406 20 SF188 ENSG00000184903|IMMP2L  
chr7 149736176 4+12- chr7 149739225 14+3- ITX 2057 12 SF188  ENSG00000241449| 
chr7 154876549 36+40- chr7 154881085 41+35- ITX 3153 40 SF188 ENSG00000157219|HTR5A  
chr8 15289876 25+33- chr13 74313847 24+32- CTX -406 56 SF188 ENSG00000104723|TUSC3 ENSG00000118922|KLF12 
chr8 52730430 0+38- chr11 38812243 39+50- CTX -406 37 SF188 ENSG00000168300|PCMTD1  
chr8 96265842 1+15- chr19 18835272 15+0- CTX -406 14 SF188 ENSG00000156172|C8orf37 ENSG00000105662|CRTC1 
chr8 128215568 42+1171- chr12 58019610 250+1356- CTX -406 1124 SF188  ENSG00000135454|B4GALNT1 
chr8 128997301 1390+791- chr12 58150692 1391+792- CTX -406 614 SF188 ENSG00000249859|PVT1 ENSG00000139266|MARCH9 
chr9 3107616 13+10- chr9 4190288 10+0- ITX 1081996 10 SF188  ENSG00000107249|GLIS3 
chr9 73105725 0+15- chr17 29767045 14+0- CTX -406 14 SF188  ENSG00000131242|RAB11FIP4 
chr9 73130362 2+31- chr17 29702985 33+1- CTX -406 31 SF188  ENSG00000196712|NF1 
chr9 73158216 27+0- chr17 29706699 28+1- CTX -406 27 SF188 ENSG00000083067|TRPM3 ENSG00000196712|NF1 
chr9 88246706 24+1- chr17 29877072 24+1- CTX -406 24 SF188 ENSG00000135049|AGTPBP1  
chr9 88293892 15+0- chr17 29768963 1+14- CTX -406 13 SF188 ENSG00000135049|AGTPBP1 ENSG00000131242|RAB11FIP4 
chr9 109305732 4+15- chr9 109354148 15+0- ITX 47573 15 SF188 ENSG00000234323| ENSG00000229297| 
chr9 124505824 1+15- chr16 30630816 15+1- CTX -406 15 SF188 ENSG00000136848|DAB2IP  
chr9 124521292 10+0- chr16 66292217 1+11- CTX -406 10 SF188 ENSG00000136848|DAB2IP  
chr10 101588047 4+10- chr22 24606887 3+9- CTX -406 12 SF188 ENSG00000023839|ABCC2  
chr10 127575372 7+132- chr13 20371210 131+1- CTX -406 129 SF188 ENSG00000089876|DHX32  
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chr10 127586240 26+4- chrY 59032305 25+4- CTX -406 19 SF188 ENSG00000203780|FANK1  
chr10 127594439 5+48- chrY 59025664 13+61- CTX -406 48 SF188 ENSG00000203780|FANK1  
chr11 29534037 1+46- chr11 69947170 47+1- ITX 40412260 46 SF188 ENSG00000254530| ENSG00000131620|ANO1 
chr11 57812425 19+1- chr20 3753964 20+0- CTX -406 19 SF188 ENSG00000186509|OR9Q1  
chr12 73239952 28+0- chr15 94888163 28+2- CTX -406 28 SF188  ENSG00000140563|MCTP2 
chr14 105628776 64+66- chr14 105628961 64+66- ITX -361 34 SF188 ENSG00000184916|JAG2 ENSG00000257622| 
chr15 75622782 0+12- chr15 75739744 13+1- ITX 116118 11 SF188  ENSG00000169375|SIN3A 
chr16 542305 24+25- chr16 542428 24+25- ITX -323 14 SF188 ENSG00000090565|RAB11FIP3 ENSG00000256323| 
chr16 23640617 0+40- chr16 23914058 41+2- ITX 272186 40 SF188 ENSG00000083093|PALB2 ENSG00000166501|PRKCB 
chr16 23791248 0+48- chr16 26084062 49+1- ITX 2290900 45 SF188  ENSG00000182601|HS3ST4 
chr16 48280936 10+11- chr16 48281199 10+11- ITX -325 10 SF188 ENSG00000102910|LONP2 ENSG00000121270|ABCC11 
chr16 56411916 2+18- chr16 56829788 18+5- ITX 416526 16 SF188 ENSG00000159461|AMFR ENSG00000102900|NUP93 
chr17 36636571 14+0- chr19 10029848 15+6- CTX -406 13 SF188 ENSG00000225485|ARHGAP23 ENSG00000105088|OLFM2 
chr18 110081 336+249- chrX 29270196 27+58- CTX -406 26 SF188  ENSG00000169306|IL1RAPL1 
chr19 33444427 0+11- chr20 26220364 10+1- CTX -406 10 SF188 ENSG00000121289|CEP89  
chr20 278393 0+18- chr21 17652744 22+35- CTX -406 18 SF188 ENSG00000177764|ZCCHC3 ENSG00000215386|LINC00478 
chr20 1840412 14+0- chr21 17125470 1+15- CTX -406 14 SF188  ENSG00000155313|USP25 
chr20 4895215 1+32- chr20 25459154 31+0- ITX 20562950 31 SF188 ENSG00000089057|SLC23A2 ENSG00000101004|NINL 
chr21 11054613 1+28- chrY 59000805 14+35- CTX -406 27 SF188 ENSG00000187172|BAGE2  
chrX 1236190 1+20- chrX 1321896 18+0- ITX 84927 18 SF188  ENSG00000205755|CRLF2 
chr1 569070 14+0- chr8 63015045 20+35- CTX -453 14 UW479 ENSG00000230021|  
chr1 20371660 1+16- chr3 87620063 15+25- CTX -453 15 UW479 ENSG00000127472|PLA2G5  
chr1 27103911 1+19- chr1 27340815 19+2- ITX 235149 17 UW479 ENSG00000117713|ARID1A  
chr1 28515712 96+1- chr19 24027325 108+12- CTX -453 96 UW479 ENSG00000169403|PTAFR  
chr1 38328968 2+25- chr1 38428686 24+0- ITX 98648 23 UW479 ENSG00000204084|INPP5B ENSG00000183431|SF3A3 
chr1 47836334 1+34- chr14 53815391 0+34- CTX -453 33 UW479 ENSG00000162368|CMPK1 ENSG00000237356| 
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chr1 55029942 27+0- chr22 19435945 0+29- CTX -453 27 UW479 ENSG00000162390|ACOT11 ENSG00000185065| 
chr1 59096776 17+0- chr2 32048520 0+20- CTX -453 17 UW479 ENSG00000185839| ENSG00000242272|AK2P2 
chr1 91853126 3069+471- chr8 70602300 10+1115- CTX -453 1106 UW479 ENSG00000162669|HFM1 ENSG00000137571|SLCO5A1 
chr1 91853219 1963+459- chr12 127650864 454+3- CTX -453 451 UW479 ENSG00000162669|HFM1 ENSG00000239776| 
chr1 103311283 20+5- chr5 102750041 18+2- CTX -453 15 UW479 ENSG00000230864|  
chr1 109495349 16+13- chr3 110413011 13+18- CTX -453 28 UW479 ENSG00000121940|CLCC1  
chr1 112960870 24+1- chr12 52615093 23+1- CTX -453 23 UW479 ENSG00000143079|CTTNBP2NL ENSG00000258279| 
chr1 113149456 18+0- chr20 3902968 17+18- CTX -453 18 UW479 ENSG00000007341|ST7L ENSG00000125779|PANK2 
chr1 153299201 1+46- chr1 153641153 52+8- ITX 333306 45 UW479  ENSG00000143621|ILF2 
chr1 154914163 0+42- chr1 155232085 41+2- ITX 316908 41 UW479  ENSG00000116521|SCAMP3 
chr1 161668108 0+14- chr1 161800589 13+0- ITX 131721 13 UW479  ENSG00000118217|ATF6 
chr1 164240569 12+14- chr2 190998938 14+1- CTX -453 14 UW479  ENSG00000187699|C2orf88 
chr1 168025510 102+0- chr19 24031551 11+113- CTX -453 102 UW479 ENSG00000143164|DCAF6  
chr1 170926316 0+14- chr6 123171229 24+1- CTX -453 13 UW479 ENSG00000117501|C1orf129  
chr1 173909966 1+22- chr1 174187941 24+2- ITX 276849 21 UW479 ENSG00000135870|RC3H1 ENSG00000152061|RABGAP1L 
chr1 182275010 21+0- chr17 74319270 0+21- CTX -453 21 UW479 ENSG00000228918| ENSG00000161542|PRPSAP1 
chr1 189715582 2+13- chr11 32042611 0+13- CTX -453 13 UW479  ENSG00000049449|RCN1 
chr1 200068784 16+5- chr2 23697827 18+4- CTX -453 18 UW479 ENSG00000116833|NR5A2 ENSG00000119771|KLHL29 
chr1 207579542 21+1- chr6 57493597 25+6- CTX -453 21 UW479  ENSG00000146143|PRIM2 
chr1 219923945 15+4- chr12 98034739 17+1- CTX -453 15 UW479 ENSG00000196660|SLC30A10  
chr1 225133402 3+12- chr1 225248296 11+0- ITX 114141 11 UW479 ENSG00000143799|PARP1 ENSG00000185842|DNAH14 
chr1 240091360 15+25- chr22 29065227 144+50- CTX -453 40 UW479  ENSG00000100154|TTC28 
chr2 11432966 0+22- chr2 11545236 25+3- ITX 111348 22 UW479 ENSG00000134318|ROCK2  
chr2 18253884 2+20- chr2 19077190 20+2- ITX 822294 18 UW479 ENSG00000170745|KCNS3  
chr2 42052748 35+8- chr4 66413204 9+35- CTX -453 37 UW479  ENSG00000145242|EPHA5 
chr2 68914690 11+0- chr5 64467726 12+1- CTX -453 11 UW479 ENSG00000163219|ARHGAP25 ENSG00000049192|ADAMTS6 
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chr2 79376836 10+0- chr13 107845299 22+3- CTX -453 10 UW479  ENSG00000204442|FAM155A 
chr2 91937509 13+6- chr12 123873181 11+2- CTX -453 10 UW479 ENSG00000223703| ENSG00000183955|SETD8 
chr2 99167934 23+0- chr11 46252923 23+0- CTX -453 23 UW479 ENSG00000040933|INPP4A  
chr2 132977273 4+13- chr14 19034839 39+38- CTX -453 12 UW479 ENSG00000163046|ANKRD30BL  
chr2 132987614 28+0- chr15 20000009 57+31- CTX -453 27 UW479 ENSG00000163046|ANKRD30BL  
chr2 133001831 1+36- chr14 19000169 7+46- CTX -453 36 UW479 ENSG00000163046|ANKRD30BL  
chr2 133004923 7+0- chr21 10707760 184+173- ITX -394 62 UW479 ENSG00000163046|ANKRD30BL  
chr2 162138495 26+4- chr21 9829856 0+22- CTX -453 22 UW479 ENSG00000225813|  
chr2 187514641 2+11- chr2 188784801 11+1- ITX 1269112 10 UW479 ENSG00000138448|ITGAV ENSG00000231689| 
chr3 49442178 1+18- chr12 86120307 2+19- CTX -453 18 UW479 ENSG00000067560|RHOA  
chr3 50879613 28+5- chr5 81987180 25+6- CTX -453 30 UW479 ENSG00000088538|DOCK3  
chr3 52435832 19+0- chr19 56217031 19+3- CTX -453 17 UW479 ENSG00000163930|BAP1  
chr3 53300460 1+14- chr19 53495576 15+3- CTX -453 12 UW479  ENSG00000242779|ZNF702P 
chr3 53335607 17+1- chr19 52478810 2+19- CTX -453 16 UW479 ENSG00000162290|DCP1A ENSG00000246125| 
chr3 55024288 37+0- chr19 47734383 1+37- CTX -453 37 UW479 ENSG00000157445|CACNA2D3 ENSG00000105327|BBC3 
chr3 55380592 0+16- chr19 52614592 20+3- CTX -453 15 UW479 ENSG00000242568|  
chr3 56766012 19+21- chr7 147538955 22+20- CTX -453 40 UW479 ENSG00000163947|ARHGEF3 ENSG00000174469|CNTNAP2 
chr3 85686452 12+4- chr16 11673269 4+15- CTX -453 11 UW479 ENSG00000175161|CADM2 ENSG00000189067|LITAF 
chr3 87410003 21+4- chr7 78953929 13+13- CTX -453 13 UW479  ENSG00000187391|MAGI2 
chr3 99389332 0+27- chr15 26705465 29+13- CTX -453 27 UW479 ENSG00000144810|COL8A1  
chr3 110889290 14+0- chrX 57292578 15+1- CTX -453 14 UW479 ENSG00000177707|PVRL3  
chr3 111274994 2+110- chr8 128533275 8+117- CTX -453 110 UW479 ENSG00000153283|CD96  
chr3 114154875 0+18- chr3 168102681 18+0- ITX 53946956 18 UW479 ENSG00000181722|ZBTB20 ENSG00000206120|EGFEM1P 
chr3 134299172 36+1- chr6 36913072 36+1- CTX -453 34 UW479  ENSG00000164530|PI16 
chr3 139226960 2+21- chr19 53106091 4+24- CTX -453 19 UW479 ENSG00000248932|  
chr3 142553308 0+83- chr14 22776228 1+84- CTX -453 83 UW479 ENSG00000163710|PCOLCE2  
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chr3 178769835 1+16- chr15 87685223 18+13- CTX -453 15 UW479 ENSG00000172667|ZMAT3  
chr4 80894474 21+0- chr19 31113491 3+23- CTX -453 21 UW479 ENSG00000163297|ANTXR2  
chr4 95518653 21+10- chr7 46904209 13+22- CTX -453 31 UW479 ENSG00000163110|PDLIM5  
chr4 112258318 0+14- chr4 112816034 14+1- ITX 556933 14 UW479  ENSG00000249815| 
chr4 186117225 40+31- chr13 40674751 3+33- CTX -453 31 UW479 ENSG00000164323|KIAA1430  
chr5 100497538 0+11- chr21 26214157 11+0- CTX -453 11 UW479  ENSG00000226983| 
chr6 150670 7+31- chr11 191186 34+13- CTX -453 31 UW479  ENSG00000177951|BET1L 
chr6 20112078 10+1- chr9 117857715 14+11- CTX -453 10 UW479 ENSG00000172197|MBOAT1 ENSG00000041982|TNC 
chr6 45229405 26+2- chr8 62847098 26+3- CTX -453 23 UW479 ENSG00000196284|SUPT3H ENSG00000254119| 
chr6 58779262 790+768- chr7 53801572 6+22- CTX -453 17 UW479  ENSG00000205628| 
chr6 116774524 4+12- chr7 26251457 32+22- CTX -453 11 UW479 ENSG00000217241|CBX3P9 ENSG00000122565|CBX3 
chr6 126239149 5+49- chr20 34416968 56+4- CTX -453 48 UW479 ENSG00000111912|NCOA7 ENSG00000025293|PHF20 
chr7 22120450 1+22- chr17 73963834 2+23- CTX -453 22 UW479  ENSG00000161533|ACOX1 
chr7 68695954 0+22- chr7 106200173 22+0- ITX 37503284 22 UW479 ENSG00000225718| ENSG00000243797| 
chr7 71425213 0+21- chr7 99282578 23+1- ITX 27856510 12 UW479 ENSG00000183166|CALN1  
chr7 88827600 30+2- chr8 143781332 35+7- CTX -453 30 UW479 ENSG00000182348|ZNF804B  
chr7 101667589 1+14- chr8 91903678 14+16- CTX -453 12 UW479 ENSG00000257923|CUX1 ENSG00000123119|NECAB1 
chr7 111053660 44+41- chr12 108202877 43+47- CTX -453 82 UW479 ENSG00000184903|IMMP2L  
chr7 147472510 5+8- chr17 35071532 9+6- CTX -453 11 UW479 ENSG00000174469|CNTNAP2  
chr8 14946075 21+26- chrX 124433507 25+21- CTX -453 46 UW479 ENSG00000185053|SGCZ  
chr8 40433239 0+27- chr14 55716413 29+5- CTX -453 27 UW479 ENSG00000165061|ZMAT4  
chr8 47159193 31+0- chr9 137280905 30+0- CTX -453 30 UW479  ENSG00000186350|RXRA 
chr8 51886715 5+6- chr12 108002659 6+4- CTX -453 10 UW479  ENSG00000151136|BTBD11 
chr8 52730477 1+57- chr11 38812217 56+64- CTX -453 56 UW479 ENSG00000168300|PCMTD1  
chr8 57896780 1+16- chr19 31716239 20+8- CTX -453 14 UW479 ENSG00000104331|IMPAD1  
chr8 62579337 1+32- chr8 62708134 31+0- ITX 127822 31 UW479 ENSG00000198363|ASPH ENSG00000254119| 
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chr8 96643384 20+19- chr18 4086683 19+19- CTX -453 38 UW479 ENSG00000253773| ENSG00000170579|DLGAP1 
chr8 117230013 20+9- chr17 49354767 15+0- CTX -453 15 UW479 ENSG00000249917| ENSG00000011260|UTP18 
chr8 134879116 0+10- chr8 135683085 11+0- ITX 803270 10 UW479  ENSG00000066827|ZFAT 
chr8 141832537 22+3- chr15 42650218 1+19- CTX -453 19 UW479 ENSG00000169398|PTK2 ENSG00000092529|CAPN3 
chr8 145554246 0+21- chr8 145655751 23+0- ITX 100345 21 UW479  ENSG00000160949|TONSL 
chr8 146058423 1+12- chr17 27112965 0+11- CTX -453 11 UW479 ENSG00000147789|ZNF7 ENSG00000173065|C17orf63 
chr9 22741727 0+13- chr9 128368012 16+4- ITX 105624816 13 UW479 ENSG00000234840| ENSG00000119487|MAPKAP1 
chr9 25865280 21+0- chr18 31751559 27+21- CTX -453 21 UW479  ENSG00000101746|NOL4 
chr9 27935991 0+21- chr9 135661990 23+3- ITX -96797295 21 UW479  ENSG00000165695|AK8 
chr9 27945060 12+1- chr18 30711907 12+0- CTX -453 12 UW479  ENSG00000166960|C18orf34 
chr9 28000942 0+14- chr9 86632969 14+1- ITX 58631084 14 UW479 ENSG00000174482|LINGO2  
chr9 30392631 0+12- chr9 86610459 14+2- ITX 56216928 12 UW479  ENSG00000178966|RMI1 
chr9 32381210 0+21- chr9 33849115 20+0- ITX 1466998 20 UW479  ENSG00000107341|UBE2R2 
chr9 78899983 22+0- chr17 18077236 7+27- CTX -453 22 UW479 ENSG00000099139|PCSK5 ENSG00000091536|MYO15A 
chr9 86638539 0+14- chr18 30729821 2+15- CTX -453 13 UW479  ENSG00000166960|C18orf34 
chr9 102086745 0+17- chr18 31750899 20+2- CTX -453 17 UW479  ENSG00000101746|NOL4 
chr9 102146807 14+0- chr18 30736184 17+2- CTX -453 14 UW479  ENSG00000166960|C18orf34 
chr9 131081825 0+20- chr18 14823395 20+15- CTX -453 20 UW479 ENSG00000167112|TRUB2 ENSG00000180777|ANKRD30B 
chr9 136327728 1+22- chr14 56290681 4+24- CTX -453 22 UW479 ENSG00000160325|C9orf7  
chr10 1114901 12+0- chr20 5021199 2+14- CTX -453 11 UW479 ENSG00000047056|WDR37  
chr10 5202158 0+10- chr10 5324856 10+1- ITX 121967 10 UW479 ENSG00000196326|AKR1CL1 ENSG00000215267| 
chr10 26226198 7+4- chr17 6554228 4+7- CTX -453 11 UW479 ENSG00000095777|MYO3A ENSG00000108590|MED31 
chr10 34822411 9+26- chr12 55472537 26+0- CTX -453 26 UW479 ENSG00000148498|PARD3  
chr10 45422946 25+35- chr10 45424592 37+25- ITX 290 35 UW479 ENSG00000187783|TMEM72 ENSG00000224812| 
chr10 109325960 27+23- chr13 107846599 48+70- CTX -453 47 UW479  ENSG00000204442|FAM155A 
chr10 127575172 1+52- chr13 20371005 52+4- CTX -453 52 UW479 ENSG00000089876|DHX32  
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chr10 127586296 16+5- chrY 59032932 11+1- CTX -453 10 UW479 ENSG00000203780|FANK1  
chr11 49839008 2+22- chr11 49873895 19+0- ITX 33689 19 UW479  ENSG00000254714| 
chr11 55373517 31+3- chr18 76876931 30+0- CTX -453 29 UW479  ENSG00000166377|ATP9B 
chr12 12453997 1+19- chr20 62851844 3+20- CTX -453 18 UW479  ENSG00000196132|MYT1 
chr12 20704524 8+25- chr16 33963005 28+1259- CTX -453 20 UW479 ENSG00000172572|PDE3A  
chr13 23487980 1+25- chr13 24902217 25+0- ITX 1413371 25 UW479 ENSG00000248788|  
chr13 89981969 0+18- chr15 39504892 1+18- CTX -453 16 UW479  ENSG00000259345| 
chr13 100589796 1+17- chr21 34847166 0+18- CTX -453 16 UW479 ENSG00000255768| ENSG00000142188|TMEM50B 
chr14 31036241 0+17- chr15 30984655 0+16- CTX -453 16 UW479 ENSG00000092140|G2E3 ENSG00000175344|CHRNA7 
chr14 32066014 1+47- chr14 33251221 46+1- ITX 1183569 45 UW479 ENSG00000151413|NUBPL ENSG00000151320|AKAP6 
chr14 67834188 1+12- chr14 67862968 13+2- ITX 28007 12 UW479 ENSG00000134001|EIF2S1 ENSG00000100558|PLEK2 
chr14 88035460 3+92- chr19 33010389 104+8- CTX -453 90 UW479 ENSG00000258859|  
chr15 34326914 1+24- chr15 34419814 28+4- ITX 91589 23 UW479 ENSG00000169857|AVEN  
chr15 35352133 1+16- chr17 8516724 5+43- CTX -453 15 UW479  ENSG00000133026|MYH10 
chr15 85867818 2+26- chr15 85913538 27+4- ITX 44137 24 UW479 ENSG00000218052| ENSG00000170776|AKAP13 
chr17 8745523 1+17- chr17 9557484 20+1- ITX 810986 15 UW479 ENSG00000174083|PIK3R6 ENSG00000154914|USP43 
chr17 17916041 5+20- chr17 18055066 35+22- ITX 137263 15 UW479 ENSG00000171962|LRRC48 ENSG00000091536|MYO15A 
chr17 41713672 24+1- chr22 18470346 28+5- CTX -453 22 UW479  ENSG00000093100| 
chr19 23934384 470+472- chr19 23943716 470+472- ITX -413 354 UW479 ENSG00000196172|ZNF681  
chr19 52505400 2+21- chr19 56253579 22+1- ITX 3746818 19 UW479 ENSG00000197619|ZNF615  
chr19 53186921 0+27- chr19 53482483 29+8- ITX 294327 22 UW479 ENSG00000167766|ZNF83 ENSG00000242779|ZNF702P 
chr19 55475788 0+14- chr19 55476878 14+0- ITX 299 14 UW479 ENSG00000167634|NLRP7 ENSG00000022556|NLRP2 
chr20 31521723 2+34- chr20 31553810 32+0- ITX 31082 32 UW479 ENSG00000215529|EFCAB8  
chr21 11055054 2+25- chrY 59001084 0+21- CTX -453 19 UW479 ENSG00000187172|BAGE2  
Abbreviations : Chr – chromosome; Pos – position ; Ori – reads orientation; 
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Appendix VI 
Table S5.2. Genic structural variants predicted by the Breakdancer in which either region 
involved has copy number gain or loss has. 
Cell Line Fusion ID Gene 1 Gene 2 Gene1.diff.smo Gene2.diff.smo 
KNS42_1_156051752_3_189542047  TP63  0.4177 
KNS42_2_171814878_13_49848076 GORASP2 CDADC1 0.02305 0.3368 
KNS42_1_58802590_10_74176383 DAB1 CBARA1 0.2695 0.3825 
KNS42_2_43437013_6_45891802 THADA CLIC5 0.1975 0.2072 
KNS42_6_14261299_8_8718282  MFHAS1  0.3237 
KNS42_6_15532273_8_8667072 DTNBP1 MFHAS1 0.2771 0.3237 
KNS42_1_152387895_11_132713260  OPCML  0.5185 
KNS42_12_96967216_X_100735303 C12orf63  0.2565  
KNS42_7_103159742_12_98598388 RELN  0.2606  
KNS42_3_164722685_5_57093054 SI  0.4412  
KNS42_12_96977487_X_98569531 C12orf63  0.2565  
KNS42_5_64964650_5_65433006 SGTB  0.2663  
SF188_3_44466690_9_73176666  TRPM3  0.405 
SF188_20_4895215_20_25459154 SLC23A2  0.3601  
SF188_3_75984130_19_33444289 ROBO2  0.2728  
SF188_9_73105725_17_29767045  RAB11FIP4  0.4491 
SF188_3_44853404_17_29848790 KIF15 RAB11FIP4 0.8036 0.4491 
SF188_9_88293892_17_29768963 AGTPBP1 RAB11FIP4 0.4196 0.4491 
SF188_4_54127071_17_29741322 SCFD2 RAB11FIP4 0.1755 0.4491 
SF188_3_44844784_17_29795166 KIF15 RAB11FIP4 0.8036 0.4491 
SF188_11_29534037_11_69947170  ANO1  1.6909 
SF188_4_53882777_9_88287132 SCFD2 AGTPBP1 0.0166 0.4196 
SF188_6_158783682_17_78736108 TULP4  0.2787  
SF188_4_54327856_4_54561209 LNX1 FIP1L1 1.976 2.1076 
SF188_20_1840412_21_17125470  USP25  0.2904 
SF188_4_54211080_9_71691856 SCFD2  0.5206  
SF188_11_47249941_11_118298167  ATP5L  2.2766 
SF188_4_54283618_11_118277406 FIP1L1 ATP5L 2.1076 2.2766 
SF188_1_144680231_1_144954567  PDE4DIP  0.2049 
SF188_11_88909186_15_27561047  GABRG3  0.1039 
SF188_3_44468743_4_53879701  SCFD2  0.5206 
SF188_4_52798913_4_54214944  SCFD2  0.5206 
SF188_9_73158216_17_29706699 TRPM3  0.405  
SF188_20_278393_21_17652744  C21orf34  0.4874 
SF188_4_54291376_8_128942087 FIP1L1  2.1076  
SF188_16_542305_16_542428 RAB11FIP3  0.3206  
SF188_4_54165402_8_128043959 SCFD2  0.5206  
SF188_9_88246706_17_29877072 AGTPBP1  0.4196  
SF188_4_55045259_17_29881541 FIP1L1  2.1076  
SF188_4_54224715_4_55298688 SCFD2  0.5206  
SF188_4_55068948_4_55763485 FIP1L1  2.1076  
SF188_4_54044675_8_128265420 SCFD2  0.0166  
SF188_4_54224715_4_55298688 SCFD2  0.0166  
SF188_4_54165402_8_128043959 SCFD2  0.0166  
SF188_4_54224715_4_55298688 SCFD2  0.1755  
SF188_11_57812425_20_3753964 OR9Q1  0.4632  
UW479_8_137751825_17_49361503  UTP18  0.4898 
232 
UW479_8_117230013_17_49354767  UTP18  0.4898 
UW479_8_141832537_15_42650218 PTK2 CAPN3 0.01635 0.2261 
UW479_3_47028066_22_19936322 NBEAL2  0.3468  
UW479_3_55024288_19_47734383 CACNA2D3  0.6856  
UW479_9_32381210_9_33849115  UBE2R2  0.5006 
UW479_1_113149456_20_3902968 ST7L  0.2146  
UW479_14_32066014_14_33251221 NUBPL AKAP6 0.3064 0.3727 
UW479_17_8745523_17_9557484 PIK3R6  0.3554  
UW479_9_27945060_18_30711907  C18orf34  0.4284 
UW479_9_102146807_18_30736184  C18orf34  0.4284 
UW479_9_86638539_18_30729821  C18orf34  0.4284 
UW479_1_82756062_14_67423798  GPHN  0.4351 
UW479_14_31036241_15_30984655 G2E3  0.2964  
UW479_12_1695918_12_9246077  A2M  0.2579 
UW479_8_47159193_9_137280905  RXRA  0.4528 
UW479_12_3690145_20_62854780 PRMT8  0.3924  
UW479_3_114154875_3_168102681 ZBTB20  0.2724  
UW479_20_15544438_22_35396912 MACROD2  0.2331  
UW479_5_93556435_22_35366567 C5orf36  0.2471  
UW479_1_47836334_14_53815391 CMPK1  0.3541  
UW479_6_45229405_8_62847098 SUPT3H  0.1742  
UW479_8_62579337_8_62708134 ASPH  0.2395  
UW479_8_57896780_19_31716239 IMPAD1  0.2229  
UW479_7_71425213_7_99282578 CALN1  0.4129  
UW479_8_40433239_14_55716413 ZMAT4  0.4246  
UW479_9_28000942_9_86632969 LINGO2  0.7717  
UW479_7_88827600_8_143781332 ZNF804B  0.516  
Gene1.diff.smo and Gene2.diff.smo refer to smoothed log ratios covering each gene (Gene 1 and 
Gene 2) involved in the SV. 
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